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ABSTRACT
Adaptive Phase I and II Clinical Trial Designs in Oncology with Repeated
Measures using Markov Models for the Conditional Probability of Toxicity
by
Laura Levette Fernandes
Co-chairs: Professor Jeremy M.G. Taylor
Professor Susan Murray
We consider models for the dose toxicity relationship in early clinical trials in oncol-
ogy where different dose levels of a study drug are being tested over multiple cycles
in the same patient and an assessment of toxicity is made for each cycle. We propose
three models using conditional probability of toxicity in specifying the dose-toxicity
relationship in patients receiving repeated doses assuming that they did not have
any dose limiting toxicities (DLTs) on past cycles. We first develop the conditional
Markov model in a phase I settings where the patients are allowed to escalate/de-
escalate dose levels, from a choice of five possibilities, over six cycles. In the second
setting the conditional Markov model is applied to a completed phase II clinical trial
xiii
in sarcoma patients from the paper by Worden et al. (2005) where two dose levels
of the study drug, ifosamide, were tested over four cycles. The model adequately
fits the dose-toxicity relationship at each of the cycles and demonstrates flexibility
offered in including additional covariate terms to describe the relationship. Finally
the conditional Markov model is extended to the ordinal case where patient responses
are classified as severe, mild or none and might prove beneficial in assigning future
doses closer to the patient’s actual frailty. Bayesian estimation of the parameters is
formulated and evaluated through simulations in all the three methods. Methods for
utilizing the dichotomous and ordinal outcome method to conduct a phase I study,
including choices for selecting doses for the next cycle for each patient, are developed
and designs of clinical trials using the models in simulation settings are presented.
Comparison of the dichotomous and ordinal outcome Markov models are also pre-





Early phase I clinical trials of a new agent in oncology are conducted as dose-
finding experiments with a focus on estimating the maximum tolerated dose (MTD)
and understanding the dose-toxicity relationship. The designs of such trials typically
explore the toxicity at a predefined set of possible dose levels of the agent. Since
the MTD will be used in subsequent studies of the agent it is important that it
be established with some level of confidence from the phase I trial. The trials are
typically small with less than 30 patients, non-randomized and sequential in nature
so that during the trial patients are assigned the maximum dose considered safe
and tolerable based on available information at that point. A key question in the
conduct of these studies is what dose should be assigned to the next patient who is
about to enroll in the study. There are many different approaches that can be taken,
some are algorithmic, such as the commonly used ‘3+3’ design, others are based
on a statistical model such as the continual reassessment method (CRM) [O’Quigley
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et al., 1990] and variations of it such as the escalation with overdose control (EWOC)
[Babb et al., 1998] design. Model based designs are based on statistical principles
and use information from all the patients in the trial to make decisions on dose
assignment for new patients. Much research has shown that model based designs
are better at estimating the MTD and in treating patients closer to the therapeutic
dose level than the ‘3+3’ design [O’Quigley and Chevret, 1991, Thall and Lee, 2003].
In model based designs an explicit target toxicity rate of say 30% is specified, and
a statistical model is posited for the relationship between the dose and the toxicity.
At the time the new patient is about to enroll the model is fit to the data, then the
dose that would give at or just below the expected target toxicity rate is selected for
the new patient. The form of the statistical model for the relationship between dose
and probability of a dose limiting toxicity (DLT) would usually be simple and have
a smooth, sigmoid, monotonic shape. As the data accumulates during the trial the
model is refit, leading to possibly a different dose assignment for the next patient.
The initial patients in single-dose trials are started off in their first cycle of treat-
ment at low dose levels and even if they continue to receive multiple doses on addi-
tional cycles only the data from the first cycle is used when deciding the dose level
for the next patient. A clinical drawback of considering the outcome measure to be
based on just the first one or two cycles, is what if there is a DLT at a later cycle,
it would probably be important to take that into consideration in recommending a
dose to use in the future. [Postel-Vinay et al., 2011] showed that DLT’s do frequently
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occur in later cycles. From an ethical standpoint this design could be improved by
allowing patients to receive the highest dose level that is the most safest and by using
the data from all the patients in the trial when making dose assignment decisions.
Trials that allows multiple doses per patient, impose restrictions on the dose assign-
ment choices available to the patients wherein patients are administered the same
dose level on all the cycles. Such restrictions prevent patients from escalating to a
higher dose level and receiving more of the study drug when other patients in the
trial are performing well and vice versa the patients are prevented from de-escalating
to a lower dose level in the event that many toxicities are observed in the trial from
the other patients.
The benefit of accelerated titration designs was recognized by [Simon et al., 1997]
who provided the rationale for allowing patients to vary doses across cycles. [Simon
et al., 1997] considered a random effects models to simulate data with separate
toxicities measures for each cycle. This model was used to simulate data for the
evaluation of the accelerated titration method, but the model was not used for data
analysis and trial conduct. Motivated by considerations of pharmacokinetics [Leg-
edza and Ibrahim, 2000] developed a model for repeated toxicity measures for each
patient. Their model included a random effect to allow for different levels of frailty
for a person, giving within subject correlation, and also included a term to represent
cumulative effects of toxicity. However, they had considerable computational diffi-
culties in fitting their model and eventually a much simplified version of the model
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was able to be fit without estimating the random effects. More recently [Doussau
et al., 2013] presented models incorporating ordinal outcomes from patients receiv-
ing multiple cycles of doses. One of the major drawbacks of these models is that
they only apply to situations in which the patients receive the same dose level on
all the cycles thereby taking away the advantages of intra-patient dose escalation or
de-escalation described earlier.
If a patient does experience a toxicity on any cycle they are typically taken off
the study and they would not provide further data for the assessment of toxicity.
Denoting 0 to represent no dose limiting toxicity (DLT) and 1 to represent a DLT
from a dosing cycle, where the National Cancer Institute [NCI, 2003] criteria of
grading toxicities defines grades higher than 3 as a DLT. The data for each patient
would either consist of a series of zeroes (for example 000000) or a series of zeroes
followed by a one (for example 001). While a subject-specific random effect is an
appealing way to incorporate concepts of frailty, it is clear that fitting models with
random effects to the above type of data is going to be very challenging.
This dissertation presents a new approach of using conditional probability of
toxicity to model the dose-toxicity relationship in patients with multiple cycles of
the study drug assuming that further drugs are given only if the patient had no
DLTs in the previous cycles. The use of conditional Markov models is the novel
unifying idea in the three chapters of the dissertation.
In Chapter 2 the conditional Markov model in presented in a phase I setting.
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We develop a two-state Markov model, with the states being 0 and 1. State 1 is
considered a terminating state occurring when a patient experiences a DLT. The
model is presented for five dose levels assuming that patients in the study would
receive doses until completion of six cycles without a DLT. We adopt a Bayesian
approach to estimation and to provide improved small sample performance of the
estimates we utilize informative priors that can be solicited from experts prior to the
trial. Parameter estimation by allowing patients to vary dose levels over the course of
the trial will be demonstrated. Additional simulations to demonstrate the potential
benefits of analyzing data from all the patients over all the cycles as opposed to
reducing it to a single binary outcome per patient will be presented. Finally the use
of the model in designing and executing a sequential trial will be presented.
Chapter 3 focuses on the applicability and extensions of the conditional Markov
model in modeling the data generated from a completed phase II clinical trial. Data
from the oncology trial conducted by [Chugh et al., 2007] is used as an example. In
this randomized phase II clinical trial two dose levels of the study drug ifosamide
were tested over four cycles in patients having soft tissue sarcoma. Various models
incorporating covariates are proposed to correctly specify the dose-toxicity relation-
ship. Priors are developed for the parameters in the model and the flexibility offered
in including additional covariate terms is demonstrated both via simulations and
through the example dataset.
Chapter 4 provides extensions to the concept of modeling the conditional proba-
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bilities in a phase I setting with three ordinal outcomes; severe, mild or none toxicity
in the response. The dichotomized conditional Markov model is modified to account
for the mild toxicity responses in the past and its use is demonstrated in the con-
duct of an adaptive clinical trial. The benefits of using the ordinal outcomes are
presented via simulations when compared to the initial two-state Markov model pre-
sented in Chapter 2. To conclude Chapter 5 presents an overall discussion of the
proposed conditional Markov models and considers a number of potential extensions
and modifications of these models in other settings.
CHAPTER 2
Adaptive Phase I Clinical Trial Design Using
Markov Models for Conditional Probability of
Toxicity
2.1 Introduction
A key question in the conduct of dose-finding phase I trials in oncology is what
dose should be assigned to the next patient who is about to enroll in the study. The
algorithmic approach could use ‘3+3’ design [Storer, 1989] while a statistical model
based approach could use the continual reassessment method (CRM) [O’Quigley
et al., 1990] and variations of it such as the escalation with overdose control (EWOC)
design [Babb et al., 1998]. Much research [O’Quigley and Chevret, 1991, Thall and
Lee, 2003] has shown that model based designs are better in estimating the maximum
tolerated dose (MTD) and in treating patients closer to the therapeutic dose level
than the ‘3+3’ design. In such model based designs a smooth, sigmoid, monotonic
7
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shape is posited for the relationship between the dose and the probability of toxicity
and an explicit target toxicity rate of say 30% is specified. When a new patient is
about to enroll the model is fit to the data, and the dose at the acceptable expected
target toxicity rate is selected for the new patient. As the data accumulates during
the trial the model is refit, leading to possibly a different dose assignment for the
next patient.
Because the trials typically start at a cautiously low dose level, some of the pa-
tients, especially early on in the study, are treated at a low dose level and hence
probably receive limited benefit from the treatment. [Simon et al., 1997] provided
the rationale for the accelerated titration design, where patients were allowed to re-
ceive different doses on each cycle. A random effects model was used to simulate
the toxicities that could occur on different cycles. Motivated by pharmacokinetic
considerations [Legedza and Ibrahim, 2000] developed models for repeated toxicity
measures for each patient by including a random effect to account for patient corre-
lation and a term for capturing the cumulative effect of toxicity. Due to considerable
computational difficulties in fitting the model, owing to the nature of the data, they
were only able to fit a much simplified version.
If a patient does experience a dose limiting toxicity (DLT) on any cycle they are
typically taken off the study not providing further data for the assessment of toxicity.
If 0 represents no toxicity from a cycle and 1 represents a DLT then the data for each
patient would either consist of a series of zeroes (for example 000000) or a series of
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zeroes followed by a one (for example 001). While a subject-specific random effect
is an appealing way to incorporate concepts of frailty, fitting models with random
effects to such example data is challenging. In this chapter as an alternative we
develop a two-state Markov model, with the states being 0 and 1. Because 1 is a
terminating state, we only need to consider the transition probabilities out of state
0. We explicitly model conditional probabilities of toxicity in a cycle given that the
patient is toxicity-free to date. At the first cycle the probability of toxicity depends
just on the dose, at later cycles the conditional probability of toxicity can depend
on additional covariates such as the cumulative dose and the maximum of the past
doses.
The model includes a number of parameters, which need to be estimated from
the data. Since we envision that the model would be fit during the conduct of the
trial, an estimation method is necessary that can be used even for small sample sizes,
as would be the situation early in the trial. We adopt a Bayesian approach and to
provide improved small sample performance of the estimates we utilize informative
priors that can be solicited from experts prior to the trial.
Once the parameter values are known the form of the model allows a number of
different calculations to be made. For example, the probability of toxicity on the
next cycle as a function of dose can be calculated. Also the probability of toxicity on
any future cycle can be calculated, and this will be a function of the sequence of doses
that will be given on each of the future cycles. This raises an interesting question
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as to how to select the next dose. Should it only be influenced by the probability of
toxicity on the next cycle, or should a more long term horizon be taken into account
and the probability of toxicity at any future time be considered. In selecting the
dose for the next cycle it may be beneficial to think not just about the dose for that
cycle, but also the doses for future cycles.
Since the design allows for intra-patient dose changes during the conduct of the
trial, the recommendation at the end of the trial could also be a sequence of doses,
which vary from one cycle to the next. Wild between-cycle variations in the recom-
mended dose level are unlikely to be clinically acceptable, however a modest variation,
such as dose level 3 for the first 2 cycles, then dose level 4 for the last four cycles,
could be envisioned. Allowing for intra-patient dose variation also presents another
practical concern. At the end of the trial a recommended schedule of doses will be
provided, yet no patient in the trial may have exactly followed this regimen. Thus
another consideration in deciding the next dose for each patient, is that the schedule
of doses for that patient should be one that could be recommended at the end of the
trial, or at least close to one that it is conceivable to recommend.
In Section 2.2 we describe the Markov model providing intuition on model fea-
tures. The Bayesian estimation method is described, with consideration given to
the selection of the prior distributions. In Section 2.3 we evaluate properties of the
estimation method in a static situation of a small and a moderate sample size. In
Section 2.4 we consider using the model in the design and conduct of a trial and
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consider optimality criteria for choosing the next dose for a patient. We evaluate the
designs and compare them with some simple alternatives. We end with a discussion
in Section 2.5.
2.2 Methodology
2.2.1 Notation and data structure
We assume that there are five increasing dose levels of an experimental study
drug represented by dg, g = 1, . . . 5, that will be studied in i = 1 . . . N patients.
Each patient i completes Ki ≤ 6 cycles, where Ki may be less than six if a patient
experiences a DLT or if the patient drops out for other reasons. On each cycle
k = 1, . . . , Ki, patient i receives a dose di,k equal to one of the five values of dg.
A patient’s cumulative dose prior to cycle k = 1, . . . , Ki is Di,k =
∑k
j=1 di,j−1, so
that Di,1 = 0. We also use the notation that di,k−1 = 0 for cycle k = 1 and
d‡i,k = max(di,1, . . . , di,k−1), the maximum of doses assigned to patient i until current
cycle k.
The occurrence of a DLT for patient i on cycle k is Yi,k, with Yi,k = 0 indicating
no DLT and Yi,k = 1 for a DLT. Patients stop receiving the drug if they experience
a DLT thus the possible patterns of Yi,k values for a patient are a sequence of zeroes
or a sequence of zeroes followed by one. The observed data after n patients have
enrolled in the trial is {(Yi,1, . . . , Yi,Ki , di,1, . . . , di,Ki), i = 1, . . . , n}.
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2.2.2 Proposed Markov model
We propose Model 2.1 for the conditional probability of toxicity, pi,k = P (Yi,k =
1|Yi,k−1 = 0, . . . , Yi,1 = 0), for patient i on cycle k given that patient i has experienced
no previous DLTs as,















The term (di,k− ρd‡i,k)+ is, equal to (di,k− ρd
‡
i,k) if di,k > ρd
‡
i,k, and is zero otherwise.
Intuition behind Model 2.1 can be appreciated by starting with the first cycle, k = 1,
when pi,1 = 1−exp(−αdi,1) and only α comes into play in explaining the dose related
toxicity. To obtain valid probability estimates, α ∈ [0,∞] so that pi,1 ∈ [0, 1] is
an increasing function of di,1. Note that we do not need to develop a model for
P (Yi,k = 1|Yi,k−1 = 1) since once a patient develops a DLT at cycle k − 1 no further
dose is administered to the patient.
On subsequent cycles we have two different terms to account for the conditional
probability of toxicity. The first term (di,k − ρd‡i,k)+ accounts for difference between
the current assigned dose di,k and a factor (ρ) of the maximum of the previous doses
13
d‡i,k, while the second term tries to capture the effect of the cumulative dose Di,k.
The parameter ρ can be thought of as reflecting the amount of memory about




the difference between the current assigned dose and the maximum of the previous
doses. If the current dose is less or equal to the maximum of the previous doses, the
difference will be zero and will not contribute towards the probability estimate i.e.,
there is a strong memory that a dose equal to or higher than the current dose was
tolerable hence the current dose is more likely to be tolerable. When ρ = 0, the term
(di,k − ρd‡i,k)+ reduces to di,k and implies that there is no memory of the previous
doses that had been tolerated. Intermediate values of ρ between zero and one have
intermediate amount of memory. Thus this term tries to capture the within-patient
correlation between dose cycles.
The term βdi,kDi,k, β ≥ 0 is designed to capture the idea that there may be
“damage” accumulated from prior doses and the amount of this “damage” plays a
role in determining the probability of toxicity when a new dose is administered. This
term is constructed so that the contribution of the cumulative dose is in proportion
to the current dose di,k and will not be relevant if di,k = 0.
Figure 2.1 plots the conditional probability of toxicity for different instances of
α, β and ρ and aids in understanding the working properties of the Markov Model
2.1. The solid line with open circles shows the probability of toxicity for the first
cycle at each of the five dose groups. The curve is the same in all the nine panels
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since the probability of toxicity on the first cycle is influenced only by α which is the
same in all the instances. The dashed line with crosses corresponds to the conditional
probability of toxicity on the second cycle assuming that patients have received dose
level three with no DLTs on cycle 1 and any one of the five dose levels on the second
cycle. In the top left panel with β = 0, ρ = 0 cycle 2 gives probabilities equivalent to
those seen in cycle 1. This is because there is no cumulative effect of dose (β = 0) and
patients surviving the first cycle are treated as though they are similar to patients
on cycle 1 with respect to chance of toxicity since (ρ = 0) i.e., no memory. The
first row from left to right indicates that increasing β gives increasing probabilities
of toxicity on cycle 2 even when ρ = 0. Panels in the first column from top to
bottom indicate that when there is no cumulative effect of dose (β = 0) on cycle 2
increases in ρ make patients less likely to experience a toxicity. For instance ρ = 1
suggests that all patients who would have experienced toxicity at dose level three
(di,1 = d3) were eliminated from the trial during cycle 1 resulting in probability of
toxicity equal to zero until di,2 > d3 in the lower left panel. Hence toxicities in cycle
2 are both a function of patient selection in subsequent cycles as influenced by ρ as
well as cumulative dose effects as influenced by β
2.2.2.1 Comparison to existing models
This section provides a brief comparison of the dose-toxicity relationship captured
by the Markov Model 2.1 compared to alternative models. [Simon et al., 1997]
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modeled a latent continuous toxic response Wi,j for person i at time period j as,
Wi,j = β
S




where dSi,j is the dose for person i at time j, D
S
i,j is the ith person’s cumulative
dose prior to time j and the two random effect terms, βSi ∼ N(µβS , σ2βS) accounting
for inter-patient variability or frailty and εi,j ∼ N(0, σ2ε ) representing the intra-
patient variability. This model was used to model data generated from a trial using
a pre-defined escalation plan with the continuous toxicity response categorized into
different levels using pre-defined thresholds. On the first cycle there is no cumulative
dose and there is no parameter to capture the contribution of the current dose dSi,j
which is simply reduced to a log transformed term, βSi and εi,j are the only terms that
help in explaining the effect of the first dose. On subsequent cycles αS captures the
effect of the cumulative dose and can be likened to the β parameter in the Markov
model. The effect of the current dose is not captured by any parameter but is tied
in with the σ2ε which also tries to capture the intra-patient dose dependency. Hence
in broad terms βSi can be likened to the α term and σ
2
ε to the ρ term in the Markov
model. The Markov Model 2.1 has one less parameter to estimate and yet provides
a similar explanation of the dose toxicity profile.
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[Legedza and Ibrahim, 2000] proposed the use of clearance rate λL for cumulative
effects. The form of their model is as follows,
logit(pLi,j) = ε
L + βL log(dLi,j +D
L
i,jexp(−λL)) (2.3)
where pLi,j and d
L
i,j is the probability of toxicity and the dose for person i at time j
respectively, DLi,j is the ith person’s cumulative dose prior to time j. The ε
L term
is not patient or cycle dependent. A simpler model which excluded the εL term was
also considered. Due to the in-feasibility in estimating λL with small sample sizes
the clearance rate was assumed to be a constant, λL = log(2). The model has a
fixed intercept and the effect of the current dose is captured by βL while λL captures
the effect of the cumulative dose. Legedza’s model needs the estimation of only two
parameters and in the absence of the εL term a single parameter βL, however it does
not capture any dependency between the response of a patient on different cycles.
Notice that Legedza’s model has increasing probability of toxicity with dose on
subsequent cycles. There is no concession given to the patient for surviving a higher
dose level on the first cycle. In comparison the Markov model 2.1 allows the toxicity
on the second cycle to be higher or lower than that on the first cycle. Depending
upon the cumulative effect of the dose, patients surviving a higher dose on the first
cycle are less likely to have a toxicity on the second cycle and the model adequately
accounts for this.
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A third approach using a cure rate model for estimating the cumulative effect of
multiple administrations of the study drug is provided by [Zhang and Braun, 2013].
This approach considers multiple dose levels administered to patients at fixed time
points with a goal to select the optimal dose level and schedule (regimen) at the
end of the study. Individual hazard contributions from the doses are summed up in
estimating the cumulative effect of the multiple administrations. A cure rate model
is used to describe the hazard function. The hazard of a DLT at time t following
administration of dose d1 at t1 is given by the formula, h(t) = θi,1F (νi,1|φ). Thus
the probability of having a DLT in an interval (tk, tk+1) can be calculated by solving
the integral, pk = exp(−
∫ tk+1
tk
h(u)du). Zhang et al assumes that the time to DLT
from any of the individual administrations is independent in contrast to the Markov
model that considers the dependency between patient responses through the concept
of frailty in ρ. This also leads to the second difference where the probability of
toxicity (defined via the hazard) is assumed to increase with dose administrations
while the Markov model allows flexibility for a decrease in probability on the second
cycle. The Markov Model 2.1 assumes that the observed response in a cycle is
due to the drug administered during that cycle while in Zhang’s method, doses are
administered based on a schedule until the toxic response is observed allowing for
delayed toxicities which are not allowed in the Markov model. Although the Markov
model is presented for six cycles the final recommendation of the regimen could be
made for cycles less than six that provide an acceptable overall probability of toxicity
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which is similar to the idea used by Zhang in schedule selection.
[Pye and Whitehead, 2012] presented at a conference a Bayesian designs for phase
I clinical trials in cancer by assuming the the observations arose as interval-censored
from a survival model. They used a generalized linear model to represent the relation-
ship between the probability of experiencing a DLT during cycle j of the treatment
conditional on there being no DLT prior to cycle j on dose level k in a time to event
(survival) setting. The probability of observing a toxicity on cycle j assuming dose
level k has been administered is given by pPk,j and estimated using the model:
pPk,j = 1− exp(−exp(γj + βP log(dk))) (2.4)
A Beta prior is assigned on pPk,j by incorporating prior beliefs through pseudo-data.
Parameters estimates are found using GLM software. Their model would have to
estimate j + 1 parameters, corresponding to the j dosing cycles and the effect of the
dose. For the particular case with six cycles a total of seven parameters would have to
be estimated, in contrast the Markov model estimates only three parameters. Their
model also assumes proportional hazard across the dose levels and requires that the
same dose level be given on all the cycles. There is no parameter to account for the
cumulative effect of the dose. The conditional aspect of the model is similar to our
Markov model and shares the same feature of estimating the probability of toxicity
on all the cycles.
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More recently [Doussau et al., 2013] provided a mixed effects proportional odds
model to incorporate ordinal outcomes in a phase I setting to describe the probability
of a severe toxicity and the trend in the risk of toxicity with time. This method
does not explicitly model the tendency to discontinue cycles for patients who have
demonstrated previous DLT, although the resulting estimated toxicity rates may be
conditional in nature. In addition the cumulative effect of the dose is not captured
and patients are not allowed to escalate or de-escalate doses. The details of this
method will be discussed further in Chapter 4 when the ordinal Markov model is
presented.
2.2.3 The likelihood, prior and posterior distributions
2.2.3.1 Probability Skeleton
The dose levels to be studied are transformed to dg via pre-specified skeleton prob-
abilities denoted by qg. The skeleton probabilities incorporate prior beliefs about the
dose-toxicity relationship and correspond to the probability of observing a toxicity
on the first cycle for each of the dose levels. In our set up of the Markov model
the probability of toxicity on the first cycle is given by ln(1 − pi,1) = −αdi,1 and
does not depend on ρ and β. The doses dg are obtained by transforming qg via
dg = − ln(1 − qg) and thereby setting the prior mean on α = 1. Similar transfor-
mations are described by [Lee and Cheung, 2009] in the context of the CRM and
have been used by many other authors in other contexts [Lee et al., 2011, Cheung
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and Elkind, 2010]. The probability skeleton information can be elicited from prior
animal studies or from the clinicians. In the absence of such information, [Lee and
Cheung, 2009] suggest sensitivity analysis across different skeleton choices.
2.2.3.2 Prior selection and posterior distribution
Based on the study design, patients contribute to the likelihood until they ex-
perience a DLT or the final Kth cycle is completed. That is, a person with toxicity
on cycle Ki gives data (Yi,1 = 0, Yi,Ki−1 = 0, . . . , Yi,Ki = 1, di,1 . . . di,Ki) and the
contribution to the likelihood is,




And a person completing K cycles without toxicity gives data (Yi,1 = 0, . . . , Yi,K−1 =
0, Yi,K = 0, di,1 . . . di,K) with likelihood contribution as




In general, subject i on cycle k contributes Li,k(Yi,k|α, β, ρ) = (pi,k)Yi,k(1− pi,k)1−Yi,k
to the likelihood, with pi,k parameterized as in Model 2.1 and interpreted as the
probability of toxicity on cycle k conditional on having no prior DLTs in previous
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cycles. The resulting likelihood for the entire study population is given by,






Our goal lies in estimating the posterior distribution of pi,k, k = 1, . . . , K in
terms of the posterior distributions of parameters α, β and ρ. Prior distributions on
these parameters should reflect any auxiliary knowledge of the toxicity profile for the
drug/agents being used in the trial, with a large prior variance when this knowledge
is limited. In setting the prior on α, the positive real axis is the permitted range of
values and a lognormal (µ, σ2) is used as a suitable prior having the form




Specifying the prior mean for α as 1 and the prior variance as 4, providing a coefficient
of variance (CV) of 2, µ, σ are estimated using the expressions for the mean and
variance of the lognormal density, E(α|µ, σ) = exp(µ + σ2/2) and V ar(α|µ, σ) =
exp{2(µ+ σ2)} − exp(2µ+ σ2).
On cycles k > 1 we have multiple dose administrations and need to assign priors
on β and ρ. As mentioned earlier in Section 2.2.2 ρ ∈ [0, 1] and captures the corre-
lation within patients receiving multiple doses, with values near zero indicating that
the toxicity outcome is not influenced by previously administered doses and a value
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near one indicating a lower chance of toxicity from a previously administered dose.
A Beta(a, b) prior is used on ρ having density of the form
π(ρ|a, b) = (ρ)a−1(1− ρ)1−b
The hyperparameters are set to a = 5 and b = 1 and using the expressions for the
mean a/{a + b} and variance ab/{(a + b)2(a + b + 1)} the prior on ρ has a mean of
0.833 and variance of 0.02.
The lognormal density is used as the prior on β > 0. In setting the prior mean
for β two approaches could be considered. Based on the construction of the βDi,kdi,k
term its contribution is likely to be much smaller than that of the α(di,k − ρd‡i,k)
term. Arbitrarily set the ratio of these two terms to be 0.2 for patients receiving the
third dose level (dg = d3) on the fourth (k = 4) cycle. Setting ρ = 0.80 and solving
for β provides the mean of the prior on β. The standard deviation (SD) of the prior
is set to two times the mean to provide a coefficient of variation of two. A second
method for setting the prior involves eliciting another skeleton, the probabilities of
completing the entire regimen of K = 6 cycles with no toxicities assuming that the
dose was the same on all the cycles. By setting α = 1 and ρ = 0.80, five different
values of β corresponding to the dose levels dg are obtained. The prior mean is set
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to the mean of these five values of β and the variance is set to either the SD of these
five values or to two times the mean to obtain a CV of two.
The posterior distribution for α, β and ρ given the observed data Y is then













k=1 Li,k(Yi,k|α, β, ρ)πβ(β)πα(α)πρ(ρ)dβdαdρ
.
The posterior distribution of α, β and ρ from Model 2.1 can be estimated via Markov
Chain Monte Carlo (MCMC) methods [Robert and Casella, 1999] using just another
Gibbs sampler (JAGS) rjags [Plummer, 2011] package through [R Development Core
Team, 2011]. JAGS includes several algorithms for sampling from the posterior dis-
tributions produced from the MCMC iterations, for instance the standard Gibbs
sampler is available for this purpose. Details of setting up the MCMC simulations
are given in Section 2.2.4.
2.2.4 MCMC sampling procedure
MCMC is a general method based on drawing values of α, β and ρ from approx-
imate distributions and then correcting the draws to better approximate the target
posterior distribution f(α, β, ρ|Y ) [Gelfand and Smith, 1990, Gilks et al., 1993]. New
samples are drawn based on the current value (the Markov property) and often from
two chains starting at disparate initial values. The goal is to have the simulated
draws trace a path throughout the parameter space of α, β and ρ, this is achieved by
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running the simulations for a large number of draws and monitoring the convergence
through diagnostic tests. The Gibbs sampler is the most frequently used algorithm
for drawing samples in a multivariate set up. At each iteration of the Gibbs sampler,
samples are drawn for each of the parameters conditional on the values of the other
parameters. In practice JAGS uses different samplers for each of the parameters de-
pending on the best choice i.e., ease in simulation and simplicity. Inference is based
on the posterior samples which need to be assessed for convergence. The early sim-
ulation runs known as the burn-in period are discarded, to allow the model to cover
most of the sample space values before drawing values for the posterior distribution.
Assessing the dependence of iterations in each sequence through correlation plots,
helps in determining the need for thinning. If samples are found to have a high
degree of correlation between samples they defy the assumption that subsequent
draws from the posterior are independent. To remedy this issue a thinning factor is
used to discard the samples in the sequence and retain only a subset of the samples.
Monitoring the convergence based on multiple sequences with over disparate starting
or initial values gives rise to mixing of several chains and provides the calculation of
the R statistic or the potential scale reduction factor [Gelman and Rubin, 1992]. The
idea is that the distributions generated from the two separate initial values should
converge to the same target distribution confirmed through the Gelman-Rubin plots
and R statistic which measures whether there is a significant difference between
the variance within several chains and the variance between several chains by scale
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reduction factors. Values lower than 1.1 are considered to be acceptable indications of
convergence. Samples are discarded and additional samples are iteratively generated
until acceptable convergence diagnostics are obtained. Posterior means and other
quantities are then estimated from the final chosen sample.
2.2.4.1 Implementation in JAGS
The JAGS MCMC approach runs in three stages. In the first compilation stage,
the data likelihood and the density definitions of the priors are specified in a model
file saved under a .bug extension. The model file and the data are passed into the
JAGS for compilation along with the list of parameters , α, β and ρ, that have to
be monitored. The number of parallel chains to be run by JAGS are also defined
at the compilation stage, where each parallel chain produces independent samples
from the posterior distribution. At this stage the compiled model also contains the
initial values for all the parameters that are monitored in each of the chains. The
JAGS code is provided in Appendix 2.6.1. In the second adaptive stage, samplers
are automatically assigned by JAGS after a pre-specified adaptive phase for each of
the parameters based on the likelihood definition of the model. In the third burn-
in stage, 10K samples are discarded and finally posterior samples of 100K (thinned
by 20) are used in simulations presented in later sections. Before using the samples
from the two chains for reporting they are monitored and assessed through diagnostic
tests. The correlation between samples generated at each iteration of the MCMC
26
chain for each of the parameters needs to be sufficiently low. The posterior means,
α̂, β̂ and ρ̂ of the three parameters, are used to calculate the various probabilities of
interest.
2.3 Operating characteristics/Results
All simulation results presented in this section demonstrate the estimation of pa-
rameters assuming that all the patients have completed the trial. This section studies
the following model properties when used in estimating the conditional probabilities
1) the effect of the priors on parameter estimation, 2) the efficiency gains obtained
in the parameter estimates when patients are allowed to have dose escalation and/or
de-escalation over multiple cycles and lastly 3) demonstration of the benefits in us-
ing the Markov Model 2.1 in comparison to two different models with single binary
endpoints.
2.3.1 Effect of priors on estimation
The effect of the degree of informativeness as defined by the SD of the priors in
estimating the parameters is explored in this section via simulations. In addition the
robustness of the estimation process to prior misspecification when the mean of the
prior does not coincide with the parameter true values used in generating the data
is also studied. A total of 500 datasets were generated under four different cases
and using the skeleton probabilities qg = (0.02, 0.05, 0.10, 0.15, 0.23). In the first and
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second case, true values of the parameters were α = 1, β = 0.5 and ρ = 0.8 which
were changed to α = 0.8, β = 0.5 and ρ = 0.8 in the third case and α = 1, β = 0.8
and ρ = 0.8 in the fourth case. The N = 30 patients were distributed equally to
receive one of the five dose levels on all the cycles until completion of K = 6 cycles
or occurrence of a DLT.
The degree of informativeness in the priors differed at the estimation stage. The
prior means E(α) = 1 and E(β) = 0.5 were the same in all the four cases and
matched the true value in Cases 1 and 2 but differed from the true values in Cases 3
and 4. The SD was set to two times the mean, SD(α) = 2 and SD(β) = 1 in Cases
1, 3 and 4. In the second case the prior standard deviations were set to five times
the mean, SD(α) = 5 and SD(β) = 2.5. In all the four cases Beta(5, 1) prior was
used on ρ.
The parameter estimates from the 500 simulated datasets are presented in Table
2.1 with the rows grouped by the four cases. The four columns report (1) the
true value of the parameters, (2) the mean and SD of the prior, (3) the mean of
the estimated values from 500 datasets and the mean bias from the true value in
parenthesis, (4) the mean SD (MSD) of the estimates from 500 datasets, (5) the
empirical SD (ESD) of the 500 estimates, (6) the coverage rate of the 95% credible
interval across the 500 datasets. Results indicate that the bias in parameter estimates
is low except for β in Case 4. The mean SD is slightly higher than the ESD giving
slightly conservative estimates of variability that lead to higher coverage rates. The
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MSD of the estimates is lower than the prior SD for α and β but comparable in the
case of ρ indicating minimal information in estimating this parameter.
The probability estimates obtained from the 500 simulated datasets are presented
in Table 2.2 grouped by the four cases and each of the rows corresponding to one
of the five dose levels. The columns indicate the mean estimate of the conditional
probability of toxicity on the first, the second, the sixth cycle and the overall prob-
ability of toxicity on any of the cycles along with the bias from the true values in
parenthesis. The results suggest that the model performs suitably, even with prior
misspecification, in estimating the true values. It was decided to use the prior from
the first case for the simulation results presented hereafter.
2.3.2 Properties of parameter estimates with intra-patient dose variabil-
ity
The simulation results presented in Section 2.3.1 assumed that the patients were
assigned to receive the same dose level on each of the six cycles. This section explores
the effects on estimation in the presence of dose heterogeneity within each patient
i.e., allowing patients to have dose escalation and de-escalation across the six cycles
assuming that there are a total of N = 30 patients in the trial. In actual trial
conduct we would have dose combinations that are sensible and that do not vary
at every cycle. For instance in a regimen of six cycles we might expect to have the
first three cycles on d1 and then switch to d2 on the subsequent cycles, implying that
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dose escalation happened on the fourth cycle. A typical combination of de-escalation
might include higher doses d3, d4 or d5 on the first three cycles and the lower dose
on the next three cycles. Given that we have five dose levels it is possible to have
P 52 = 20 different combinations of two doses at a time with either escalation or
de-escalation. In general we do not allow patients to skip dose levels and ignoring
such dose combinations results in eight assignable combinations, d1d2, d2d3, d3d4, d4d5
and d2d1, d3d2, d4d3, d5d4 where patients change their dose level on the fourth cycle.
Additional dose combinations include three dose levels with changes on cycle three
and cycle five of the form, d1d2d3, d2d3d4, d3d4d5 and d3d2d1, d4d3d2, d5d4d3, providing
another six combinations. In total there are 19 possible treatment courses including
the five without dose variation listed in Table 2.3.
In the simulation results presented earlier with N = 30 patients there was an
equal distribution of patients over the five dose levels dg, with each of the six patients
having the same dose level on all the six cycles. This gives 36 assigned cycles for
every dg i.e., d1 is assigned 36 times, d2 is assigned 36 times etc.. To obtain a fair
comparison to the current setting, the N = 30 patients were assigned to each of the
19 combinations while ensuring that there were 36 cycles of each of the dose levels.
The dosing profile of these 30 patients is given in Table 2.25 in the Appendix 2.6.3.
The skeleton probability used for the dose transformations is dg is qg = (0.02, 0.05
, 0.10, 0.15, 0.23) similar to the one used in earlier simulations. A total of 500 datasets
were simulated with patients having regimens as listed in Table 2.25. Conditional
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probability of toxicity, pi,k, for each patient i at each cycle k was calculated using
the Markov Model 2.1 for fixed values of α = 1 and β = 0.5 and ρ = 0.8 and their
probabilities were used to simulate toxicities. Priors on the parameters used were
similar to those in the previous analyses.
The results of the parameter estimates from the simulations are presented in
Table 2.4 under Section 2.3.2. The corresponding parameter estimates from Case
1 in Table 2.1 are placed under Section 2.3.1 for easy comparison. We notice that
the bias and mean SD of α is slightly lower in Section 2.3.2 but that of β is slightly
higher.
Table 2.5 presents the corresponding probability estimates. The columns present
the probability of toxicity estimates with the bias from the true value in parenthesis
and the empirical SD (ESD) of the estimates from the 500 replicates. The results
indicate that the bias is comparable but the variability across simulation goes down
slightly when patients have the same dose. We conclude that there were no problems
in fitting the model by allowing patients to have dose variability and that the results
do not have major deviations with regard to the bias and efficiency.
2.3.3 Comparison with models for a single binary endpoint
This section explores the potential gains in using all the data from the six cycles
in estimating the probability of toxicity on the first cycle or on any cycle using the
Markov Model 2.1 versus models with a single binary end point per patient. We
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consider the special case with no dose variation across cycles.
Simulation results are presented based on 500 datasets each having either N = 10
and N = 30 patients, distributed equally to receive one of the five doses dg for a
maximum of K = 6 cycles. The probability skeleton used for the doses is qg =
(0.02, 0.05, 0.10, 0.15, 0.23). For every patient i assigned to dose dg on cycle k the
probability of a toxic response pi,k is calculated using the Markov Model 2.1 and
known values of α = 1, β = 0.5 and ρ = 0.8. A DLT response Yi,k is assigned based
on a Bernouli(pi,k) random draw. A patient i continues to receive the same dose on
cycle k + 1 until Yi,k = 1, k < 6 or k = 6.
As mentioned earlier in Chapter 1 existing methods for analyzing trials with
multiple cycles for a single patient either consider the data only from the first cycle
in estimating the probability of toxicity ignoring the toxicities that happen on later
cycles or consider an overall toxic response that might have occurred on any of the
cycles. In either of the two cases the data for each patient is reduced to a single
binary outcome.
Continuing with the notation from the Markov Model 2.1, in the first instance
the data is reduced to a single binary outcome by defining Ỳi = 1 for patient i if
Yi,1 = 1 and Ỳi = 0 if Yi,1 = 0. The probability of toxicity, p̀i, on the first cycle is
given by Model 2.7 as follows,
ln(1− p̀i) = −γdi. (2.7)
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The prior on γ is similar to that used on α, a lognormal density with mean one and
variance four.
In the second instance the data is reduced to a single binary outcome Y ′i = 1,
across all of the cycles for each patient i if Yi,j = 1, for any j ≤ 6 and Y ′i = 0 if
Yi,6 = 0. The Model 2.8 used in estimating the probability of toxicity on any cycle,
p′i in this case is,
ln(1− p′i) = −δd′i. (2.8)
Where the probability of toxicity on any of the six cycles (mj) corresponds to





with pi,j as defined in equation 2.6. The doses d
′
i are based on using a probability
skeleton (m1,m2,m3,m4,m5) corresponding to having a toxicity on any of the six
cycles. We then assume that δ has a lognormal prior distribution with mean of one
and variance four.
Results in Table 2.6 indicates adequate model fit for the parameters from Markov
Model 2.1 and Models 2.7 and 2.8. Table 2.7 presents the simulation results from
comparing the Markov Model 2.1 to the two alternatives, Model 2.7 and Model 2.8.
The rows are grouped based on the comparison with Model 2.7 or Model 2.8. The
columns are grouped by N = 10 and N = 30 patients and present the probability
33
of toxicity estimates with the bias in parenthesis and the Empirical SD (ESD) of
the 500 estimates. Comparing the results from N = 10 and N = 30 patients we
notice that there is a gain in efficiency and decrease in the bias for all the three
models for the larger sample size. The efficiency is slightly higher with comparable
bias in the estimates from the Markov Model 2.1 in comparison to both the simpler
models. We conclude that there is mild gain in efficiency especially when using
N = 10 patients and no harm is done is fitting a larger model. The slight gain
in efficiency in comparison to Model 2.8 could be attributed to fact the Markov
Model 2.1 incorporates the cycle specific information in the process of estimating the
parameters and hence provides better overall estimates of the probability of toxicity.
2.3.4 Comparison with models for a single binary endpoint with unequal
subjects at the dose levels
In the previous Section 2.3.3 the comparison of the Markov Model 2.1 with the
alternative two models was presented when the patients were distributed equally over
all the dose levels. In practice there is unequal distribution of patients in a trial at the
various dose levels. Simulations results in this section explore the differences in the
estimation when there are 3, 3, 10, 10 and 4 patients assigned to each of the five dose
levels in a trial with a total of N = 30 patients. In the case with N = 10 patients the
distribution of the patients was 1, 2, 3, 3 and 1 among the five dose levels. Keeping
all other features of the data generation unchanged from the equal patient per dose
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level case described in Section 2.3.3 a total of 500 datasets were simulated. Table
2.8 presents the results of the parameter estimates for the three models while Table
2.9 presents the probability estimates from comparing the Markov Model 2.1 to the
two alternatives, Model 2.7 and Model 2.8.
Comparing the results from N = 10 and N = 30 patients in Table 2.9 we notice that
there is a gain in efficiency and decrease in the bias for all the three models. The
bias is lower and the efficiency is higher in the estimates from the Markov Model
2.1 in comparison to the Binary Model 2.7. In the case of comparison to the Binary
Model 2.8, either the bias or the empirical SD of the estimates is lower in Markov
Model 2.1 if not both simultaneously.
2.4 Implementation of a clinical trial
This section describes the application of the Markov Model 2.1 in designing a
sequential clinical trial. The safety criteria for dose assignment, two possible plans
in conducting the trial and the evaluation of the trial properties are considered.
2.4.1 Safety Criteria
We begin by defining the safety criteria rules for dose assignment in carrying out
a trial with dose escalation and/or de-escalation. Define rg,k = g, g = 1 . . . 5 as one
of the five dose levels on cycle k corresponding to dg, g = 1 . . . 5 the transformed
doses using the probability skeleton. Let rmaxg,k+1 denote the maximum allowed dose
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that could be assigned on cycle k+ 1. The following commonly used dose escalation
rules will be followed in defining the safety criteria to be used while carrying out an
adaptive clinical trial based on Markov Model 2.1.
• The first and the second patient on the trial will be assigned the second lowest
dose level, rg,1 = 2, on cycle 1, allowing the lowest dose level to be eligible for
future patients if DLTs are seen in the first few patients on study. For the first
patient if there is no DLT, the same dose level is assigned on the second cycle.
For subsequent patients and cycles the following rules will be effective.
• Patients are allowed to escalate by one dose level from their previous dose, i.e.,
a patient tolerating dose level rg,k on cycle k can be assigned doses no higher
than min(rg,k + 1, 5) on cycle k + 1.
• A patient can experience a maximum of three dose levels in a dosing regimen,
unless de-escalation to a lower dose is required. I.e.,a patient tolerating dose
level rg,1 on cycle 1 can possibly receive rg,1 + 2, as its highest dose level in the
dosing regimen. In combination with the previous rule a patient tolerating dose
level rg,k on cycle k can be assigned doses no higher than r
max
g,k+1 = min(rg,1 +
2,rg,k + 1, 5) on the cycle k + 1.
• For each new patient being assigned a dose level on cycle 1, the maximum dose
level choice would be limited to rmaxg,1 = max(r
‡





maximum of all the past dose levels assigned to the patients on cycle k = 1
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and r‡g,k is the maximum of all the past dose levels assigned to the patients in
the study on cycles k > 1. This ensures that the new patient may only jump
one dose level from previously assigned cycle 1 doses and may not exceed doses
experienced on the trial otherwise.
• The study will conclude when none of the dose levels are included in the tolera-
ble range as determined by the safety criteria defined below or the N th patient
has completed the trial.
2.4.2 Defining the eligible regimen set, Rregimeni,k
Typically in single dose, single cycle trials one assumes a toxicity bound of, say,
30%. Then the current estimate of the probability of toxicity for each dose is com-
pared with this bound to decide on the next dose. Defining bounds is more complex
when patients can receive multiple doses on multiple cycles. We will consider the
probability of toxicity for the next dose, for the whole sequence of doses and for the
sequence of future doses. Let P̊ (A) = {P̊ (A1), . . . , P̊ (AK)} be a vector of acceptable
toxicity limits for each cycle 1, . . . , K. It is convenient to restrict limits for cycles
2, . . . , K to be equivalent and equal to P̊ (A2), rather than justify different acceptable
toxicity levels at each cycle. Define P̊ (C) as the upper limit of the acceptable prob-
ability of toxicity across all K cycles, and for patients who have already completed
at least one cycle let P̊ (B) be the acceptable probability of toxicity limit on all the
remaining cycles.
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In general, for the bounds to be consistent with one another, we require {1 −
P̊ (C)} ≤
∏K
k=1{1−P̊ (Ak)} and {1−P̊ (B)} ≤
∏K
k=2{1−P̊ (Ak)}; these further reduce
to {1− P̊ (C)} ≤ {1− P̊ (A1)}×{(1− P̊ (A2)}K−1 and {1− P̊ (B)} ≤ {(1− P̊ (A2)}K−1
when we assume the limit P̊ (A2) for cycles 2, . . . , K. In practice, one selects bounds
for P̊ (A1) and P̊ (C), and this automatically places restrictions on P̊ (A2) and P̊ (B).
For instance with P̊ (A1) in the range of 0 − 0.2 and setting P̊ (C) as either 0.30 or
0.40, legitimate values for P̊ (A2) are presented in Table 2.10. So for P̊ (A1) = 0.20,
P̊ (C) = 0.30, we find that P̊ (A2) can be no larger than 2.64% and P̊ (B) can be no
larger than 12.5% so that conditional probabilities of toxicity on later cycles 2, . . . , K
are very small.
Monitoring the safety of the patients is ensured by assigning doses that sat-
isfy the set of safety criteria defined in Section 2.4.1 as well as satisfy the bounds
P̊ (A1), P̊ (A2), P̊ (B) and P̊ (C) defined above.
In general denote dosing regimens by the vector of doses across the K cycles
(rg,1, . . . , rg,K). As each patient progresses through cycles k = 1 . . . K, members m of
the set of eligible regimens denoted by Rregimeni,k change over time as experience on the
study matures. For instance, on cycle k, potential members m, of Rregimeni,k for patient
i take the form (oi,1, . . . , oi,k−1, rg,k, rg,6) where oi,k denote previously tolerated doses
for patient i on cycle k and future assigned doses (rg,k, . . . , rg,6) must not exceed r
max
g,l
for l = k, . . . , 6 and must not conflict with bounds defined by P̊ (A1), P̊ (A2), P̊ (B)
and P̊ (C). For a patient on cycle 1, it is convenient to limit members of Rregimeni,1 to
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reduce computation. Table 2.3 lists a set of desirable regimens that can be used to
construct a limited version of Rregimeni,1 satisfying safety constraints.
The following random variables are useful to collect and statistically summarize
immediate and accumulated toxicities during the conduct of the trial. Define Ai,k,j
as the event of toxicity on cycle k for patient i at dose level j given that there
were no DLTs in the past. Hence P(Ai,k,j) = pi,k, where pi,k is calculated using the
Markov Model 2.1 for dose level j, and current estimates of α̂, β̂ and ρ̂ can be used
to define its corresponding estimate, P̂ (Aî,k,j) = p̂i,k. Define Bi,k,m as the event of
having a toxicity on any remaining cycle k until K for a member m of the regimen
set Rregimeni,k , where P(Bi,k,m) = 1−
∏K
l=k(1− pi,l) and P̂ (Bi,k,m) = 1−
∏K
l=k(1− p̂i,l).
Also define Ci,k,m as the event of toxicity for a future patient assigned to regimen m
from person i′s regimen set Rregimeni,k i.e., Ci,k,m = Bi,1,m with P̂ (Ci,k,m) = P̂ (Bi,1,m).
During the course of the trial P̂ (Bi,k,m) estimates the current best guess of patient
toxicity probability on the remaining cycles while P̂ (Ci,k,m) estimates the best guess
of the toxicity probability profile for future patients undergoing regimen m.
2.4.3 Expected dose
A higher planned dose might not be attractive if fewer cycles can be completed
at that dose level due to DLTs. During the course of the trial, Markov Model 2.1 can
be used to estimate the expected total dose for members m of the eligible regimen
set Rregimeni,k+1 and potentially use this information as part of selecting the current best
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regimen for patient i. Using the expression presented in equations 2.5 and 2.6 the





















For a continuing patient i in the study who is ready for dose administration on cycle
























2.4.4 Running the trial
Dosing decisions are governed by Markov Model 2.1 and safety criteria laid out in
section 2.4.1. In practice, this requires having current information on all patients in
the trial so that new and continuing patients have the most up-to-date information as
dose recommendations are made. In particular, each time a dose is recommended we
should have current estimates α̂, β̂ and ρ̂, a defined set of eligible regimensRregimeni,k for
patient i being dosed on cycle k and estimates of P̂ (Ai,k,j), P̂ (Bi,k,m) and P̂ (Ci,k,m).
Hence, development of an automated procedure is recommended for this trial design.
At the start of the trial assign two patients to the second lowest dose level,
rg,1 = 2. Patients completing a cycle without a DLT will usually either stay at the
same dose level or escalate to a higher dose level, although a de-escalation recom-
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mendation is possible if additional data on other patients is trending toward lower
dose recommendations. On the first cycle a patient i on the study has rmaxg,1 pos-
sible choices for dose level with corresponding estimated conditional probabilities
of toxicity P̂ (Ai,1,j), j = 1 . . . r
max
g,1 . Eligible choices for dose level j must satisfy
P̂ (Ai,1,j) ≤ P̊ (A1) on cycle one and P̂ (Ai,k,j) ≤ P̊ (A2) on cycles, k > 1. If no eligi-
ble doses are identified, then the model fit indicates that the trial has no remaining
safe dose levels. More often, multiple dose levels satisfy the P̊ (A) safety criterion,
and we consider not just the subsequent dose, but all remaining doses in making a
recommendation. I.e., we must consider the estimates of P̂ (Bi,k,m) and P̂ (Ci,k,m) of
all possible members m of Rregimeni,k .
Two plans for choosing a dose level in this case include 1) maximizing the expected
dose over the entire regimen for a patient or 2) selecting a dose that aligns (matches)
with one of the dosing schemes from a list of desirable regimens presented in Table
2.3. These two plans are outlined below.
2.4.4.1 Maximizing the expected dose
For a patient being dosed on cycle k, the expected dose is calculated using ex-
pressions in Section 2.4.3 for each of the regimens in Rregimeni,k . The dose level that
maximizes the expected dose and satisfies P̂ (Bi,k,m) ≤ P̊ (B) and P̂ (Ci,k,m) ≤ P̊ (C)
is selected for cycle k.
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2.4.4.2 Matching a regimen
Cycle 1 patients still base their first dose on maximizing their expected dose using
current data and subject to eligibility of regimens as previously described. Otherwise,
to gain the most possible experience with regimens that would be recommended at
the end of the trial, one may favor members m of Rregimeni,k that “nudge” the current
patient’s regimen toward one of the q = 1, . . . , 19 suggested dosing regimens in Table
2.3, some subset of these or completely different user defined regimens not included
in this table.
Define distance between a regimen vector m in Rregimeni,k and a regimen vector q
from Table 2.3 as Rl =
∑K
c=1 |mc − qc|. We may wish to select the regimen m that
minimizes this distance across all m and q. Alternatively, one might select the subset
of regimens from Rregimeni,k that satisfy some prespecified distance limit Rl < a and
then choose the regimen that assigns the maximum allowable dose from that subset
on the next cycle.
2.4.5 Recommending a regimen
At the conclusion of the study, the estimates α̂, β̂ and ρ̂ are used to calculate
the overall probability of toxicity P̂ (Cj) for all of the j = 1 . . . 19 regimens listed
in Table 2.3. During the conduct of the trial the target probability bounds used
were P̊ (A), P̊ (B) and P̊ (C). These bounds especially, P̊ (C), are usually set at
higher than acceptable values in practice and when selecting the final regimen we
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would use P r(A1) and P
r(C) which might be lower than or equal to P̊ (A1) and
P̊ (C) respectively. For example in running the trial P̊ (C) = 0.40 which implies an
overall toxicity of 40% but in practice 30% toxicities are what we would want to
see in the trials. The final recommended (R) regimen can be selected using both
P r(A1) and P
r(C) or using P r(C) alone. In the first option the regimen satisfying
P̂ (A1) ≤ P r(A1), P̂ (Cj) ≤ P r(C) and maximizing the expected dose is selected as
the recommended dosing regimen while in the second option only P̂ (Cj) ≤ P r(C)
and maximizing the expected dose condition is used in regimen selection.
A corresponding target (T) regimen is also selected and used as a reference for
gauging the properties of the completed trial. The target regimen is selected by
calculating P (A1) and P (C) based on the true values of α, β and ρ and is also selected
from one of the 19 regimens presented in Table 2.3. For example corresponding to the
19 regimens, the columns in Table 2.11 list the probability of toxicity on the first cycle
P (A1), the probability of toxicity on any cycle P (C), the expected dose on the entire
regimen, a flag set to one if the regimen qualifies when using only P r(C) = 0.30 and
three other flags set to one when using P r(C) = 0.30 and P r(A1) = (0.05, 0.10, 0.20).
The regimen 12, 444333, has the maximum expected dose and is selected when only
option one P r(C) = 0.30 is used. If option 2 is used for the selection of the target
regimen then regimen 15, 223344 is selected when P (A1) = 0.05 or 0.10 and regimen
12, 444333, when P (A1) = 0.20. In this instance with α = 1, β = 0.2, ρ = 0.8
regimens that offered dose variation were recommended since they offered a higher
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expected dose.
2.4.6 Algorithmic form of the two plans
Plan 1 - Maximize the expected dose on the study for each patient i.
• For new patient î on cycle 1
1. Estimate P̂ (Aî,1,j) using current estimates α̂, β̂ and ρ̂ at each of the









maximum of all the past dose levels assigned to the patients on cycle k = 1
and r‡g,k is the maximum of all the past dose levels assigned to the patients
in the study on cycles k > 1.
2. Subset the dose levels that satisfy P̂ (Aî,1,j) ≤ P̊ (A1) over all dose levels.
3. For the dose levels satisfying P̂ (Aî,1,j) ≤ P̊ (A1) subset the list of possible
regimens from Table 2.3 and calculate the overall probability of toxicity
P̂ (Cî,1,j).
4. Select the dose level that has an overall probability of toxicity P̂ (Cî,1,j) ≤
P̊ (C) and maximum expected dose.
5. If none of the doses satisfy P̂ (Aî,1,j) ≤ P̊ (A1) and if there are continuing
patients in the study then wait until updated estimates α̂, β̂ and ρ̂ allow
doses to be assigned else the study is terminated.
• For continuing patient i on cycle k > 1,
44
1. List doses P̂ (Ai,k+1,j) ≤ P̊ (A2) from rmaxg,k+1 = min(rg,1 + 2,rg,k + 1, 5)
possible choices.
2. If there is more than one satisfying dose level then list the possible dose
regimen set Rregimeni,k+1 .
3. Calculate the probability of toxicity P̂ (Bî,k+1,m) on the remainder of the
cycles for each of the regimens m in Rregimeni,k+1 and the corresponding ex-
pected dose using the current estimates α̂, β̂ and ρ̂.
4. Select the dose level that has probability of toxicity P̂ (Bî,k+1,m) ≤ P̊ (B)
and maximizes the expected dose.
5. If none of the doses satisfy P̂ (Aî,k+1,j) ≤ P̊ (A2) and if there are continuing
patients in the study then wait until updated estimates α̂, β̂ and ρ̂ allow
doses to be assigned else the study is terminated.
Plan 2 - Observing a favorable dosing regimen by the end of the study
• For new patient î on cycle 1
1. Estimate P̂ (Aî,1,j) at each of the j = 1 . . . r
max
g,1 dose levels. Where r
max
g,1 =




g,1 is the maximum of all the past dose levels assigned
to the patients on cycle k = 1 and r‡g,k is the maximum of all the past
dose levels assigned to the patients in the study on cycles k > 1.
2. Subset the dose levels that satisfy P̂ (Aî,1,j) ≤ P̊ (A1) over all dose levels.
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3. For the dose levels satisfying P̂ (Aî,1,j) ≤ P̊ (A1) subset the list of possible
regimens from Table 2.3 and calculate the overall probability of toxicity
P̂ (Cî,1,j) using the current estimates α̂, β̂ and ρ̂
4. Select the dose level that has an overall probability of toxicity P̂ (Cî,1,j) ≤
P̊ (C). Select the highest dose if more than one satisfying dose level.
5. If none of the doses satisfy P̂ (Aî,1,j) ≤ P̊ (A1) and if there are continuing
patients in the study then wait until updated estimates of α̂, β̂ and ρ̂ allow
doses to be assigned else the study is terminated.
• For continuing patient i on cycle k > 1,
1. List doses P̂ (Ai,k+1,j) ≤ P̊ (A2) from rmaxg,k+1 = min(rg,1 + 2,rg,k + 1, 5)
possible choices.
2. If there is more than one satisfying dose level then list the possible dose
regimen Rregimeni,k+1 set.
3. Subset the regimens satisfying probability of toxicity P̂ (Bi,k+1,m) ≤ P̊ (B)
from the Rregimeni,k+1 set.
4. For each of the regimens l in the subset calculate the distance Rl from the
favorable dosing regimens based on Table 2.3.
5. Select the highest dose level that has Rl ≤ a pre-specified value. If none
of the regimens satisfy the Rl condition then select the dose level that
maximizes the total expected dose.
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6. If none of the doses satisfy P̂ (Ai,k+1,j) ≤ P̊ (A2) and if there are continuing
patients in the study then wait until updated estimates α̂, β̂ and ρ̂ allow
doses to be assigned else the study is terminated.
2.4.7 Properties of the design
For the purposes of evaluating the properties of the simulation of clinical trials
over multiple replications and comparing the various plans and properties of the tar-
get probabilities various test statistics will be calculated that can be grouped into 1)
trial conduct or patient characteristics and 2) regimen characteristics as explained
below.
Patient characteristics
1. Mean dose per patient over all the replicates. In each of the replicates the
total dose given to all the patients will be tracked and then averaged across the
number of the patients in that trial. A higher mean dose is desirable implying
that the patients in the trial were able to receive as much of the study drug as
possible.
2. Mean number of toxicities per study across all the replicates. Also noting the
percentage of trials stopping early. Lower values of the mean toxicities are
desirable and lower number of trials of stopping early indicate that all patients
were assigned to dose levels within the framework of the safety criteria.
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3. At the conclusion of every trial the proportion of patients receiving a cumulative
dose greater than the expected dose of the recommended regimen is averaged
over all the iterations. Higher values are desirable indicating that patients in
the trial had experience of the dose quantity recommended at the end of the
trial.
4. The proportion of patients receiving dose greater than the expected dose based
on the target regimen target (T) regimen is also considered. A higher value
is desirable indicating patients in the trial received dose quantities considered
safe by the target regimen.
5. Mean number of patients whose regimen matches exactly with the recom-
mended regimen. The distance from the recommended regimen is calculated
for each of the patients in the study, and the proportion of patients having
distance = 0 are averaged all the replications. Higher values are desirable indi-
cating that patients in the trial had experience with the recommended regimen.
6. Mean number of patients having a regimen that matches the target regimen.
Higher values are desirable indicating that patients in the trial had dosing
regimens matching the target regimen.
7. Mean number of patients having distance ≤ 2 from the recommended (R)
regimen. A slightly less stricter rule checking patients with regimens differing
by two dose levels. Higher values are desirable.
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8. Mean number of the patients having distance ≤ 2 from the target (T) regimen.
Higher values are desirable.
Regimen characteristics
1. The mean distance between the target (T) and the recommended (R) regimen
over all the replicates. Lower values are desirable indicating a match between
the target and recommended regimen.
2. The proportion of trials with an exact match between the target and the rec-
ommended regimen. Higher values are desirable.
3. Mean of expected dose based on the target regimen. Higher values are desirable.
4. Mean of expected dose based on the recommended regimen. Higher values
matching the target regimen are desirable.
5. The mean of target regimen toxicities. The probability of observing a toxi-
city on any cycle given the target regimen and the true parameter values is
calculated. Low values are desirable.
6. The mean of recommended regimen toxicities. Low values are desirable.
2.4.8 Simulation Design and Results
A clinical trial recruiting a maximum of N=30 patients and each patient hav-
ing a maximum of six cycles was conducted over 500 replicates. The values of
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α = 1, β = 0.2, ρ = 0.8 were used as the true values in generating the patient
response. The skeleton probability used for the doses was 0.02, 0.05, 0.10, 0.16, 0.23.
It is assumed that a new patient is ready to be assigned a dose on the first cycle when
the continuing patients in the trial have completed their dosing cycles. This assump-
tion tallies with simulation settings in [Pye and Whitehead, 2012] and simplifies the
number of iterations performed during the estimation process. An alternative to this
assumption would be to induce an arrival time model via an Exponential distribution
and has been excluded to present simplified results.
The following factors and questions were studied via simulation studies:
1. Differences in trial properties when using Plan 1 - Maximize the expected dose
or Plan 2 - Match a regimen.
2. Selection of distance restriction Rj in executing Plan 2.
3. Whether to use both P̊ (B) and P̊ (C) or only P̊ (C) in trial conduct?
4. What values to use for P̊ (A), P̊ (B) and P̊ (C)?
5. Whether to use P r(C) = 0.30 or P r(A1) = P̊ (A1) and P
r(C) = 0.30 in regimen
selection at trial conclusion for recommended regimen selection?
6. Acceptable values for P r(C) and P r(A1).
For different combinations of P̊ (A), P̊ (B) and P̊ (C) a total of 500 trials were
simulated. Table 2.12 lists the results for the patient characteristics with the rows
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grouped by the option used to select the regimen (option 1 or 2) at the conclusion
of the trials executed using Plan 1, maximizing the expected dose. The rows are
further grouped by P̊ (B) = (0.30, 0.40) within which each row correspond to cases
of P̊ (A1) = (0.05, 0.10, 0.20). The columns list the eight criteria presented in Section
2.4.7 for the patient characteristics. Tables 2.13 through 2.15 list the patient charac-
teristics of trials executed when Plan 2 was in effect with Rl ≤ 3, Rl ≤ 2 and Rl set
to the minimum distance possible. The results for the regimen characteristics are in
Tables 2.16 through 2.19. The columns list the six criteria presented in Section 2.4.7
for the regimen characteristics. Results within each table are grouped by the two
options for regimen selection and P̊ (B) = (0.30, 0.40) with the rows corresponding
to P̊ (A1) = (0.05, 0.10, 0.20). Some remarks are presented on the various aspects of
the trial results.
Remark 1: Contrast using P̊ (A1) = (0.05, 0.10, 0.20). Varying the cap on the
first cycle affects the trial conduct in terms of which dose level is eligible on the first
cycle. Lower values of P̊ (A1) = (0.05, 0.10, 0.20) imply stringent rules for selecting
doses with higher toxicities but also results in a less stringent rules on subsequent
cycles due to the relationship between P̊ (A1), P̊ (A2) and P̊ (C). Based on Tables 2.12
through 2.15 we notice that as the values of P̊ (A1) increase the mean dose received by
the patients in the trial also increases. Secondly the observed mean toxicities tend to
be low when P̊ (A1) is high, this could be because the toxicities on subsequent cycles
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are averted due to the low P̊ (A2) value and also because ρ = 0.8 in the simulations
once the patients receive a high dose and survive it without a DLT, they are less
likely to have a DLT on subsequent cycles. No clear trend is observed in the number
of patients receiving cumulative dose greater than the recommended expected dose.
The number of patients receiving the recommended regimen increases with increase
in P̊ (A1). The number of trials stopping early also decreases with increase in P̊ (A1)
suggesting that higher values of P̊ (A1) allow patients to have dose assignment. In
the case of the regimen characteristics the mean distance between the target (T) and
the recommended (R) regimen increases as P̊ (A1) increases. In general it seems that
having a high value of P̊ (A1) = 0.20 gives rise to properties that are favored in terms
of patients receiving a higher mean dose and recommended dose matching the target
regimen selection more often.
Remark 2: Contrast the effect of distance in the regimen matching plan. Com-
paring Tables 2.13, 2.14 and 2.15 for differences in the patient characteristics results
corresponding to distance less than 3, distance less than 2 and distance equal to the
minimum possible value some differences are observed. In the first two instances
when none of the regimens satisfy the distance criterion the algorithm switches to
Plan 1 - maximizing the dose, while in the third instance the algorithm selects the
dose that offers the the minimum distance from one of the 19 regimens. At low values
of P̊ (A1) = 0.05 the difference in the number of patients matching the recommended
regimen exactly increases drastically to 12.14 from 0.61 but not much of a differ-
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ence when P̊ (A1) = 0.20. The Tables 2.17 and 2.19 do have major differences since
they deal mostly with the regimen selection at the conclusion of the trial. We can
conclude that patients having an exact match with the recommended regimen differs
when using Plan 2 for low values of P̊ (A1) and that the differences are minimal when
P̊ (A1) increases.
Remark 3: Contrast using P r(A1) and P
r(C) versus only P r(C) in selection of
the regimens. These flags are concerned with the selection of the recommended and
the target regimen at the end of the trial. Consider results within Table 2.12 and
2.13 for contrasting the effects of the regimen selection option. The number of pa-
tients having total dose higher than the recommended or the target expected dose is
higher in option 1 when both the flags P r(A1) and P
r(C) are considered. The results
in both the options are comparable in the instance when P̊ (A1) = 0.20 (the third
row). Comparing the proportion of trials having an exact match between the target
and the recommended regimen within Table 2.16 and 2.17 the proportions drop for
restrictive P r(A1) = 0.05, 0.10 case while remain unchanged for the P
r(A1) = 0.20
case. The expected dose of the regimens selected based on the single condition is
higher than that when using both the conditions. The number of trials that cannot
offer a recommended regimen reduces when using a single condition for the regimen
selection. Having a restrictive condition on the first cycle plays a huge role in running
of the trial and definitely affects the regimen selection.
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Remark 4: Contrast the two plans of maximizing the dose and regimen matching.
Comparing 2.12 and 2.15 for differences in the patient characteristics. The mean
dose received is higher in Plan 1 when P̊ (A1) = 0.05, 0.10 and not much different
from Plan 2 when P̊ (A1) = 0.20. The proportion of toxicities is slightly higher in
Plan 1. The proportion of expected dose received in patients similar in both the
plans but differs only when P̊ (A1) = 0.20 being much higher in plan 2. The number
of patients having an exact match with the recommended regimen is higher in Plan
2. The mean of the distance between the true and recommended regimens is mostly
higher in Plan 1 based on Tables 2.16 and 2.19. The results depict differences in
trial properties between the two plans. Although Plan 1 offers higher mean dose
the number of toxicities are also slightly higher. Plan 2 on the other hand offers a
higher number of patients matching the recommended regimen and lower toxicities
but tends to have lower mean dose per patient.
Remark 5: Is there a difference in using different values of P̊ (B) = (0.30, 0.40).
Within each of the Tables 2.12 - 2.15 comparing the results of the mean dose and
toxicity of the trials there does not seem to be huge differences in the results. It is
not so obvious how the use of P̊ (B) affects the patient trial properties. In reference
to the regimen characteristic Tables 2.16 through 2.19 there seem to be some slight
differences in Plan 1 but no difference in the tables for regimen matching Plan 2.
There does not seem to be any effect of using P̊ (B) during the trial conduct. To
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further understand the effect of using both P̊ (C) and P̊ (B) versus only P̊ (C) in
conducting the trial an additional set of simulations were carried out by assigning
doses on cycles after the first cycle by calculating the probability of toxicity on the
entire regimen and selecting the regimens that satisfy the P̊ (C) condition. In the
case of Plan 2 Rl was set to the minimum distance possible. Simulations were carried
out for a single setting of P̊ (A1) = 0.20 and P̊ (C) = 0.40 and are presented in Table
2.20 which should be compared to the case when P̊ (A1) = 0.20 from results in Table
2.12 and Table 2.15. The mean dose and toxicities are comparable in both Plan 1
and Plan 2. The numbers are different in the case of patients having dose greater
than the recommended dose, the patients with distance ≤ 2 is higher.
Remark 6: Contrast the use of differing values of P̊ (C) = (0.30, 0.40) for fixed
P̊ (A1) = 0.20 and absence of P̊ (B) . Based on Table 2.20 it was seen that having
higher value of P̊ (C) has better trial properties in terms of higher mean dose. The
mean number of toxicities increase but are still lower than 30%. The number of
patients matching the recommended regimen are also higher when the P̊ (C) is higher.
2.5 Discussion
The Markov Model 2.1 presented in this chapter is simple in the sense that it
allows for estimation of only three parameters and yet is capable of modeling the
complex repeated data structure by accounting for the within-patient dose depen-
dency through ρ. In the instance with larger amounts of data, more terms could be
55
added to the model that account for patient characteristics like gender or age but
in the setting of small number of patients it might not be feasible to estimate the
parameters especially in the early stages of the trial.
Besides the conditional nature, the major feature of the Markov Model 2.1 is its
ability to allow patients surviving previous dose levels to have a lower probability of
toxicity on subsequent cycles. The extension of the Markov Model 2.1 in carrying
out a trial within the framework of safety criteria provides an excellent model based
approach in designing adaptive clinical trials. The dose level selection considered
in this chapter is complicated because of repeated measures aspect of the data and
the choices that have to be made regarding skeleton probabilities, prior probabili-
ties, escalation rules and safety criteria. The model presented and the simulations
performed represent a framework for considering these issues. The results obtained
apply to the specific situation that is being considered in the simulations for the
probability skeleton, particular values of α,β and ρ. Further simulations need to be
done to understand the working of the model in a broader framework. Thus while
the specific choices we made are, we believe, reasonable, we do not claim they are
optimal or necessarily appropriate in every conceivable context. But we do think
that the framework and ideas are adequate and adaptable to match other contexts.
Through simulations we have demonstrated that the Markov model is able to
estimate the conditional probabilities adequately in both small (N = 10) and larger
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(N = 30) sample sizes. The model also performs better in comparison to using a
single binary endpoint and shows that that there are gains in estimation through use
of all the data from all the patients in the trial. Simulation results have also shown
that there are benefits in allowing patients to escalate or de-escalate dose levels to
both the patients and the estimation of the parameters.
The simulation results for carrying out an adaptive clinical trial are affected by
multiple factors and further investigation of how the parameters, safety rules, target
probabilities and the regimen selection criteria on the selection of the doses for each
of the patients in needed. The model could be extended to any number of dose levels
and cycles although we have presented the model for five dose levels and six cycles.
The Markov model presented in this chapter is most relevant to clinical trials
involving cytotoxic drugs where the toxicity is assumed to increase with the cumu-
lative effect. Having non-delayed outcomes is also essential to the study design so




































































































































































Figure 2.1: Conditional P(toxicity) with cycle 1 as the reference based on Model
2.1. Open circles depict probabilities for cycle 1 with α = 0.5 across the five dose
levels; crosses depict conditional probabilities of toxicity on cycle 2, assuming dose
level three was administered on cycle 1 and one of five dose levels on the second
cycle. Probabilities on cycle 2 are arranged by increasing β shown left to right and
increasing ρ shown from top to bottom
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Table 2.1: Table comparing the effect of priors in estimating the parameters using
Model 2.1 from 500 simulated datasets containing N = 30 patients each receiving
one of five dose groups d1 . . . d5.
True Value Prior Mean (SD) Estimate(Bias) MSD1 ESD2 Coverage
Case 1
α 1 1 (2) 0.957 ( -0.043 ) 0.458 0.417 96.6
β 0.50 0.50 (1) 0.511 ( 0.011 ) 0.338 0.296 97.8
ρ 0.80 0.83 (0.14) 0.806 ( 0.006 ) 0.132 0.056 100
Case 2
α 1 1 (5) 0.969 ( -0.031 ) 0.477 0.455 94.6
β 0.50 0.50 (2.5) 0.464 ( -0.036 ) 0.353 0.338 95.0
ρ 0.80 0.83 (0.14) 0.793 ( -0.007 ) 0.136 0.057 100
Case 3
α 0.80 1 (2) 0.795 ( -0.005 ) 0.407 0.360 96.0
β 0.50 0.50 (1) 0.500 (< 0.001) 0.318 0.274 97.8
ρ 0.80 0.83 (0.14) 0.809 ( 0.009 ) 0.134 0.053 100
Case 4
α 1 1 (2) 1.013 ( 0.013 ) 0.477 0.450 95.4
β 0.80 0.50 (1) 0.719 ( -0.081 ) 0.450 0.373 95.2
ρ 0.80 0.83 (0.14) 0.793 ( -0.007 ) 0.140 0.055 100
1 MSD is mean of the SD from 500 estimates
2 ESD is empirical SD of the 500 estimates
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Table 2.2: Table comparing the effect of priors in estimating the conditional prob-
ability of toxicity (with bias from the true value in parenthesis) using Model 2.1
from 500 simulated datasets containing N = 30 patients each receiving one of five
dose groups d1 . . . d5. Case 1 and 2 use α = 1, β = 0.5, ρ = 0.8 , while Case 3 use
α = 0.8, β = 0.5, ρ = 0.8 and Case 4 uses α = 1, β = 0.8, ρ = 0.8 to generate the
datasets. The priors have means of α = 1, β = 0.5, ρ = 0.8 and SD = 2 in Cases 1,
3 and 4 and SD = 5 in Case 2.
Cycle 1 Cycle 2 Cycle 6 Any Cycle
Est(bias) Est(bias) Est(bias) Est(bias)
Case 1
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.041 ( -0.002 )
d2 0.048 ( -0.002 ) 0.011 (< 0.001) 0.016 (< 0.001) 0.111 ( -0.004 )
d3 0.095 ( -0.005 ) 0.025 ( -0.001 ) 0.047 (< 0.001) 0.246 ( -0.008 )
d4 0.152 ( -0.008 ) 0.048 ( -0.001 ) 0.104 ( -0.001 ) 0.425 ( -0.014 )
d5 0.217 ( -0.013 ) 0.081 ( -0.002 ) 0.197 ( -0.002 ) 0.623 ( -0.022 )
Case 2
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.041 ( -0.002 )
d2 0.048 ( -0.002 ) 0.011 (< 0.001) 0.016 ( -0.001 ) 0.110 ( -0.005 )
d3 0.096 ( -0.004 ) 0.025 ( -0.001 ) 0.045 ( -0.003 ) 0.242 ( -0.013 )
d4 0.153 ( -0.007 ) 0.047 ( -0.002 ) 0.098 ( -0.007 ) 0.413 ( -0.025 )
d5 0.218 ( -0.012 ) 0.079 ( -0.004 ) 0.184 ( -0.016 ) 0.604 ( -0.040 )
Case 3
d1 0.016 (< 0.001) 0.003 (< 0.001) 0.004 (< 0.001) 0.034 ( -0.001 )
d2 0.040 (< 0.001) 0.009 (< 0.001) 0.014 (< 0.001) 0.094 ( -0.003 )
d3 0.080 ( -0.001 ) 0.021 ( -0.001 ) 0.043 ( -0.001 ) 0.216 ( -0.007 )
d4 0.128 ( -0.002 ) 0.041 ( -0.002 ) 0.096 ( -0.002 ) 0.385 ( -0.013 )
d5 0.184 ( -0.004 ) 0.071 ( -0.003 ) 0.186 ( -0.005 ) 0.583 ( -0.023 )
Case 4
d1 0.020 (< 0.001) 0.005 (< 0.001) 0.006 (< 0.001) 0.045 ( 0.001 )
d2 0.050 (< 0.001) 0.013 (< 0.001) 0.020 ( -0.001 ) 0.125 ( -0.001 )
d3 0.100 (< 0.001) 0.03 (< 0.001) 0.060 ( -0.003 ) 0.282 ( -0.009 )
d4 0.159 ( -0.001 ) 0.057 ( -0.001 ) 0.134 ( -0.010 ) 0.487 ( -0.023 )
d5 0.227 ( -0.003 ) 0.098 ( -0.003 ) 0.254 ( -0.024 ) 0.700 ( -0.039 )
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Table 2.3: Table with the 19 favorable dose regimen combinations over the six cycles.
Each of the row regimens indicate the dose level assigned on corresponding cycle.
Cycle 1 2 3 4 5 6
Regimen 1 1 1 1 1 1 1
Regimen 2 2 2 2 2 2 2
Regimen 3 3 3 3 3 3 3
Regimen 4 4 4 4 4 4 4
Regimen 5 5 5 5 5 5 5
Regimen 6 1 1 1 2 2 2
Regimen 7 2 2 2 3 3 3
Regimen 8 3 3 3 4 4 4
Regimen 9 4 4 4 5 5 5
Regimen 10 2 2 2 1 1 1
Regimen 11 3 3 3 2 2 2
Regimen 12 4 4 4 3 3 3
Regimen 13 5 5 5 4 4 4
Regimen 14 1 1 2 2 3 3
Regimen 15 2 2 3 3 4 4
Regimen 16 3 3 4 4 5 5
Regimen 17 5 5 4 4 3 3
Regimen 18 4 4 3 3 2 2
Regimen 19 3 3 2 2 1 1
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Table 2.4: Parameter estimates from two different patient profiles, based on Model
2.1 from 500 simulated datasets containing N = 30 patients receiving one of five dose
groups d1 . . . d5 over six cycles. Results presented for α = 1, β = 0.5 and ρ = 0.8
Estimate(Bias) MSD1 ESD 2 Coverage
Section 2.3.2
α 0.989 ( -0.011 ) 0.446 0.425 95.2
β 0.561 ( 0.061 ) 0.361 0.322 98
ρ 0.808 ( 0.008 ) 0.134 0.056 100
Section 2.3.1
α 0.957 ( -0.043 ) 0.458 0.417 96.6
β 0.511 ( 0.011 ) 0.338 0.296 97.8
ρ 0.806 ( 0.006 ) 0.132 0.056 100
1 MSD is mean of the SD from 500 estimates
2 ESD is empirical SD of the 500 estimates
Table 2.5: Estimates with bias from the true value of conditional probability of
toxicity on each of the six cycles estimated using Model 2.1 from 500 simulated
datasets containing N = 30 patients with dose variability in Section 2.3.2 and same
dose level in Section 2.3.1, each receiving one of five dose groups d1 . . . d5. Results
presented for α = 1, β = 0.5 and ρ = 0.8
Cycle 1 Cycle 2 Cycle 6 Any Cycle
Section 2.3.2 Est(bias) ESD1 Est(bias) ESD1 Est(bias) ESD1 Est(bias) ESD1
d1 0.020 (< 0.001) 0.008 0.004 (< 0.001) 0.002 0.005 (< 0.001) 0.002 0.041 ( -0.001 ) 0.016
d2 0.049 ( -0.001 ) 0.021 0.011 ( -0.001 ) 0.005 0.017 (< 0.001) 0.006 0.113 ( -0.002 ) 0.037
d3 0.098 ( -0.002 ) 0.04 0.026 ( -0.001 ) 0.010 0.049 ( 0.002 ) 0.018 0.253 ( -0.001 ) 0.067
d4 0.156 ( -0.004 ) 0.06 0.048 ( -0.001 ) 0.017 0.110 ( 0.005 ) 0.042 0.437 ( -0.001 ) 0.098
d5 0.223 ( -0.007 ) 0.082 0.083 (< 0.001) 0.027 0.209 ( 0.009 ) 0.080 0.640 ( -0.005 ) 0.113
Section 2.3.1
d1 0.019 ( -0.001 ) 0.008 0.004 (< 0.001) 0.002 0.005 (< 0.001) 0.002 0.041 ( -0.002 ) 0.016
d2 0.048 ( -0.002 ) 0.020 0.011 (< 0.001) 0.004 0.016 (< 0.001) 0.005 0.111 ( -0.004 ) 0.036
d3 0.095 ( -0.005 ) 0.039 0.025 ( -0.001 ) 0.008 0.047 (< 0.001) 0.016 0.246 ( -0.008 ) 0.065
d4 0.152 ( -0.008 ) 0.060 0.048 ( -0.001 ) 0.014 0.104 ( -0.001 ) 0.038 0.425 ( -0.014 ) 0.093
d5 0.217 ( -0.013 ) 0.081 0.081 ( -0.002 ) 0.023 0.197 ( -0.002 ) 0.073 0.623 ( -0.022 ) 0.108
1 ESD is empirical SD of the 500 estimates
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Table 2.6: Parameter estimates from 500 simulated datasets containing N = 10 and
N = 30 patients receiving one of five dose groups d1 . . . d5 over six cycles comparing
comparing estimates based on Model 2.1 to estimates based on Models 2.7 and 2.8
and having equal patients on all the dose levels.
Estimate(Bias) MSD1 ESD2 Coverage
N=10 patients
α 0.945 ( 0.055 ) 0.682 0.585 99.6
β 0.515 ( -0.015 ) 0.464 0.308 100
ρ 0.820 ( -0.020 ) 0.137 0.040 100
γ 0.916 ( 0.084 ) 0.703 0.630 99.8
δ 0.976 ( 0.024 ) 0.548 0.536 92.6
N=30 patients
α 0.989 ( 0.011 ) 0.466 0.408 96.0
β 0.507 ( -0.007 ) 0.343 0.285 98.8
ρ 0.802 ( -0.002 ) 0.133 0.058 99.8
γ 0.940 ( 0.060 ) 0.474 0.428 96.6
δ 0.998 ( 0.002 ) 0.333 0.331 94
1 MSD is mean of the SD from 500 estimates
2 ESD is empirical SD of the 500 estimates
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Table 2.7: Probability of toxicity estimates based on 500 simulated datasets contain-
ing N = 10 and N = 30 patients receiving one of five dose groups d1 . . . d5 over six
cycles with α, β, ρ based on Model 2.1, γ from Model 2.7, δ from Model 2.8. Results
presented for α = 1, β = 0.5 and ρ = 0.8 and with equal patients on the five dose
levels.
N = 10 N = 30
Estimate(Bias) ESD1 Estimate(Bias) ESD1
First cycle
Markov Model 2.1
d1 0.019 (-0.001) 0.011 0.020 (< 0.001) 0.008
d2 0.047 (-0.003) 0.028 0.049 (-0.001) 0.020
d3 0.093 (-0.007) 0.053 0.098 (-0.002) 0.038
d4 0.148 (-0.012) 0.081 0.156 (-0.004) 0.059
d5 0.21 (-0.02) 0.109 0.223 (-0.007) 0.081
Binary Model 2.7
d1 0.018 (-0.002) 0.012 0.019 (-0.001) 0.008
d2 0.045 (-0.005) 0.030 0.047 (-0.003) 0.021
d3 0.090 (-0.010) 0.057 0.093 (-0.007) 0.040
d4 0.143 (-0.017) 0.086 0.149 (-0.011) 0.062
d5 0.203 (-0.027) 0.114 0.213 (-0.017) 0.085
Any cycle
Markov Model 2.1
d1 0.038 (-0.004) 0.021 0.042 (-0.001) 0.016
d2 0.105 (-0.011) 0.050 0.113 (-0.002) 0.038
d3 0.234 (-0.021) 0.092 0.250 (-0.005) 0.068
d4 0.405 (-0.033) 0.132 0.428 (-0.010) 0.095
d5 0.598 (-0.046) 0.152 0.626 (-0.019) 0.109
Binary Model 2.8
d1 0.041 (-0.001) 0.022 0.042 (< 0.001) 0.014
d2 0.111 (-0.004) 0.055 0.114 (-0.001) 0.035
d3 0.241 (-0.014) 0.107 0.251 (-0.004) 0.070
d4 0.407 (-0.032) 0.153 0.428 (-0.011) 0.102
d5 0.590 (-0.055) 0.176 0.624 (-0.02) 0.115
1 ESD is empirical SD of the 500 estimates
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Table 2.8: Parameter estimates from 500 simulated datasets containing N = 10
and N = 30 patients receiving one of five dose groups d1 . . . d5 over six cycles with
α, β, ρ based on Model 2.1, γ from Model 2.7, δ from Model 2.8 and having unequal
patients on all the dose levels.
Estimate(Bias) MSD1 ESD2 Coverage
N=10 patients
α 0.965 ( 0.035 ) 0.688 0.566 99.8
β 0.530 ( -0.030 ) 0.489 0.340 100
ρ 0.818 ( -0.018 ) 0.137 0.046 100
γ 0.924 ( 0.076 ) 0.704 0.590 99.8
δ 0.995 ( 0.005 ) 0.543 0.570 94.6
N=30 patients
α 0.986 ( 0.014 ) 0.446 0.398 95.8
β 0.487 ( 0.013 ) 0.329 0.236 99.0
ρ 0.803 ( -0.003 ) 0.131 0.058 100
γ 0.945 ( 0.055 ) 0.455 0.419 92.2
δ 0.980 ( 0.020 ) 0.311 0.299 95.6
1 MSD is mean of the SD from 500 estimates
2 ESD is empirical SD of the 500 estimates
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Table 2.9: Probability of toxicity estimates based on 500 simulated datasets contain-
ing N = 10 and N = 30 patients receiving one of five dose groups d1 . . . d5 over six
cycles comparing estimates based on Model 2.1 to estimates based on Models 2.7 and
2.8. Results presented for α = 1, β = 0.5 and ρ = 0.8 and with unequal patients on
the five dose levels.
N = 10 N = 30
Estimate(Bias) ESD1 Estimate(Bias) ESD1
First cycle
Markov Model 2.1
d1 0.019(-0.001) 0.011 0.02(< 0.001) 0.008
d2 0.048(-0.002) 0.027 0.049(-0.001) 0.019
d3 0.095(-0.005) 0.052 0.098(-0.002) 0.037
d4 0.151(-0.009) 0.079 0.156(-0.004) 0.057
d5 0.215(-0.015) 0.106 0.223(-0.007) 0.078
Binary Model 2.7
d1 0.018(-0.002) 0.012 0.019(-0.001) 0.008
d2 0.046(-0.004) 0.028 0.047(-0.003) 0.02
d3 0.091(-0.009) 0.054 0.094(-0.006) 0.039
d4 0.144(-0.016) 0.082 0.15(-0.010) 0.06
d5 0.206(-0.024) 0.11 0.214(-0.016) 0.083
Any cycle
Markov Model 2.1
d1 0.04(-0.003) 0.022 0.041(-0.001) 0.016
d2 0.108(-0.007) 0.053 0.112(-0.003) 0.036
d3 0.24(-0.015) 0.097 0.246(-0.008) 0.064
d4 0.413(-0.025) 0.137 0.423(-0.016) 0.088
d5 0.605(-0.04) 0.156 0.621(-0.024) 0.101
Binary Model 2.8
d1 0.042(< 0.001) 0.023 0.042(-0.001) 0.012
d2 0.113(-0.003) 0.058 0.112(-0.003) 0.032
d3 0.244(-0.011) 0.112 0.247(-0.007) 0.064
d4 0.41(-0.028) 0.158 0.424(-0.015) 0.094
d5 0.592(-0.052) 0.179 0.621(-0.024) 0.107
1 ESD is empirical SD of the 500 estimates
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Table 2.10: Target probability bound choices for P̊ (A2) assuming bounds on P̊ (A1)
and P̊ (C).
P̊ (C)






Table 2.11: Table listing the probability of toxicity on the first cycle P (A1), the
probability of toxicity on any cycle P (C), the expected dose on the entire regimen,
flags set to one if the regimen qualifies when using only option 1, P r(C) = 0.30
and three instances of using option 2, P r(C) = 0.30 and P r(A1) = (0.05, 0.10, 0.20)
corresponding to the 19 favorable dose regimen listed in Table 2.3. α = 1, β =
0.2, ρ = 0.8 are the true values of the parameters.
Reg Regimen P (A1) P (C) Exp P
r(C) P r(A1) P
r(A1) P
r(A1)
ID Dose ≤ 0.30 ≤ 0.05 ≤ 0.10 ≤ 0.20
1 1 1 1 1 1 1 0.02 0.04 5.86 1 1 1 1
2 2 2 2 2 2 2 0.05 0.10 11.29 1 1 1 1
3 3 3 3 3 3 3 0.10 0.22 15.84 1 0 1 1
4 4 4 4 4 4 4 0.16 0.36 19.33 0 0 0 0
5 5 5 5 5 5 5 0.23 0.52 21.54 0 0 0 0
6 1 1 1 2 2 2 0.02 0.08 8.63 1 1 1 1
7 2 2 2 3 3 3 0.05 0.18 13.71 1 1 1 1
8 3 3 3 4 4 4 0.10 0.31 17.81 0 0 0 0
9 4 4 4 5 5 5 0.16 0.46 20.76 0 0 0 0
10 2 2 2 1 1 1 0.05 0.07 8.57 1 1 1 1
11 3 3 3 2 2 2 0.10 0.15 13.46 1 0 1 1
12 4 4 4 3 3 3 0.16 0.26 17.43 1 0 0 1
13 5 5 5 4 4 4 0.23 0.40 20.21 0 0 0 0
14 1 1 2 2 3 3 0.02 0.15 11.22 1 1 1 1
15 2 2 3 3 4 4 0.05 0.26 15.89 1 1 1 1
16 3 3 4 4 5 5 0.10 0.41 19.48 0 0 0 0
17 5 5 4 4 3 3 0.23 0.34 18.67 0 0 0 0
18 4 4 3 3 2 2 0.16 0.22 15.34 1 0 0 1
19 3 3 2 2 1 1 0.10 0.13 10.96 1 0 1 1
68
Table 2.12: Trial/Patient summary results for Plan 1, maximizing expected dose over 500 simulated clinical
trials. Columns present 1) mean dose received per patient, 2) mean toxicities over the trials with trial stopping
early in parenthesis, 3) average patients having dose ≥ the recommended expected dose, 4) average patients
having dose ≥ the target expected dose, 5) average patients having regimen exactly equal to the recommended
regimen 6) average patients having regimen exactly equal to the target regimen, 7) average patients having
regimen ≤ 2 from the recommended regimen and 8) average patients having regimen ≤ 2 from the target
regimen.
Mean Mean Patients Patients Patients Patients P.R.Dist P.T.Dist
Dose Toxicities* ≥R.Edosea ≥T.Edosea =R.Distb =T.Distb ≤2 ≤ 2
Using P r(A1)&P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.48 0.31 ( 48 ) 20.27 15.02 0.62 0.83 5.66 5.35
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.91 0.30 ( 25 ) 18.09 18.09 1.64 0.64 11.75 4.89
P̊ (A1) = 0.2, P̊ (A2) = 0.06 16.21 0.27 ( 11 ) 16.73 17.22 3.96 1.83 10.86 8.57
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.53 0.31 ( 48 ) 20.28 14.96 0.60 0.83 5.40 5.24
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.99 0.31 ( 25 ) 17.98 17.68 1.59 0.69 11.3 4.67
P̊ (A1) = 0.2, P̊ (A2) = 0.06 16.33 0.28 ( 11 ) 16.82 17.38 4.46 2.16 11.26 9.31
Using P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.48 0.31 ( 48 ) 12.84 12.71 0.45 0.13 8.15 2.09
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.91 0.3 ( 25 ) 15.46 13.51 1.81 0.68 11.09 4.95
P̊ (A1) = 0.2, P̊ (A2) = 0.06 16.21 0.27 ( 11 ) 16.73 17.22 3.95 1.83 10.81 8.57
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.53 0.31 ( 48 ) 12.81 12.77 0.43 0.12 7.68 2.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.99 0.31 ( 25 ) 15.29 13.37 1.72 0.65 10.71 5.44
P̊ (A1) = 0.2, P̊ (A2) = 0.06 16.33 0.28 ( 11 ) 16.82 17.38 4.47 2.16 11.24 9.31
* Values in parenthesis indicates the number of trials out of 500 that stopped early
a T/R.Edose - Target/Recommended expected dose.
b T/R.Dist - Distance of patient regimen from Target/Recommended regimen.
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Table 2.13: Trial/Patient summary results for Plan 2- matching a regimen with Rl ≤ 3 over 500 simulated
clinical trials.
Mean Mean Patients Patients Patients Patients P.R.Dist P.T.Dist
Dose Toxicities* ≥R.Edosea ≥T.Edosea =R.Distb =T.Distb ≤2 ≤ 2
Using P r(A1)&P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.57 0.31 ( 48 ) 20.18 15.02 0.61 0.82 5.52 5.18
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.07 0.31 ( 25 ) 17.98 17.8 1.44 0.64 10.85 4.7
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.33 0.31 ( 11 ) 19.75 18.98 4.57 3.33 12.83 11.81
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.55 0.31 ( 48 ) 20.28 15.03 0.6 0.82 5.36 5.21
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.10 0.31 ( 25 ) 17.89 17.88 1.39 0.63 10.89 4.71
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.34 0.31 ( 11 ) 19.76 19.00 4.64 3.36 12.94 11.85
Using P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.57 0.31 ( 48 ) 12.85 12.92 0.42 0.11 7.47 2.36
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.07 0.31 ( 25 ) 15.60 13.71 1.87 1.08 10.74 6.13
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.33 0.31 ( 11 ) 19.75 18.98 4.7 3.33 12.99 11.81
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.55 0.31 ( 48 ) 13 12.88 0.42 0.11 7.49 2.36
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.10 0.31 ( 25 ) 15.62 13.79 1.85 1.09 10.76 6.10
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.34 0.31 ( 11 ) 19.76 19.00 4.73 3.36 13.04 11.85
* Values in parenthesis indicates the number of trials out of 500 that stopped early
a T/R.Edose - Target/Recommended expected dose.
b T/R.Dist - Distance of patient regimen from Target/Recommended regimen.
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Table 2.14: Trial/Patient summary results for Plan 2- matching a regimen with Rl ≤ 2 instead of 3 over 500
simulated clinical trials.
Mean Mean Patients Patients Patients Patients P.R.Dist P.T.Dist
Dose Toxicities* ≥R.Edosea ≥T.Edosea =R.Distb =T.Distb ≤2 ≤ 2
Using P r(A1)&P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.54 0.31 ( 48 ) 20.4 14.99 0.58 0.82 5.31 5.21
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.11 0.31 ( 25 ) 17.97 17.88 1.41 0.63 10.97 4.71
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.34 0.31 ( 11 ) 19.74 18.99 4.65 3.35 12.86 11.82
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.54 0.31 ( 48 ) 20.2 14.93 0.60 0.84 5.38 5.2
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.08 0.31 ( 25 ) 17.91 17.84 1.40 0.63 10.82 4.71
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.34 0.31 ( 11 ) 19.73 19.00 4.60 3.37 12.81 11.84
Using P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.54 0.31 ( 48 ) 12.83 12.88 0.41 0.12 7.63 2.36
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.11 0.31 ( 25 ) 15.7 13.79 1.81 1.09 10.64 6.07
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.34 0.31 ( 11 ) 19.73 18.99 4.75 3.35 12.98 11.82
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 15.54 0.31 ( 48 ) 12.75 12.83 0.42 0.12 7.47 2.36
P̊ (A1) = 0.1, P̊ (A2) = 0.08 16.08 0.31 ( 25 ) 15.58 13.74 1.81 1.08 10.68 6.11
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.34 0.31 ( 11 ) 19.73 19.00 4.70 3.37 12.91 11.84
* Values in parenthesis indicates the number of trials out of 500 that stopped early
a T/R.Edose - Target/Recommended expected dose.
b T/R.Dist - Distance of patient regimen from Target/Recommended regimen.
71
Table 2.15: Trial/Patient summary results for Plan 2- matching a regimen with min(Rl) over 500 simulated
clinical trials.
Mean Mean Patients Patients Patients Patients P.R.Dist P.T.Dist
Dose Toxicities* ≥R.Edosea ≥T.Edosea =R.Distb =T.Distb ≤2 ≤ 2
Using P r(A1), P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 13.91 0.26 ( 48 ) 17.28 15.12 12.14 10.82 18.06 15.31
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.15 0.27 ( 25 ) 15.91 17.84 2.84 2.40 11.75 9.03
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17 0.30 ( 11 ) 19.2 18.76 4.41 3.46 10.96 10.30
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 13.92 0.27 ( 50 ) 17.21 15.53 11.81 10.73 18.69 15.72
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.2 0.28 ( 25 ) 16.12 18.01 2.42 2.42 12.26 9.27
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.01 0.30 ( 11 ) 19.24 18.79 4.61 3.48 11.24 10.40
Using P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 13.91 0.26 ( 48 ) 7.91 11.58 2.08 0.15 7.31 1.88
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.15 0.27 ( 25 ) 13.64 13.49 3.24 1.30 10.33 4.81
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17 0.3 ( 11 ) 19.19 18.76 4.54 3.46 11.03 10.30
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 13.92 0.27 ( 50 ) 8.03 11.49 1.60 0.14 7.50 1.95
P̊ (A1) = 0.1, P̊ (A2) = 0.08 15.2 0.28 ( 25 ) 13.95 13.39 2.98 1.32 10.73 4.99
P̊ (A1) = 0.2, P̊ (A2) = 0.06 17.01 0.30 ( 11 ) 19.22 18.79 4.72 3.48 11.3 10.40
* Values in parenthesis indicates the number of trials out of 500 that stopped early
a T/R.Edose - Target/Recommended expected dose.
b T/R.Dist - Distance of patient regimen from Target/Recommended regimen.
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Table 2.16: Regimen recommendation summary for Plan 1 -maximizing the expected dose over 500 simulated
clinical trials. Columns correspond to 1) the mean distance between the target (T) and recommended (R)
regimen, 2) the proportion of trials have an exact match between the T and R regimens, 3) the expected dose
for the T regimen, 4) the expected dose for the R regimen, 5) the probability of toxicity on any cycle under
the T regimen and 6) the probability of toxicity on any cycle under the R regimen.
Mean(T-R)a Prop of Target Rec Target Rec
Distance* T-R=0* Exp Dose* Exp Dose* Toxicities Toxicities
Using P r(A1)&P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.77 ( 452 ) 0.51 ( 452 ) 15.89 ( 500 ) 15 ( 452 ) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.92 ( 475 ) 0.25 ( 475 ) 15.89 ( 500 ) 16.25 ( 475 ) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.99 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.03 ( 489 ) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.84 ( 452 ) 0.51 ( 452 ) 15.89 ( 500 ) 15 ( 452 ) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.96 ( 475 ) 0.23 ( 475 ) 15.89 ( 500 ) 16.18 ( 475 ) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 4.04 ( 489 ) 0.18 ( 489 ) 17.43 ( 500 ) 17.17 ( 489 ) 0.26 0.28
Using P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.70 ( 489 ) 0.16 ( 489 ) 17.43 ( 500 ) 17.11 ( 489 ) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.32 ( 489 ) 0.21 ( 489 ) 17.43 ( 500 ) 16.82 ( 489 ) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.96 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.04 ( 489 ) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.61 ( 489 ) 0.18 ( 489 ) 17.43 ( 500 ) 17.14 ( 489 ) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.22 ( 489 ) 0.19 ( 489 ) 17.43 ( 500 ) 16.79 ( 489 ) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.99 ( 489 ) 0.18 ( 489 ) 17.43 ( 500 ) 17.19 ( 489 ) 0.26 0.28
* Values in parenthesis indicates the number of trials out of 500 that had a regimen selection
a T - Target/True regimen, R - Recommended regimen
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Table 2.17: Regimen recommendation summary for Plan 2 - matching the regimen with Rl ≤ 3 over 500
simulated clinical trials.
Mean(T-R)a Prop of Target Rec Target Rec
Distance* T-R=0* Exp Dose* Exp Dose* Toxicities Toxicities
Using P r(A1)&P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.84 ( 452 ) 0.5 ( 452 ) 15.89 ( 500 ) 15.09 ( 452 ) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.86 ( 475 ) 0.25 ( 475 ) 15.89 ( 500 ) 16.21 ( 475 ) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.85 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.21 ( 489 ) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.83 ( 452 ) 0.5 ( 452 ) 15.89 ( 500 ) 15.02 ( 452 ) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.84 ( 475 ) 0.24 ( 475 ) 15.89 ( 500 ) 16.26 ( 475 ) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.84 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.24 ( 489 ) 0.26 0.28
Regimen selected using P r(C)
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.64 ( 489 ) 0.17 ( 489 ) 17.43 ( 500 ) 17.16 ( 489 ) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.24 ( 489 ) 0.21 ( 489 ) 17.43 ( 500 ) 16.78 ( 489 ) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.78 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.24 ( 489 ) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.65 ( 489 ) 0.17 ( 489 ) 17.43 ( 500 ) 17.12 ( 489 ) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.23 ( 489 ) 0.21 ( 489 ) 17.43 ( 500 ) 16.83 ( 489 ) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.76 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.26 ( 489 ) 0.26 0.28
* Values in parenthesis indicates the number of trials out of 500 that had a regimen selection
a T - Target/True regimen, R - Recommended regimen
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Table 2.18: Regimen recommendation summary for 500 simulated clinical trials executed using Plan 2,
matching the regimen with Rl ≤ 2.
Mean(T-R)a Prop of Target Rec Target Rec
Distance* T-R=0* Exp Dose* Exp Dose* Toxicities Toxicities
Regimen selected using P r(A1)&P r(C)
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.87 (452) 0.5 (452) 15.89 (500) 14.95 (452) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.83 (475) 0.25 (475) 15.89 (500) 16.26 (475) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.87 (489) 0.22 (489) 17.43 (500) 17.26 (489) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.93 (452) 0.49 (452) 15.89 (500) 15.03 (452) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.81 (475) 0.25 (475) 15.89 (500) 16.25 (475) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.89 (489) 0.22 (489) 17.43 (500) 17.24 (489) 0.26 0.28
Regimen selected using P r(C)
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.65 (489) 0.17 (489) 17.43 (500) 17.13 (489) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.24 (489) 0.20 (489) 17.43 (500) 16.82 (489) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.80 (489) 0.22 (489) 17.43 (500) 17.28 (489) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.62 (489) 0.18 (489) 17.43 (500) 17.13 (489) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.25 (489) 0.21 (489) 17.43 (500) 16.80 (489) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.81 (489) 0.22 (489) 17.43 (500) 17.26 (489) 0.26 0.28
* Values in parenthesis indicates the number of trials out of 500 that had a regimen selection
a T - Target/True regimen, R - Recommended regimen
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Table 2.19: Regimen recommendation summary for 500 simulated clinical trials executed using Plan 2,
matching the regimen with regimen distance equal to min(Rl) and switching to Plan 1 not allowed.
Mean(T-R)a Prop of Target Rec Target Rec
Distance* T-R=0* Exp Dose* Exp Dose* Toxicities Toxicities
Regimen selected using P r(A1)&P r(C)
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.71 ( 452 ) 0.51 ( 452 ) 15.89 ( 500 ) 14.87 ( 452 ) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.89 ( 475 ) 0.27 ( 475 ) 15.89 ( 500 ) 16.13 ( 475 ) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.89 ( 489 ) 0.21 ( 489 ) 17.43 ( 500 ) 17.17 ( 489 ) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 2.64 ( 450 ) 0.52 ( 450 ) 15.89 ( 500 ) 14.91 ( 450 ) 0.26 0.22
P̊ (A1) = 0.1, P̊ (A2) = 0.08 2.82 ( 475 ) 0.27 ( 475 ) 15.89 ( 500 ) 16.16 ( 475 ) 0.26 0.26
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.77 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.21 ( 489 ) 0.26 0.28
Using P r(C) = 0.30
P̊ (B) = 0.3, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.68 ( 489 ) 0.17 ( 489 ) 17.43 ( 500 ) 16.85 ( 489 ) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.26 ( 489 ) 0.2 ( 489 ) 17.43 ( 500 ) 16.69 ( 489 ) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.83 ( 489 ) 0.21 ( 489 ) 17.43 ( 500 ) 17.19 ( 489 ) 0.26 0.28
P̊ (B) = 0.4, P̊ (C) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.09 4.7 ( 489 ) 0.18 ( 489 ) 17.43 ( 500 ) 16.81 ( 489 ) 0.26 0.28
P̊ (A1) = 0.1, P̊ (A2) = 0.08 4.17 ( 489 ) 0.21 ( 489 ) 17.43 ( 500 ) 16.74 ( 489 ) 0.26 0.28
P̊ (A1) = 0.2, P̊ (A2) = 0.06 3.72 ( 489 ) 0.22 ( 489 ) 17.43 ( 500 ) 17.23 ( 489 ) 0.26 0.28
* Values in parenthesis indicates the number of trials out of 500 that had a regimen selection
a T - Target/True regimen, R - Recommended regimen
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Table 2.20: Trial/Patient summary -using only P̊ (C) flag in carrying out 100 simulated trials.
Mean Mean Patients Patients Patients Patients P.R.Dist P.T.Dist
Dose Toxicities* ≥R.Edosea ≥T.Edosea =R.Distb =T.Distb ≤2 ≤ 2
Plan 1: P r(A1)&P r(C) = 0.30
P̊ (C) = 0.30 P̊ (A1) = 0.20, P̊ (A2) = 0.03 15.91 0.24 ( 2 ) 13.55 15.48 3.26 1.25 11.08 6.28
P̊ (C) = 0.40P̊ (A1) = 0.20, P̊ (A2) = 0.06 16.40 0.27 ( 2 ) 16.67 17.68 4.87 1.97 11.69 8.68
Using P r(C) = 0.30 in regimen selection
P̊ (C) = 0.30 P̊ (A1) = 0.20, P̊ (A2) = 0.03 15.91 0.24 ( 2 ) 13.5 15.48 2.72 1.25 10.57 6.28
P̊ (C) = 0.40P̊ (A1) = 0.20, P̊ (A2) = 0.06 16.40 0.27 ( 2 ) 16.64 17.68 4.19 1.97 11.04 8.68
Plan 2:P r(A1)&P r(C) = 0.30
P̊ (C) = 0.30P̊ (A1) = 0.20, P̊ (A2) = 0.03 16.45 0.27 ( 2 ) 18.62 18.39 5.09 8.20 10.04 12.67
P̊ (C) = 0.40 P̊ (A1) = 0.20, P̊ (A2) = 0.06 17.20 0.30 ( 2 ) 19.19 19.25 5.37 3.63 12.02 10.91
Using P r(C) = 0.30 in regimen selection
P̊ (C) = 0.30P̊ (A1) = 0.20, P̊ (A2) = 0.03 16.45 0.27 ( 2 ) 18.59 18.39 4.68 8.20 9.60 12.67
P̊ (C) = 0.40 P̊ (A1) = 0.20, P̊ (A2) = 0.06 17.20 0.30 ( 2 ) 18.93 19.25 5.10 3.63 11.66 10.91
* Values in parenthesis indicates the number of trials out of 100 that stopped early
a T/R.Edose - Target/Recommended expected dose.
b T/R.Dist - Distance of patient regimen from Target/Recommended regimen.
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Table 2.21: Regimen recommendation summary using P̊ (C) instead of P̊ (B) on later cycles for Plan 1 and
2, with Plan 2 executed by setting Rl to the minimum distance possible in 100 simulated trials.
Mean(T-R)a Prop of Target Rec Target Rec
Distance* T-R=0* Exp Dose* Exp Dose* Toxicities Toxicities
Plan 1: Regimen selected using P r(A1)&P r(C)
P̊ (C) = 0.30, P̊ (A1) = 0.20, P̊ (A2) = 0.03 4.26 ( 98 ) 0.14 ( 98 ) 17.43 ( 100 ) 18.06 ( 98 ) 0.26 0.27
P̊ (C) = 0.40,P̊ (A1) = 0.20, P̊ (A2) = 0.06 4.01 ( 98 ) 0.15 ( 98 ) 17.43 ( 100 ) 17.62 ( 98 ) 0.26 0.28
Regimen selected using P̂ (C)
P̊ (C) = 0.30,P̊ (A1) = 0.20, P̊ (A2) = 0.03 4.13 ( 98 ) 0.17 ( 98 ) 17.43 ( 100 ) 18.12 ( 98 ) 0.26 0.28
P̊ (C) = 0.40,P̊ (A1) = 0.20, P̊ (A2) = 0.06 3.89 ( 98 ) 0.18 ( 98 ) 17.43 ( 100 ) 17.67 ( 98 ) 0.26 0.28
Plan 2: Regimen selected using P r(A1)&P r(C)
P̊ (C) = 0.30,P̊ (A1) = 0.20, P̊ (A2) = 0.03 4.21 ( 98 ) 0.20 ( 98 ) 17.43 ( 100 ) 17.62 ( 98 ) 0.26 0.27
P̊ (C) = 0.40,P̊ (A1) = 0.20, P̊ (A2) = 0.06 3.89 ( 98 ) 0.21 ( 98 ) 17.43 ( 100 ) 17.77 ( 98 ) 0.26 0.28
Regimen selected using P r(C)
P̊ (C) = 0.30, P̊ (A1) = 0.20, P̊ (A2) = 0.03 4.09 ( 98 ) 0.23 ( 98 ) 17.43 ( 100 ) 17.67 ( 98 ) 0.26 0.28
P̊ (C) = 0.40, P̊ (A1) = 0.20, P̊ (A2) = 0.06 3.64 ( 98 ) 0.26 ( 98 ) 17.43 ( 100 ) 17.87 ( 98 ) 0.26 0.28
* Values in parenthesis indicates the number of trials out of 100 that had a regimen selection
a T - Target/True regimen, R - Recommended regimen
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2.6 Appendix
2.6.1 Outline of the code written in JAGS
The code presented below corresponds to applying Model 2.1 in simulations for
parameter estimation from the posterior samples.
#Defining the model.bug file1
model {2
#Define the likelihood for each of the N subjects3
for (i in 1:N) {4




#Setting up the priors9
#prior on α - E(α) = 1 and V ar(α) = 210
mu1 < − -0.8047190; tau1 < − 0.621334911
alpha ∼ dlnorm(mu1,tau1)12
#prior on ρ13
a1 < − 5 ; b1 < − 114
rho ∼ dbeta(a1,b1)15
#Prior on β - E(β) = 0.5 and V ar(β) = 116














update(jags,10000) # burin samples30













2.6.2 Parameter Estimation with different burn-in period
In this section simulation results are presented explaining the rationale behind
the decisions for setting the variance of the priors and the choice of burn-in period.
The effect of changing the variance of the prior distributions of α and β was
studied with N = (10, 30) patients in completed trials. The probability skeleton
qg = (0.02, 0.05, 0.10, 0.15, 0.23) was used to obtain doses dg. Patients were assumed
to receive the same dose on all the K = 6 cycles and the N patients were divided
equally among the five dose levels. The conditional probability of toxic response
pi,k for patient i on cycle k was calculated using Model 2.1 for dose dg and fixed
parameters α = 1, β = 0.5 and ρ = 0.8. A Bernoulli (pi,k) random variable was used
to assign the response for each patient at every cycle. Further doses were assigned
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until a DLT response was observed or until completion of K = 6 cycles. Simulation
results are presented over 500 such replicates/datasets.
The use of probability skeleton requires that the prior mean of α be set at one.
The prior mean of β was set to 0.5, matching the true value used for data generation
in simulations. To study the effect of the priors at the estimation stage, two different
cases were considered. In the first case the prior means used were E(α) = 1 and
E(β) = 0.5 matching the true values used to generate the data. The SD was set to
two times the mean, SD(α) = 2 and SD(β) = 1.
In the second case the means of the prior were E(α) = 1 and E(β) = 0.5 matching
the true values used to generate the data while the standard deviation was set to
five times the mean, SD(α) = 5 and SD(β) = 2.5
In both the cases Beta(5, 1) prior was used on ρ. The goal was to observe the
effect of varying the informativeness of the priors on the estimation of the parameters.
After an adaptive phase of 10K samples and a burn-in period of 10K samples, 100K
MCMC samples were drawn from the posterior with a thinning of 20. The effect
of using a longer burn-in period was also studied by drawing an additional 100K
MCMC samples effectively increasing the burn-in period to 110K (10K from the
initial burn-in and 100K from the first sample). The goal of studying estimates from
two different burn-in periods was to study and determine the appropriate burn-in
period for use in further simulations.
The simulation results of the parameter estimates from these simulations are
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presented in Table 2.22 for N = (10, 30, 90) patients. Within each of the sample size,
the rows are grouped by the two cases followed by the two burn-in periods with each
row corresponding to estimates of either α, β or ρ . Each of the four columns report
(1) the estimated value and the mean bias from the true value, (2) the mean SD
(MSD) of the estimates across 500 iterations, (3) the empirical SD (ESD) of the 500
estimates, (4) the credible interval coverage rate across the 500 replicates/datasets.
The corresponding probability estimates are presented in Table 2.23 for N = 10
patients and Table 2.24 for N = 30 patients. The columns indicate the mean estimate
of probability of toxicity on the first, the second, the sixth cycle and the overall
probability of toxicity on any of the cycles along with the bias from the true values
in parenthesis. The rows are grouped by the two cases studying the effect of varying
variances of the prior and within each case the results are further grouped by the
two different burn-in periods with each of the rows corresponding to one of the dose
levels. The following are the conclusions from these simulations results.
• Using a longer burn-in period does not provide improve the parameter esti-
mates in terms of the bias. Hence using the shorter burn-in period of 10K is
recommended for further simulation setups.
• The bias difference between the two cases not very different and showed that
having the SD equal to two times the mean with a CV of 2 provided a fair
degree of variability. There was not much gain from using a larger variance.
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• The bias of the parameter estimates seems quite high in Table 2.22 but when
compared to the conditional probability estimates in Tables 2.23 and 2.24 the
bias was not high. So it seems like the model estimates the values of the
conditional probabilities of toxicity correctly even though the parameters might
have a slight bias from the true values. Subsequent tables will display either the
probabilities or the parameter estimates to prevent replication of information.
• These results demonstrate the best the model can achieve in determining the
parameters and the probabilities since the prior means are completely aligned
with the true values used to generate the data. This provides a sense of how
well the model does in terms of estimation and will provide a benchmark in
assessing the model fit in later simulation settings.
• An improvement in bias and efficiency was seen in terms of lower SD of the
estimates with an increase in the sample size. Also the empirical SD of the
estimates and the mean SD from the 500 datasets was comparable as the sample
size increased. This confirms that the having a larger sample size improves
estimates and that the distribution of the estimates obtained is alike to the
sampling distribution.
83
Table 2.22: Parameter Estimates Based on Model 2.1 from 500 simulated datasets
containing N = (10, 30) patients receiving one of five dose groups d1 . . . d5 over six
cycles comparing different burin periods. Results presented for α = 1, β = 0.5 and
ρ = 0.8
Estimate(Bias) MSD 1 ESD 2 Coverage
N=10
Burn in 10K Case 1
α 0.945 ( -0.055 ) 0.683 0.584 99.6
β 0.515 ( 0.015 ) 0.463 0.308 100
ρ 0.820 ( 0.02 ) 0.137 0.040 100
Burn in 110K
α 0.945 ( -0.055 ) 0.683 0.584 99.6
β 0.515 ( 0.015 ) 0.463 0.308 100
ρ 0.820 ( 0.02 ) 0.137 0.040 100
Burn in 10K Case 2
α 0.932 ( -0.068 ) 0.725 0.697 95.2
β 0.481 ( -0.019 ) 0.498 0.387 94.6
ρ 0.813 ( 0.013 ) 0.140 0.039 100
Burn in 110K
α 0.932 ( -0.068 ) 0.724 0.697 95.2
β 0.481 ( -0.019 ) 0.498 0.386 94.8
ρ 0.813 ( 0.013 ) 0.140 0.039 100
N=30
Burn in 10K Case 1
α 0.957 ( -0.043 ) 0.458 0.417 96.6
β 0.511 ( 0.011 ) 0.338 0.296 97.8
ρ 0.806 ( 0.006 ) 0.132 0.056 100
Burn in 110K
α 0.957 ( -0.043 ) 0.457 0.416 96.6
β 0.511 ( 0.011 ) 0.339 0.296 98.0
ρ 0.806 ( 0.006 ) 0.132 0.055 100
Burn in 10K Case 2
α 0.969 ( -0.031 ) 0.477 0.455 94.6
β 0.464 ( -0.036 ) 0.353 0.338 95.0
ρ 0.793 ( -0.007 ) 0.136 0.057 100
Burn in 110K
α 0.968 ( -0.032 ) 0.476 0.455 94.4
β 0.464 ( -0.036 ) 0.353 0.338 95.0
ρ 0.793 ( -0.007 ) 0.136 0.057 100
1 MSD is mean of the SD from 500 estimates
2 ESD is empirical SD of the 500 estimates
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Table 2.23: Table comparing the effect of using two different burn-in periods and the
effect of using two different priors (Case 1 and Case 2) on the parameters. Estimates
(bias) from the true value of conditional probability of toxicity on each of the six
cycles estimated using Model 2.1 from 500 simulated datasets containing N = 10
patients each receiving one of five dose groups d1 . . . d5.Results presented for α =
1, β = 0.5 and ρ = 0.8
Cycle 1 Cycle 2 Cycle 6 Any Cycle
Est(bias) Est(bias) Est(bias) Est(bias)
Case 1
Burn in 10K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.04 ( -0.002 )
d2 0.047 ( -0.003 ) 0.011 ( -0.001 ) 0.016 (< 0.001) 0.109 ( -0.006 )
d3 0.093 ( -0.007 ) 0.025 ( -0.001 ) 0.047 ( -0.001 ) 0.242 ( -0.013 )
d4 0.148 ( -0.012 ) 0.047 ( -0.002 ) 0.104 ( -0.001 ) 0.415 ( -0.023 )
d5 0.210 ( -0.020 ) 0.081 ( -0.002 ) 0.197 ( -0.003 ) 0.609 ( -0.036 )
Burn in 110K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.04 ( -0.002 )
d2 0.047 ( -0.003 ) 0.011 ( -0.001 ) 0.016 (< 0.001) 0.109 ( -0.006 )
d3 0.093 ( -0.007 ) 0.025 ( -0.001 ) 0.047 (< 0.001) 0.242 ( -0.013 )
d4 0.148 ( -0.012 ) 0.047 ( -0.002 ) 0.104 ( -0.001 ) 0.416 ( -0.023 )
d5 0.210 ( -0.020 ) 0.081 ( -0.002 ) 0.197 ( -0.003 ) 0.609 ( -0.036 )
Case 2
Burn in 10K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.039 ( -0.003 )
d2 0.046 ( -0.004 ) 0.011 ( -0.001 ) 0.016 (< 0.001) 0.106 ( -0.009 )
d3 0.091 ( -0.009 ) 0.025 ( -0.002 ) 0.045 ( -0.003 ) 0.233 ( -0.021 )
d4 0.144 ( -0.016 ) 0.046 ( -0.003 ) 0.099 ( -0.006 ) 0.399 ( -0.040 )
d5 0.204 ( -0.026 ) 0.078 ( -0.005 ) 0.185 ( -0.015 ) 0.582 ( -0.063 )
Burn in 110K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.039 ( -0.003 )
d2 0.046 ( -0.004 ) 0.011 ( -0.001 ) 0.016 (< 0.001) 0.106 ( -0.009 )
d3 0.091 ( -0.009 ) 0.025 ( -0.002 ) 0.045 ( -0.003 ) 0.233 ( -0.022 )
d4 0.144 ( -0.016 ) 0.046 ( -0.003 ) 0.099 ( -0.006 ) 0.398 ( -0.040 )
d5 0.204 ( -0.026 ) 0.078 ( -0.005 ) 0.185 ( -0.015 ) 0.582 ( -0.063 )
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Table 2.24: Table comparing the effect of using two different burn-in periods and the
effect of using four different priors on the parameters. Parameter Estimates with bias
from the true value of conditional probability of no toxicity on each of the six cycles
estimated using Model 2.1 from 500 simulated datasets containing N = 30 patients
each receiving one of five dose groups d1 . . . d5.Results presented for α = 1, β = 0.5
and ρ = 0.8
Cycle 1 Cycle 2 Cycle 6 Any Cycle
Est(bias) Est(bias) Est(bias) Est(bias)
Case 1
Burn in 10K
d1 0.019 ( -0.001 ) 0.004(< 0.001) 0.005(< 0.001) 0.041 ( -0.002 )
d2 0.048 ( -0.002 ) 0.011 (< 0.001) 0.016 (< 0.001) 0.111 ( -0.004 )
d3 0.095 ( -0.005 ) 0.025 ( -0.001 ) 0.047 (< 0.001) 0.246 ( -0.008 )
d4 0.152 ( -0.008 ) 0.048 ( -0.001 ) 0.104 ( -0.001 ) 0.425 ( -0.014 )
d5 0.217 ( -0.013 ) 0.081 ( -0.002 ) 0.197 ( -0.002 ) 0.623 ( -0.022 )
Burn in 110K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.041 ( -0.002 )
d2 0.048 ( -0.002 ) 0.011 (< 0.001) 0.016 (< 0.001) 0.111 ( -0.004 )
d3 0.095 ( -0.005 ) 0.025 ( -0.001 ) 0.047(< 0.001) 0.246 ( -0.008 )
d4 0.151 ( -0.009 ) 0.048 ( -0.001 ) 0.104 ( -0.001 ) 0.425 ( -0.014 )
d5 0.217 ( -0.013 ) 0.081 ( -0.002 ) 0.198 ( -0.002 ) 0.623 ( -0.022 )
Case 2
Burn in 10K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.041 ( -0.002 )
d2 0.048 ( -0.002 ) 0.011 (< 0.001) 0.016 (< 0.001) 0.110 ( -0.005 )
d3 0.096 ( -0.004 ) 0.025 ( -0.001 ) 0.045 ( -0.003 ) 0.242 ( -0.013 )
d4 0.153 ( -0.007 ) 0.047 ( -0.002 ) 0.098 ( -0.007 ) 0.413 ( -0.025 )
d5 0.218 ( -0.012 ) 0.079 ( -0.004 ) 0.184 ( -0.016 ) 0.604 ( -0.040 )
Burn in 110K
d1 0.019 ( -0.001 ) 0.004 (< 0.001) 0.005 (< 0.001) 0.041 ( -0.002 )
d2 0.048 ( -0.002 ) 0.011 (< 0.001) 0.016 (< 0.001) 0.11 ( -0.005 )
d3 0.096 ( -0.004 ) 0.025 ( -0.001 ) 0.045 ( -0.003 ) 0.242 ( -0.013 )
d4 0.153 ( -0.007 ) 0.047 ( -0.002 ) 0.098 ( -0.007 ) 0.414 ( -0.025 )
d5 0.218 ( -0.012 ) 0.079 ( -0.004 ) 0.184 ( -0.016 ) 0.604 ( -0.040 )
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2.6.3 Patient profiles for mixed dose assignment
The following table shows the potential dose course for the 30 patients to be
used in the simulations to compare the efficiency gain in using dose variation within
patients.
Table 2.25: Table showing the dose level assignment at each cycle for the N = 30
patients so that each of the dose occurs 36 times over all the patients.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 1 1 1 1 1 1
2 1 1 1 1 1 1
3 1 1 1 1 1 1
4 2 2 2 2 2 2
5 3 3 3 3 3 3
6 4 4 4 4 4 4
7 5 5 5 5 5 5
8 5 5 5 5 5 5
9 5 5 5 5 5 5
10 1 1 1 2 2 2
11 1 1 1 2 2 2
12 2 2 2 3 3 3
13 2 2 2 3 3 3
14 3 3 3 4 4 4
15 3 3 3 4 4 4
16 4 4 4 5 5 5
17 4 4 4 5 5 5
18 2 2 2 1 1 1
19 3 3 3 2 2 2
20 4 4 4 3 3 3
21 5 5 5 4 4 4
22 1 1 2 2 3 3
23 1 1 2 2 3 3
24 2 2 3 3 4 4
25 2 2 3 3 4 4
26 3 3 4 4 5 5
27 3 3 4 4 5 5
28 5 5 4 4 3 3
29 4 4 3 3 2 2
30 3 3 2 2 1 1
2.6.4 Example of an adaptive trial in progress
Based on the algorithm presented in Section 2.4.4.1 for Plan 1, an example of a
trial in progress is presented in this section for demonstrating the dose assignment
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in practice. The target probability bounds used during the execution are P̊ (C) =
0.40, P̊ (B) = 0.30, P̊ (A1) = 0.05, P̊ (A2) = 0.09 and the true values of the parameters
are α = 1, β = 0.2, ρ = 0.8.
Table 2.26 presents the current patient profile in the trial. The rows correspond
to the unique patients added sequentially in the trial. The columns correspond
to the six cycles with the dose level assigned to the patient and the response in
parenthesis. A zero signifies no DLT while a 1 denotes a DLT, a cross is placed in
all cycles once a DLT response is observed for a patient. There are 12 patients in
the trial and decisions need to be made for dose assignment to patients 8, 9, 10, and
11 and a new patient 13. Before patient 12 was added to the trial the parameter
estimates were α̂ = 0.421(0.404), β̂ = 1.142(0.8377) and ρ̂ = 0.826(0.147) with the
posterior standard deviations in parenthesis. The updated current estimates of the
parameters are α̂ = 0.7635(0.566) β̂ = 0.917(0.711) and ρ̂ = 0.829(0.147). Notice
that the estimate of α̂ increases in response to the DLT observed by patient 12 on
cycle 1.
The probability of toxicity on dose levels 1 through 4 for patient 8 are 0.010,0.025,
0.051,0.103 of which dose level 3 has probability of toxicity≤ P̊ (A2) = 0.09 and is also
able to provide a regimen combination that satisfies the P̊ (C) = 0.40, P̊ (B) = 0.30
and hence is assigned to patient 8 on cycle 6. Using the true values of the parameters
and the current dose assignment the true probability of toxicity is calculated and a
Bernoulli response is generated. In a similar fashion the remaining patients are
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assigned doses and responses and the updated patient profile is presented in Table
2.27. The updated parameter estimates are now α̂ = 0.684(0.519), β̂ = 1.323(0.829)
and ρ̂ = 0.838(0.146). Notice the decrease in estimate of α̂ since no fresh toxicities
on the first cycle but there is an increase in β̂ reflecting the toxicity on cycle 6 for
patient 8.
At the end of the trial the completed patient profile is presented in Table 2.28.
The parameter estimates at the conclusion of the trial are α̂ = 0.943(0.482), β̂ =
0.738(0.4234) and ρ̂ = 0.866(0.129). The probability of toxicity on the first cycle and
on any cycle is calculated using the current estimates of the parameters for all the
19 regimens in Table 2.3 to select the recommended regimen and by using the true
parameter values to select the target regimen. By setting P r(A1) = P̊ (A1) = 0.05
and P r(C) = 0.3 and using the true parameter values the target regimen selected
is 223344 while the recommended regimen is 222333 using the parameter estimates
obtained at the conclusion of the trial. If only P r(C) = 0.3 is used the target regimen
is 444333 while the recommended regimen is 333333.
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Table 2.26: Table showing the dose level assignment and patient responses in paren-
thesis for an adaptive trial in progress with accrual of 12 patients.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 2 (0) 2 (0) 3 (0) 4 (0) 4 (1) X
2 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
3 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
4 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
5 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
6 2 (0) 3 (0) 4 (1) X X X
7 3 (0) 3 (0) 2 (0) 3 (0) 3 (0) 3 (0)
8 3 (0) 4 (0) 2 (0) 3 (0) 3 (0) ?
9 2 (0) 3 (0) 3 (0) 4 (0) ? ?
10 3 (0) 3 (0) 3 (0) ? ? ?
11 3 (0) 3 (0) ? ? ? ?
12 3 (1) X X X X X
X- Terminated patient having a severe toxicity (1)
? Continuing patient
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Table 2.27: Table showing the dose level assignment and patient responses in paren-
thesis for an adaptive trial in progress with accrual of 13 patients.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 2 (0) 2 (0) 3 (0) 4 (0) 4 (1) X
2 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
3 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
4 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
5 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
6 2 (0) 3 (0) 4 (1) X X X
7 3 (0) 3 (0) 2 (0) 3 (0) 3 (0) 3 (0)
8 3 (0) 4 (0) 2 (0) 3 (0) 3 (0) 3(1)
9 2 (0) 3 (0) 3 (0) 4 (0) 4 (0) ?
10 3 (0) 3 (0) 3 (0) 3 (0) ? ?
11 3 (0) 3 (0) 3 (0) ? ? ?
12 3 (1) X X X X X
13 2 (0) ? ? ? ? ?
X- Terminated patient having a severe toxicity (1)
? Continuing patient
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Table 2.28: Table showing the dose level assignment and patient responses in paren-
thesis for a completed adaptive trial.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 2 (0) 2 (0) 3 (0) 4 (0) 4 (1) X
2 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
3 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
4 2 (0) 3 (0) 4 (0) 4 (0) 4 (0) 3 (0)
5 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
6 2 (0) 3 (0) 4 (1) X X X
7 3 (0) 3 (0) 2 (0) 3 (0) 3 (0) 3 (0)
8 3 (0) 4 (0) 2 (0) 3 (0) 3 (0) 3(1)
9 2 (0) 3 (0) 3 (0) 4 (0) 4 (0) 3(0)
10 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
11 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
12 3 (1) X X X X X
13 2 (0) 3 (1) X X X X
14 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
15 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
16 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
17 2 (0) 3 (0) 3 (0) 3 (0) 3 (1) X
18 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
19 2 (0) 3 (0) 4 (0) 3 (0) 3 (0) 3 (0)
20 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
21 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
22 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
23 2 (0) 3 (0) 4 (0) 4 (0) 3 (0) 3 (0)
24 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
25 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
26 2 (0) 3 (1) X X X X
27 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
28 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
29 2 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
30 2 (1) X X X X X
X- Terminated patient having a severe toxicity (1)
CHAPTER 3
Multivariate Markov Models for the Conditional
Probability of Toxicity in Phase II Trials
3.1 Background and significance
The study of dose toxicity relationships in oncology occurs in phase I and phase
II clinical trials and variations of these. We focus on the setting where patients are
randomized to two, or more, dose groups administered over several cycles. An ex-
ample of this study design can be found in [Worden et al., 2005, Chugh et al., 2007],
which investigated two randomized doses of ifosamide plus doxorubicin and granu-
locyte colony-stimulating factor, hereafter called ifosamide for brevity. Depending
on whether they had metastases, patients received either six or four cycles of either
6g/m2 or 12g/m2 of ifosamide given over a 4 day period at the beginning of a 21
day cycle. As is often the case, patients who experienced treatment toxicity were not
continued in subsequent cycles. Adverse events are classified by Common Toxicity
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Criteria as defined by National Cancer Institute [NCI, 2003] and grade 3 or higher
toxic responses are considered to be a dose limiting toxicity (DLT). Proportions of
continuing patients in each cycle who had a hemoglobin DLT are show in Figure
3.1. Two important features of the data are (1) the conditional nature of toxicity
proportions observed at each cycle that are based on previously toxicity-free patients
and (2) the trend towards higher conditional toxicity rates as dose accumulates over
cycles in the high dose group. Possible analytical tools for this data are general-
ized estimating equations (GEE) or generalized linear mixed models (GLMM) that
account for correlation within a patient treated over multiple cycles. These mod-
els allow covariates for cycle, dose, cumulative dose and other mitigating factors in
modeling the probability of toxicity. An example of analyzing such data can also be
found in [Legedza and Ibrahim, 2000] that applies to phase I clinical trials and as
a special case of [Doussau et al., 2013] that uses ordinal outcomes also in a phase I
setting. All these methods do not explicitly model the tendency to discontinue cycles
for patients who have demonstrated previous DLT, although the resulting estimated
toxicity rates may be conditional in nature. In fact, conditional probabilities of tox-
icity are precisely what are needed in order to advise patients during subsequent
therapy. Developing models that explicitly capture these conditional probabilities
are key.
A large number of parameters may be necessary to capture all features of the dose-
toxicity relationship, and with the typically small sample size available for modeling
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purposes, a Bayesian approach is an attractive alternative. Our model is an extension
to transitional models with first-order Markov chains [Agresti, 2002] considering only
the previous cycle. In this chapter, we use a Markov model to explicitly model
conditional probabilities of toxicity in a cycle given that the patient did not have a
DLT in the past. The proposed model allows for a cumulative effect of dose on toxicity
after the first cycle and allows covariates to influence the toxicity profile over cycles.
A parameter is included to reflect an individual’s tendency to respond consistently
with past dose experience. In Section 3.2, we formulate a model useful in this phase II
clinical trial setting, describe the Bayesian estimation method and provide intuition
on model behavior. We then study finite sample operating characteristics through
simulation in Section 3.3. In Section 3.4 we apply the methods to the ifosfamide
study described earlier and follow with a discussion in Section 3.5.
3.2 Methodology
In Section 3.2.1, we define the data structure and the proposed dose-toxicity
model. Calculations for the expected total dose over K potential treatment cycles
as well as the expected number of completed cycles is presented in Section 3.2.2.
Technical details of dose modeling via skeleton probabilities of toxicity during the
first cycle of treatment are covered in Section 3.2.3. Selection of priors and the
formulation of the posterior distribution is presented in Section 3.2.4 followed by a
section 3.2.5 reviewing model selection strategies.
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3.2.1 Proposed Markov model
We assume patients i = 1 . . . N are randomized to one of two doses Sg, g = 1, 2. In
Section 3.2.3, we will show that it is convenient to rescale doses Sg to dg; a strategy
useful for incorporating beliefs about toxicity on the first cycle, similar to what was
proposed in [O’Quigley et al., 1990, Lee and Cheung, 2009]. For convenience, dg
terms will hereafter be referred to as the dose assigned per cycle to group g, even
though numerically dg must be transformed back to the Sg scale to reflect actual
doses.
Each dose group is scheduled to undergo K cycles of treatment, however, indi-
vidual patients complete Ki cycles, where Ki may be less than K if experiencing a
DLT. On each cycle k = 1, . . . , Ki, patient i randomized to group g receives dose
di,k = dg. Since dose is constant across cycles, we will typically use the notation
di,1 for the dose given to patient i at each cycle. A patient’s cumulative dose prior
to cycle k is Di,k = (k − 1) × di,1, with Di,1 = 0. We also use the convention that
di,k−1 = 0 for cycle k = 1.
A Bernoulli random variable, Yi,k, denotes the occurrence of a DLT for patient i
on cycle k. In general, Yi,k = 0 for k = 1, . . . , Ki − 1, indicating no DLT on these
cycles. If patient i completes Ki = K cycles, then Yi,K may be either zero or one,
depending on manifestation of a DLT in the final cycle. Additional patient covariates
(Z) are available for modeling the dose-toxicity relationship. So the observed data
becomes (Yi,1, . . . , Yi,Ki , Zi, di,1).
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We define pi,k = P (Yi,k = 1|Yi,k−1 = 0, . . . , Yi,1 = 0, Zi, di,1) as the conditional
probability of a DLT for patient i on cycle k given that patient i has experienced no
previous DLTs. Model 3.1 for pi,k is
log (1− pi,k) = −g1(α,Z)(di,1 − g2(ρ,Z)di,k−1)− g3(β,Z)Di,k, (3.1)
where α,ρ, and β parameterize the relationship between dose, Z and pi,k. In the
simplest case, g1(·), g2(·) and g3(·) are identity functions not involving Z, so that
Model 3.1 reduces to Model 3.2 below:
log (1− pi,k) = −α(di,1 − ρdi,k−1)− βDi,k (3.2)
or equivalently, pi,k = 1− exp[−α(di,1 − ρdi,k−1)− βDi,k]. (3.3)
Intuition behind the parameters is easiest to follow for the special case in Model 3.2,
where α, ρ and β are 1-dimensional parameters. The parameter, α, accounts for DLT
encountered on cycle 1. The parameter, 0 ≤ ρ ≤ 1, allows for a reduced probability of
toxicity related to dose di,1 in a subsequent cycle if patient i has previously tolerated
this dose; this term captures dependency in short-term toxicity outcomes between
cycles. The effect of cumulative dose from previous cycles is captured by β.
Figure 3.2 shows the dose-toxicity relationship across cycles and pi,k for two dose
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groups for several parameter combinations with K = 4 cycles. For instance, in the
top left panel where α is the only parameter driving the dose-toxicity relationship,
a patient has an independent DLT response at each dose administration so that pi,k
is constant across cycles. In the top right panel, the parameter ρ equals 1 indicating
that a patient tolerating dose di,1 on cycle 1, will not experience future toxicity at
this dose level. In the lower three panels, the influence of increasing β alters the
dose-toxicity relationship based on the effect of cumulative dose.
3.2.2 Expected total dose and completed cycles
A higher dose might not be attractive if fewer cycles can be completed at that
dose level based on DLTs. Investigators should gain a clear understanding of the
expected number of completed cycles for a dose level as well as the expected total
dose over the entire trial based on Model 3.1 or the special case without covariates,
Model 3.2. An individual i’s total expected dose is based on probabilities P (Yi,1 =
0, . . . , Yi,Ki−1 = 0, Yi,Ki = 1)































3.2.3 Model calibration using skeleton probabilities
For ease of interpretation of the parameter α, it is convenient to rescale the doses.
As explained below they are rescaled based on initial guesses (skeleton probabilities)
of the toxicity rate for the first cycle. For simplicity, we first describe use of skeleton
probabilities for the simple case with no covariates, as in Model 3.2, and later sug-
gest modifications for the more complex settings. Our strategy of defining skeleton
probabilities and corresponding (transformed) dose values consistent with Model 3.2
is similar to that described by [O’Quigley et al., 1990, Lee and Cheung, 2009] in
the context of the continual reassessment method in phase I studies as well as other
contexts [Lee et al., 2011, Cheung and Elkind, 2010].
In our phase II setting, patients are given S1 = 6g/m
2 of ifosamide or S2 =
12g/m2 of ifosamide over K = 4 cycles of treatment. Suppose qg is an initial guess
(skeleton probability) of a DLT at cycle one for dose Sg. Instead of using dose Sg in
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Model 3.2, we use dose values dg, g = 1, 2, satisfying ln(1− qg) = −dg. For example,
if we choose q1 = 0.10, the resulting d1 that stands in for 6g/m
2 of ifosamide in Model
3.2 is d1 = −ln(1− 0.10) ≈ 0.11. In defining dg, we’ve conveniently normalized α to
1.0 if the skeleton probability for toxicity at cycle 1 is correct, making it easier to see
deviations from the skeleton in the posterior distribution of α. Skeleton probabilities
may be elicited from clinicians, previous animal studies or earlier phase clinical trials.
In Model 3.1, g1(α,Z), will be a known function of covariates, Z, and skeleton
probabilities for toxicity will need to be defined for reference values of Z in this
relationship. For example, in Section 3.4, we consider the effect of gender (M, F) on
α via g1(α,Z) = α1 + α2I(F). In this case, we use the male gender as the reference
group, normalizing α1 to one, as before, in obtaining d1 and d2 for this group. So the
posterior distribution for α1 deviating from one gives a sense of how on target the
skeleton probabilities for the men were on the two doses. The posterior distribution
of α2 gives a sense of the effect of female gender on the toxicity rates for cycle 1.
3.2.4 Prior selection and posterior distribution
Based on the study design, patients contribute to the likelihood until they expe-
rience a DLT or the final Kth cycle is completed. That is, a person with toxicity
on cycle Ki gives data (Yi,1 = 0, Yi,Ki−1 = 0, . . . , Yi,Ki = 1, Zi, di,1) and a contri-
bution to the likelihood as in equation 3.4. And a person completing K cycles
without toxicity gives data (Yi,1 = 0, . . . , Yi,K−1 = 0, Yi,K = 0, Zi, di,1) with likeli-
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hood contribution as in equation 3.5. In general, subject i on cycle k contributes
Li,k(Yi,k|α,β, ρ) = (pi,k)Yi,k(1 − pi,k)1−Yi,k to the likelihood, with pi,k parameterized
as in equation 3.1 and interpreted as the the probability of toxicity on cycle k con-
ditional on having no prior DLTs in previous cycles. The resulting likelihood is,






Our goal lies in estimating the posterior distribution of α, β and ρ and hence of pi,k.
Prior distributions on these parameters should reflect any auxiliary knowledge of
the study design, with a large prior variance when this knowledge is limited. We
first consider priors in the case with no covariates, so that g1(α,Z)=α, g2(ρ,Z)=ρ
and g3(β,Z) = β. Modifications of this approach for more complex settings will
be discussed after this more simple case is described. The priors are programmed
using just another Gibbs sampler (JAGS) rjags [Plummer, 2011] package through [R
Development Core Team, 2011].
3.2.4.1 Special case with no covariates
Recall that with no covariates, α relates to the probability of toxicity on cycle
one, with α = 0 implying no toxicity and increasing values of α giving larger toxicity
probabilities. The skeleton described in Section 3.2.3 is calibrated to give α =1 when
correctly specified. For many phase II trials the low dose is associated with very little
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or no toxicity on the first cycle, so that a prior with a pre-specified point mass at
α = 0 and ranging across non-negative values is desirable. In Appendix 3.6.1.1, we
describe our recommended prior on α, with cumulative distribution function (cdf)
Fα(α), mean µα = 1 and variance σ
2
α, as a mixture distribution of a lognormal density
and a qα×100% point mass at zero. We denote the probability density function (pdf)
of the lognormal component of the mixture distribution as gα(x), with mean µg and




µg parameter of the lognormal distribution shifts as a function of the point mass
percentage to maintain a mean one prior; that is, µg = (1 − qα)−1 yields µα = 1.
The lognormal variance parameter, σ2g depends on the desired variance for the prior
mixture, σ2α, as well as the point mass probability, qα, that is, σ
2
g = (1−qα)−1σ2α−µ2gqα.
For convenience, an example of JAGS code for generating this prior is included on
lines 10 through 17 of Appendix 3.6.1.3.
The ρ parameter (0 ≤ ρ ≤ 1) captures dependency in toxicity outcomes within a
patient, with values near zero indicating that the current toxicity outcome is virtually
unaffected by previous tolerance of dose and values near one indicating an almost
certain chance of tolerating previously administered doses. In Appendix 3.6.1.2, we
develop this prior as a mixture distribution of pre-specified qρ × 100% point masses
at 0 and 1 and a trapezoidal density with height b at zero and slope m = 2(1 − b)
comprising the remainder of the distribution over (0, 1). The cdf of ρ is Fρ(x) =
qρ + (1 − 2qρ)
∫ x
0
[b+ 2(1− b)u] du + qρI(x = 1). The b parameter governs whether
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the trapezoidal shape favors low or high values of ρ, with b = 1 reducing to a uniform
shape and b = 0 or b = 2 reducing to triangular shapes with positive and negative
slopes. An example of JAGS code for this prior is located on lines 18 through 30 of
Appendix 3.6.1.3.
The remaining prior that we define is for the β parameter, which captures the
effect of cumulative dose on the conditional probability of toxicity. When β = 0,
the probability of toxicity does not change based on cumulative dose. When β > 0,
toxicities are more likely to occur as dose accumulates. The model also allows the
possibility of developing an increased tolerance for dose with repeated exposure, that
is, β may be negative subject to the constraint that toxicity probabilities remain in
the [0, 1] range. A lower bound for β is obtained by noting that di,k = di,1 for k ≥ 1,
in equation 3.3 giving 0 < α(di,1 − ρdi,1) + β(k − 1)di,1 <∞,∀k. It is convenient to
define the prior in terms of a shared boundary at all cycles, β > −α(1− ρ)/(K − 1).
In particular, for the ifosamide study we investigate later, K = 4 cycles and the
lower boundary on the prior for β becomes −α(1− ρ)/3, depending on α and ρ.
In constructing a prior for β conditional on α and ρ, with cdf Fβ(β|α, ρ), we use
a Normal(µ, σ2) distribution truncated on the left by −α(1− ρ)/3. To program this
truncated Normal prior with mean µβ and standard deviation σβ in JAGS, we need to
input mean µ and standard deviation σ of an untruncated Normal distribution giving
mean µβ and variance σβ upon left truncation at −α(1− ρ)/3. This can be achieved
in the following way using JAGS. Expressions for deriving µβ and σβ based on known
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parameters (µ, σ2) of the untruncated Normal distribution exist [Johnson and Kotz,
1970, Greene, 2003]. The variance, σ, of the untruncated distribution is involved in
calculating both µβ and σβ for the truncated distribution so that arbitrary specifica-
tion of these prior parameters does not always give a viable untruncated distribution
to work with. The R function, findbetaroots, in Appendix 3.6.1.4 solves for param-
eters (µ, σ2) required by the JAGS program based on desired prior parameters for β,
(µβ, σβ) or indicates that no possible solution exists for that combination of values.
For convenience, Tables 3.8 and 3.9 lists helpful examples of prior parameters for β
and the corresponding parameters of the untruncated distribution that are used in
JAGS. An example of JAGS code for this prior on lines 31 through 37 of Appendix
3.6.1.3.
A few more definitions using Stieltjes notation help in characterizing the posterior
distribution. Let hα(α) = qαI(α = 0) + {1 − qα}I(α > 0)g(α) and hρ(ρ) = qρI(ρ =
0) + {1− 2qρ}I(0 < ρ < 1){b+ 2(1− b)ρ}+ qρI(ρ = 1) capture either a probability
mass or a density function as appropriate. In addition define dFα(α) = hα(α)dα and
dFρ(ρ) = qρI(ρ = 0) + {1 − 2qρ}I(0 < ρ < 1){b + 2(1 − b)ρ}dρ + qρI(ρ = 1). Also
let fβ(β|α, ρ) be the prior density function of β. The posterior distribution for α, β



















The posterior distribution of α, β, ρ from Model 3.2 can be estimated via Markov
Chain Monte Carlo (MCMC) methods [Robert and Casella, 1999] using JAGS [Plum-
mer, 2011] called in [R Development Core Team, 2011]. JAGS includes several al-
gorithms for sampling from the posterior distributions produced from the MCMC
iterations, for instance the standard Gibbs sampler is available for this purpose.
Parallel chains starting from different initial values for each parameter (α, β, ρ) are
followed through to convergence after an appropriate burn-in period. After conver-
gence the posterior distributions of the parameters are available as well as functions
of these parameters, such as the desired conditional toxicity profiles. The mean of
the posterior distributions are used as estimates of the quantities of interest.
3.2.4.2 Covariate specific priors
Priors from section 3.2.4.1 can be easily extended to allow dependence of α,ρ,β
on Z in Model 3.1. As an instructive example, we again consider the case where
Z includes gender (M, F) and dose group (d1, d2) so that g1(α,Z) = α1I(M, d1) +
α2I(M, d2) +α3I(F, d1) +α4I(F, d2) for a total of four required priors. Each of these
four priors can be built just as in Section 3.2.4.1 if there is no prior information
suggesting deviations from Model 3.2, i.e., the model that parameterizes a single
α to account for dose-toxicity on cycle 1. We include an additional subscript to
distinguish between priors for α. That is, with a qαj point mass at zero, the prior










prior information on gender related toxicity is available, prior means of α3 and α4 may
be chosen to reflect this additional knowledge. The priors for α1 and α2 are generally
left with a mean of one since the skeleton discussed in Section 3.2.3 calibrated these
values to one based on initial assumptions about dose-toxicity on cycle 1. In the case
where we desire a prior with mean, µαj , and variance, σ
2
αj
, we would define density




Prior parameterization of ρ is technically straightforward using trapezoidal shapes
described in section 3.2.4.1. However for limited sample sizes it makes sense to
model a common prior for ρ. Priors for α and ρ affect prior definition of β.
Recall that when parameterizing the prior for β in Section 3.2.4.1, the range of
the prior was [−α(1 − ρ)/(K − 1),∞), with negative β indicating an increased
dose tolerance upon repeated exposure and positive β indicating increased toxicity
with accumulating dose. Continuing our instructive example, suppose g3(β,Z) =
β1I(M, d1) + β2I(M, d2) + β3I(F, d1) + β4I(F, d2). Priors for each of the four β
′s can
be constructed as in Section 3.2.4.1, provided that the lower bound of each βj is
maintained to be consistent with values of αj and ρ for those with the same covari-
ates, Z. In particular, in the case with gender and dose influencing all parameters,
the range of βj is restricted on the left by −αj(1− ρ)/3, j = 1, . . . , 4.
Depending upon the number of priors set up on α,ρ,β the likelihood and the
posterior distribution will change accordingly in Equation 3.8.
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For instance, assuming four subgroups for αj and βj, j = 1, . . . , 4 that correspond
to levels of gender and dose and assuming a common ρ across all Z, the posterior

























j=1Nj = N is the sum of patients in the four categories of gender and dose.
3.2.5 Model selection
There is no restriction requiring the same covariates be included in parameter-
izations of g1(α,Z), g2(ρ,Z) and g3(β,Z). We recommend two common model
selection criteria: (1) a plot of observed and predicted values of toxicity, along with
95% credible bands for the true probabilities of toxicity over the cycles. (2) The de-
viance information criteria (DIC) [Spiegelhalter et al., 2002] is calculated by adding
the effective number of parameters (pD) to the expected deviance, where the expected
deviance is the deviance at the posterior mean parameter values and the effective
number of parameters are estimated using the approach suggested by [Plummer,
2002, 2008]. Smaller DIC values indicate the preferred model.
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3.3 Operating characteristics
To study operating characteristics of Model 3.2 we consider a trial with two dose
groups (S1, S2) receiving a maximum of K = 4 cycles with 50 patients per group
for a total of N = 100 . Following Section 3.2.3, skeleton probabilities are set at
qg = (0.05, 0.10), that is, 5% and 10% of patients are expected to have a DLT on the
first cycle in the low and high dose groups, respectively. Then the transformed doses,
dg, g = 1, 2, used to stand in for Sg, g = 1, 2, in Model 3.2 become d1 = − ln(1−0.05)
and d2 = − ln(1−0.10). Model 3.2 defines conditional probabilities of toxicity during
the trial with α = 1 and varying values of β = {0, 0.2} and ρ = {0.25, 0.75}, i.e.,
4 different simulated cases. Simulated toxicity outcomes across cycles are based on
Bernoulli(pi,k) random variables until a DLT is observed or the 4
th cycle is completed.
Five hundred independent datasets (simulation replications) were created to assess
coverage rates, bias and standard deviations.
Priors are set on α, β, ρ as in Section 3.2.4.1 for Model 3.2. In particular, the
prior on α is a mixture with point mass qα = 4% on zero and a lognormal density
component with parameters µg = 1.04 and σ
2
g = 9.33 giving prior mean and variance
for α, µα = 1 and σ
2
α = 9. The prior for ρ is a mixture with point masses qρ = 2%
at zero and one and an intercept b = 0.20 trapezoidal density, resulting in prior
mean and variance µρ = 0.6280 and σ
2
ρ = 0.0736. This prior indicates a moderate
to high correlation in toxicity responses within-patient. The prior set on β is a
Normal distribution truncated at −1/3 having mean, µβ = 2 and variance, σ2β = 4,
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providing a coefficient of variance of two. Since truncation of this distribution of β
is conditional on prior values of α and ρ, current values from the MCMC simulation
are used for the truncation point at each sampling. Based on Model 3.2, toxicity
probabilities are also sampled and monitored for convergence; an adaptive phase of
1,000 samples is used to choose the best sampling algorithm and an additional 10K
samples are discarded as part of the burn-in period.
The conditional probability of toxicity for each of the four simulated cases are
presented in Table 3.1 and displayed in Figure 3.3. Each of the four columns of Table
3.1 indicate treatment cycles during the study. Rows are separated according to
different parameter selections (cases) and dose group within case, d1 or d2. Reported
values are (1) the estimated conditional probability of toxicity for an arbitrary patient
i at cycle k, p̂i,k, (2) the mean bias, p̂i,k − pi,k, across 500 iterations (3) the mean
standard deviation (SD) of p̂i,k across 500 iterations, (4) the empirical SD of the 500
p̂i,k estimates, (5) the credible interval coverage rate of pi,k across the 500 iterations
and (6) the mean number of patients who enter the following cycle toxicity-free.
Within a particular case (1 - 4), the same posterior values of α, β and ρ are used to
calculate finite sample characteristics of the eight cells of dose and cycle combinations.
Table 3.1 indicates that estimates of the conditional probability of toxicity have
very low bias and that mean SD and empirical SD are comparable. This low bias is
evident in Figure 3.3 where solid shapes (true conditional probabilities) and hollow
shapes (estimated conditional probabilities) are very close to one another. In cases
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1 and 3, where ρ takes on the lower value of 0.25, there is a higher decrease in
the average number of patients making it through successive cycles as additional
patients exhibit toxicity patterns that remove them from the study. Cases 2 and
4, with ρ = 0.75, have a higher tendency to avoid toxicity once they have tolerated
their first cycle. In cases 3 and 4, where β = 0.2, there is a tendency for slightly more
patients to discontinue due to accumulated toxicity, particularly in cycles 3 and 4.
Case 4 shows the most impact of patients dropping out due to accumulating toxicity
in cycles 3 and 4, since in this case the high value of ρ = 0.75 usually causes those
with single dose susceptibility to be eliminated in cycle one rather than later cycles.
The major focus of estimation in these small studies is typically on estimated
probabilities of toxicity, which seem to have little bias regardless of the model’s
ability to clearly identify individual parameter estimates. However, we summarize
results from simulation studies of parameter estimates α̂, β̂ and ρ̂ in Table 3.2. Each
row corresponds to one of the four simulated cases and presents (1) the mean of
the estimated values, (2) the mean bias of the estimates from the true value of the
parameter, (3) the mean SD of the parameter estimates, (4) the empirical SD from
the 500 simulated datasets and (5) the coverage rate for the true parameter value in
the credible intervals.
Higher values of ρ make it easier to isolate information on β since after tolerating
cycle 1, toxicity observed after the first cycle is more likely to be caused by accu-
mulating toxicity captured by β. This is reflected in Table 3.2 cases 2 and 4 where
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ρ = 0.75 and bias for β is at its lowest. Lower values of ρ allow the current dose on
every cycle to play a higher role in the manifestation of the toxicity, so that infor-
mation on α is better identified. Table 3.2 cases 1 and 3, where ρ = 0.25, provide
the lowest bias in estimation of α by correctly attributing toxicity to the effect of
the current dose. The ability to estimate ρ, when the prior is not compatible with
the true model, is a challenge in these small studies. In additional simulations, not
shown, larger sample sizes do improve estimation of ρ, as well as the other param-
eters. As in all early phase studies, model assumptions are relied upon in making
inferences. In the following section we perform additional sensitivity analyses for
misspecification of the skeleton probabilities on estimation of conditional probability
of toxicity.
3.3.1 Sensitivity to choice of skeleton probabilities
Given fixed values of α = 1, β = 0.2 and ρ = 0.75, as in case 4 above, data was
simulated as before. Recall that the probabilities of toxicity during the first cycle
on doses 1 and 2 are 0.05 and 0.10 and that these probabilities were assumed in
creating the skeleton used for analysis in the previous section. As opposed to the
previous section, this section mis-specifies the probability skeleton when performing
the analysis. In scenario 1, a skeleton that is 1.5 times higher than that used to
generate the data is used in the analysis. That is, the probabilities of toxicity on
cycle one are assumed to be 0.075 and 0.150 for doses 1 and 2, respectively. In
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scenario 2, the probabilities of toxicity on cycle 1 were assumed to be 0.06 and 0.15
for the two dose levels, i.e., 20% and 50% overestimates of toxicity on cycle 1 for dose
levels 1 and 2, respectively. Otherwise, the assumed priors and estimation procedure
remained unchanged from the previous section.
Table 3.3 provides results on estimation of the conditional probabilities of toxicity
across 500 iterations of the simulation study. The columns correspond to the four
cycles. Within different skeleton misspecifications (scenarios 1 and 2) the rows are
grouped by the two dose levels, d1 or d2. Reported values are (1) the estimated
conditional probability of toxicity for an arbitrary patient i at cycle k, p̂i,k, (2)
the mean bias, p̂i,k − pi,k, across 500 iterations (3) the mean SD of p̂i,k across 500
iterations, (4) the empirical SD of the 500 p̂i,k estimates, (5) the credible interval
coverage rate of pi,k across the 500 iterations and (6) the mean number of patients
who enter the following cycle toxicity-free. Within a particular scenario (1 or 2), the
same posterior values of α, β and ρ are used to calculate finite sample characteristics
of the eight cells of dose and cycle combinations.
Results are comparable to those from case 4 in Table 3.1, where the correct
skeleton was used in the analysis. The only exception is seen in scenario 2, cycle 1,
dose 1, where bias is higher and coverage is lower than desired. Since the empirical
and mean SD are very close in this case, the coverage is likely being effected by the
bias for this term.
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3.4 Application to the ifosamide study
The original ifosamide study was a phase II randomized clinical trial comparing
the toxicity and efficacy of doxorubicin with high-dose ifosamide or standard-dose
ifosamide in patients with soft-tissue sarcoma [Worden et al., 2005, Chugh et al.,
2007]. The treatment was given for 4 consecutive days at the beginning of each 21
day cycle. The original study considered six cycles for metastatic disease and four
cycles for localized disease but for convenience we consider just the first four cycles
for each group. We evaluate 77 patients with data on toxicity, where 39 of these
were randomized to the standard 6g/m2 ifosamide dose group and 38 of these were
randomized to receive 12g/m2 of ifosamide. We use a patient’s minimum hemoglobin
(HGB) value during a cycle to define a DLT in this example, so that a patient is
removed from the study if their HGB value drops below 8 mg. This criteria is defined
as a grade 3/4 toxicity by NCI. Table 3.4 and Figure 3.1 present the empirical data
from the study with conditional probabilities at each of the four cycles for the two
dose groups.
Based on DIC criteria, Model 3.2 was improved by allowing differential cumulative
effects of dose by dose group resulting in Model 3.9 of the form:
ln(1− pi,k) = −α(di,1 − ρdi,k−1)− β1Di,kI(d1)− β2Di,kI(d2). (3.9)
Resulting empirical and model-based conditional probabilities of toxicity by dose
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group on each of four cycles are shown in Figure 3.4, along with 95% credible inter-
vals. Priors for α and ρ used to perform the analysis are identical to those used in
Section 3.3. Priors for β1 and β2 are identical to the prior used for β in Section 3.3.
Parameter estimates model are shown in Table 3.5 indicate indicate a particularly
high cumulative effect of the dose in patients on the high group.
Following Section 3.2.2, the total expected completed cycles for the low and
high dose groups, respectively, are 3.69 (3.68 observed on average) and 3.19 (3.23
observed on average) with corresponding expected total doses of 22.108 g/m2 (22.06
g/m2 observed on average) and 38.259 g/m2 (38.70 g/m2 observed on average). A
patient in the high-dose group tends to receive more total ifosamide than a patient
in the low-dose group before a DLT, but is less likely to successfully complete all
four cycles without a DLT 29.3% and 71.3% respectively.
Upon further study, DLTs in the high-dose group are especially high in women,
but not necessarily men, as seen in Figure 3.5 and Table 3.6. DIC criteria suggested
further improvement in the model with inclusion of gender terms for the parameter
α and gender by dose group terms for the cumulative toxicity. To account for the
steep quadratic trend in toxicities for the females on the high-dose group a quadratic
(squared) term was also included in the model and results in Model 3.10 as follows,
log (1− pi,k) = −{α1 + α2I(F )}(di,1 − ρdi,k−1)− β1Di,kI(M,d1)
− β2Di,kI(F, d1)− β3Di,kI(M,d2)− β4D2i,kI(F, d2).
(3.10)
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Figures 3.6 and 3.7 display the empirical and model-based conditional probabil-
ities of toxicity, along with 95% credible intervals, by gender on the low and high
dose groups, respectively, using Model 3.10. Priors were identical to those used in
Section 3.3. That is, priors on α1 and α2 were identical to the prior on α in Section
3.3, the prior on ρ was left unchanged, and priors on β1, β2, β3 and β4 were identical
to the prior used for β in Section 3.3.
Parameter estimates of the model are shown in Table 3.7 indicate that the toxicity
due to cumulative effect of the dose is high in females in comparison to males on
both the dose groups.
The total expected completed cycles for the low-dose female group is 3.55 (3.62
observed) with a total expected dose of 21.27 g/m2 (21.71 g/m2 observed). Women
on the high-dose are expected to complete 2.95 cycles (2.97 observed) with a total
expected dose of 35.44 g/m2 (35.59 g/m2 observed). Men are expected to complete
roughly the same number of cycles in the low and high dose groups, 3.78 (3.58) and
3.46 (3.36) cycles, respectively, for total expected doses of 22.70 g/m2 (21.49 g/m2)
and 41.51 g/m2 (40.28 g/m2) in the corresponding dose groups.
3.5 Discussion
We have presented a novel conditional probability model for the dose toxicity
relationship in data arising from a Phase II study setting having patients with mul-
tiple cycles of the same dose over their treatment course. The conditional nature of
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the model takes into account that patients having a DLT on a particular cycle will
not continue further cycles. The use of ρ allows dependence of toxicity in a current
cycle to depend on tolerance on previous cycles. The α and β parameters capture
the effect of current and cumulative dose effects at each cycle. This three parameter
model may be all that is estimable in small studies, but the model offers flexibility to
include additional parameters to account for covariate dependent effects on toxicity.
Priors and skeletons described in this work offer a wide variety of prior beliefs to
be included in the analyses. Our investigation of mis-specified skeleton probabilities
showed very little effect on model performance.
One limitation of the model is that there must be sufficient cycles in the study
to allow plausible estimation of ρ and β parameters that are based on data beyond
cycle one; two cycles would not be sufficient to disentangle the effects of cumulative
dose from tolerance to previous dose. As most studies of this type have between































● Dose 6 mg
Dose 12 mg
Figure 3.1: Observed proportion of low HGB in continuing subjects with one stan-
dard error intervals in the ifosamide trial.
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Figure 3.2: Conditional P(Toxicity) on cycle k, pi,k based on Model 3.2, for two
dose levels with α = 1, β = (0, 0.2) and ρ = (0, 0.75, 1). Solid triangles and circles














































































































β = 0.2, ρ = 0.75
Figure 3.3: Simulation study results. Plot of conditional P(Toxicity), based on
equation 3.2 for two dose levels with α = 1 β = (0, 0.2) and ρ = (0.25, 0.75). Cases
1 through 4 in the Table 3.1. The panels in the first and second column correspond
to β = 0 and β = 0.2 respectively while the top row corresponds to ρ = 0.25 and
the bottom row to ρ = 0.75. The solid circles and triangles are the true values of
the conditional P(toxicity) at each of the cycles on the lower and higher dose group
respectively. The corresponding hollow circles and triangles are the average of the




























6 ● Dose 6 mg
Dose 12 mg
Figure 3.4: Estimates of the conditional probabilities of toxicity from Model 3.9 for
patients on the low and high dose group in hollow circles and triangles respectively





































Figure 3.5: Empirical conditional probabilities of toxicity for patients on the low (in
solid circles) and high (in solid triangles) dose groups by gender, males in solid lines







































Figure 3.6: Estimates of the conditional probabilities of toxicity from Model 3.10
for patients on the low dose group in hollow circles with empirical values in solid
circles, using two different β terms to estimate the cumulative effect for males (solid

























0 Males 12 mg
Females 12 mg
Figure 3.7: Estimates of the conditional probabilities of toxicity from Model 3.10 for
patients on the high dose group in hollow triangles with empirical values in solid
triangles, using two different β terms to estimate the cumulative effect for males
(solid lines) and females (dotted lines).
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Table 3.1: Estimates of conditional probability of toxicity based on Model 3.2 from 500 simulated datasets
containing N = 100 patients receiving one of two dose groups d1 and d2 over four cycles. Results presented
for α = 1 and various combinations of β = (0, 0.2) and ρ = (0.25, 0.75)
Cycle 1 2 3 4
Case 1: α = 1 β = 0 ρ = 0.25
d1 Mean Estimated p̂ik 0.0480 0.0335 0.0400 0.0464
Mean Bias p̂ik -0.0020 -0.0043 0.0023 0.0087
Mean SD p̂ik 0.0158 0.0093 0.0097 0.0153
Empirical SD p̂ik 0.0157 0.0077 0.0092 0.0145
Coverage rate of pik 93.0 94.6 95.2 92.8
Average patients 47.5 45.8 44.0 42.4
d2Mean Estimated p̂ik 0.0956 0.0674 0.0803 0.0926
Mean Bias p̂ik -0.0044 -0.0086 0.0043 0.0166
Mean SD p̂ik 0.0305 0.0183 0.0191 0.0297
Empirical SD p̂ik 0.0305 0.0152 0.0181 0.0282
Coverage rate of pik 93.0 94.6 95.2 92.8
Average patients 45.1 41.7 38.5 35.6
Case 2: α = 1 β = 0 ρ = 0.75
d1Mean Estimated p̂ik 0.0443 0.0161 0.0162 0.0163
Mean Bias p̂ik -0.0057 0.0034 0.0035 0.0036
Mean SD p̂ik 0.0153 0.0071 0.0059 0.0085
Empirical SD p̂ik 0.0157 0.0051 0.0051 0.0073
Coverage rate of pik 89.8 99.2 94.6 96.2
Average patients 47.5 46.9 46.8 45.8
d2 Mean Estimated p̂ik 0.0883 0.0327 0.0330 0.0331
Mean Bias p̂ik -0.0117 0.0067 0.0070 0.0071
Mean SD p̂ik 0.0297 0.0142 0.0119 0.0170
Empirical SD p̂ik 0.0305 0.0102 0.0103 0.0147
Coverage rate of pik 89.8 99.2 94.6 96.2
Average patients 44.9 43.9 42.7 41.6
Case 3: α = 1 β = 0.2 ρ = 0.25
d1Mean Estimated p̂ik 0.0498 0.0435 0.0603 0.0765
Mean Bias p̂ik -2e-04 -0.0040 0.0030 0.0096
Mean SD p̂ik 0.0163 0.0103 0.0123 0.0191
Empirical SD p̂ik 0.0155 0.0086 0.0122 0.0183
Coverage rate of pik 95.2 95.0 95.0 92.6
Average patients 47.4 45.1 42.4 39.5
d2Mean Estimated p̂ik 0.0991 0.0872 0.1195 0.1501
Mean Bias p̂ik -9e-04 -0.0081 0.0054 0.0176
Mean SD p̂ik 0.0315 0.02 0.0235 0.0359
Empirical SD p̂ik 0.0301 0.0169 0.0234 0.0344
Coverage rate of pik 95.2 95.0 95.0 92.6
Average patients 44.9 40.7 36.1 31.3
Case 4: α = 1 β = 0.2 ρ = 0.75
d1Mean Estimated p̂ik 0.0444 0.0272 0.0359 0.0444
Mean Bias p̂ik -0.0056 0.0044 0.0031 0.0018
Mean SD p̂ik 0.0153 0.0084 0.0091 0.0139
Empirical SD p̂ik 0.0162 0.0064 0.0088 0.0134
Coverage rate of pik 89.8 98.0 95.2 96.4
Average patients 47.5 46.5 44.9 43.1
d2Mean Estimated p̂ik 0.0885 0.0549 0.0721 0.0887
Mean Bias p̂ik -0.0115 0.0086 0.0060 0.0031
Mean SD p̂ik 0.0297 0.0166 0.0180 0.0271
Empirical SD p̂ik 0.0315 0.0128 0.0173 0.0261
Coverage rate of pik 89.8 98.0 95.2 96.4
Average patients 45.1 42.9 40.1 36.8
1 SD refers to the standard deviation of the estimates.
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Table 3.2: Estimates of parameters based on Model 3.2 from 500 simulated datasets
containing N = 100 patients receiving one of two dose groups d1 and d2 over four
cycles. Results presented for α = 1 and various combinations of β = (0, 0.2) and
ρ = (0.25, 0.75).
α β ρ
Case 1 : α = 1, β = 0, ρ = 0.25
Estimated Value 0.9651 0.1332 0.4370
Mean Bias -0.0349 0.1332 0.1870
Mean SD 0.3260 0.1672 0.2652
Empirical SD 0.3232 0.1446 0.1357
Coverage rate 93.0 89.2 99.6
Case 2 : α = 1, β = 0, ρ = 0.75
Estimated Value 0.8886 0.0022 0.6025
Mean Bias -0.1114 0.0022 -0.1475
Mean SD 0.3153 0.1027 0.2560
Empirical SD 0.3227 0.0729 0.1375
Coverage rate 89.8 99.8 99.8
Case 3 : α = 1, β = 0.2, ρ = 0.25
Estimated Value 1.0018 0.3455 0.4649
Mean Bias 0.0018 0.1455 0.2149
Mean SD 0.3382 0.1982 0.2761
Empirical SD 0.3203 0.1608 0.1287
Coverage rate 95.2 93.2 99.8
Case 4 : α = 1, β = 0.2, ρ = 0.75
Estimated Value 0.8909 0.1758 0.5626
Mean Bias -0.1091 -0.0242 -0.1874
Mean SD 0.3153 0.1438 0.2724
Empirical SD 0.3331 0.1193 0.1329
Coverage rate 89.8 98.0 99.0
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Table 3.3: Estimates of conditional probability of no toxicity based on Model 3.2
from 500 simulated datasets containing N = 100 patients receiving one of two dose
groups d1 and d2 over four cycles. Results presented for α = 1, β = 0.2 and ρ = 0.75
for different mis-specified probability skeletons.
Cycle 1 2 3 4
Scenario 1: d1 = 0.0780, d2 = 0.1625
d1
Mean Estimated p̂ik 0.0456 0.0271 0.0357 0.0441
Mean Bias p̂ik -0.0044 0.0043 0.0029 0.0014
Mean SD p̂ik 0.0155 0.0084 0.0091 0.0139
Empirical SD p̂ik 0.0157 0.0064 0.0088 0.0132
Coverage rate of true pik 93.2 97.6 94.8 96.2
Average patients 47.5 46.432 44.8 42.9
d2
Mean Estimated p̂ik 0.0922 0.0556 0.0728 0.0893
Mean Bias p̂ik -0.0078 0.0093 0.0066 0.0036
Mean SD p̂ik 0.0304 0.0170 0.0181 0.0273
Empirical SD p̂ik 0.0308 0.013 0.0176 0.0261
Coverage rate of true pik 94.4 97.6 94.6 96.6
Average patients 45.0 42.9 40.1 36.7
Scenario 2: d1 = 0.0620, d2 = 0.1625
d1
Mean Estimated p̂ik 0.0389 0.0232 0.0306 0.0379
Mean Bias p̂ik -0.0111 4e-04 -0.0022 -0.0048
Mean SD p̂ik 0.0133 0.0072 0.0078 0.0119
Empirical SD p̂ik 0.0135 0.0055 0.0076 0.0114
Coverage rate of true pik 84.2 97.6 93.4 92.8
Average patients 47.5 46.4 44.8 42.9
d2
Mean Estimated p̂ik 0.0982 0.0596 0.0781 0.0959
Mean Bias p̂ik -0.0018 0.0133 0.012 0.0102
Mean SD p̂ik 0.0323 0.0181 0.0194 0.0292
Empirical SD p̂ik 0.0329 0.0139 0.0190 0.0280
Coverage rate of true pik 93.0 96.0 92.2 95.0
Average patients 45.0 42.9 40.1 36.7
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Table 3.4: Grade 3/4 dose dose limiting toxicities (DLTs) observed when the
hemoglobin levels dropped below 8mg on the two dose groups in patients completing
the previous cycle without a DLT over the four cycles of treatment.
Cycle 1 Cycle 2 Cycle 3 Cycle 4
dose 6 2/39 2/35 2/29 3/24
dose 12 3/38 4/31 9/24 6/15







Table 3.6: Dose limiting toxicities (DLTs), grouped by gender, inpatients completing
the previous cycle without a DLT when the hemoglobin levels dropped below 8mg
over four cycles of the treatment
Cycle 1 Cycle 2 Cycle 3 Cycle 4
Males
dose 6 1/20 1/17 0/14 1/13
dose 12 0/18 2/15 3/12 1/9
Females
dose 6 1/19 1/18 2/15 2/11
dose 12 3/20 2/16 6/12 5/6
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3.6.1 Further details on prior distributions discussed in Section 3.2.4.1
3.6.1.1 Prior distribution for α
Recall that α is a mixture distribution of a lognormal random variable and a
point mass at zero of size qα. In the case with no covariates, the prior mean of α
should be 1.0 to be consistent with skeleton calibration beliefs described in Section
3.2.3. When α depends on covariates, we may desire more flexibility in defining prior
means. In this section, we derive parameters for the lognormal component of the
mixture distribution that give desired means and variances of the overall mixture
distribution. Let X be the lognormal random variable in the mixture distribution
of α with density gα(x), mean µg and variance σ
2
g . If B is Bernoulli(qα) then the
mixture random variable we desire can be written as α = (1−B) ∗X. The mean of
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α is
µα = E{E(α|B)} = E{(1−B)E(X)} = µg ∗ (1− qα).
When qα = 1, E(α) becomes 0 as we would expect if the prior was a point mass at
zero, and qα = 0 gives E(α) = µg, the mean of the lognormal, X. For 0 < qα < 1, we
can obtain a mean µα prior for α by defining the mean of X to be µg = µα(1−qα)−1.
The variance of α is
σ2α = V {E(α|B)}+ E{V (α|B)}
= V {µg(1−B)}+ E{(1−B)2σ2g}
= µ2gqα(1− qα) + σ2g(1− qα)
= (1− qα)(µ2gqα + σ2g)
Again, qα = 1 gives σ
2




g , the variance of
the lognormal. For 0 < qα < 1, we can obtain prior variance σ
2
α for α by defining
σ2g = (1− qα)−1σ2α − µ2gqα. Appendix 3.6.1.3, includes code for this prior on lines 10
through 17.
3.6.1.2 Prior distribution for ρ
Recall that ρ ∈ [0, 1] follows a mixture distribution with qρ × 100% point masses
at 0 and 1 and a trapezoidal density shape for 0 < ρ < 1. The family of trapezoidal
density shapes included in the mixture distribution for ρ is a special case of that
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seen in [van Dorp and Kotz, 2003] and [van Dorp et al., 2007]. In this section we
define the mixture distribution for ρ in more detail and give means and variances
associated with this prior distribution.
We define the random variable, X, to have density gρ(x) = I(0 < x < 1)(mx+ b),
with b and m standing in for the intercept and slope of the line that determines
the trapezoidal density shape over (0, 1). To be a proper density function that
integrates to 1.0 the constraint m = 2(1 − b) must be satisfied. Hence, although
m is convenient for defining the trapezoidal shape, gρ(x) may be defined in terms
of b only, gρ(x) = b + 2(1 − b)x. The expected value and variance of X are found
to be (4 − b)/6 and (2 + 2b − b2)/36 respectively. Special cases include (i) b=0,
giving gρ(x) = 2x, with a positive slope and higher mass on values favoring one
(mean=2/3); (ii) b=1, giving gρ(x) = 1, a Uniform distribution, (mean=1/2); and
(iii) b = 2, giving gρ(x) = 2 − 2x with a negative slope and higher mass on values
closer to zero (mean=1/3).
To incorporate X into a mixture distribution with point masses at 0 and 1, we
define a multinomial random variable M = (M1,M2,M3), where M1,M2 and M3 are
dependent Bernoulli random variables with M1 + M2 + M3 = 1 and probabilities
(qρ, 1− 2qρ, qρ).
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The mixture distribution of ρ can be written as M2X +M3, that is,
ρ =

0 when M1 = 1, with probability qρ
X when M2 = 1, with probability 1− 2qρ
1 when M3 = 1, with probability qρ
The CDF of ρ becomes,
Fρ(x) = P (M1 = 1) + P (ρ ≤ x|M2 = 1)P (M2 = 1) + I(x = 1)P (M3 = 1)
= qρ + (1− 2qρ)
x∫
0
[b+ 2(1− b)u] du+ qρI(x = 1).
Also,
E(ρ) = E(M2X +M3)
= E(M2)E(X) + E(M3)







V (ρ) = V {E(ρ|M)}+ E{V (ρ|M)}
V {E(ρ|M)} = V {E(M2X +M3)|M}
= V {M2E(X) +M3)}
= E(X)2V (M2) + V (M3) + 2E(X)Cov(M2,M3)
= E(X)2(1− 2qρ)2qρ + qρ(1− qρ)− 2E(X)(1− 2qρ)qρ
= 2E(X)(1− 2qρ)qρ{E(X)− 1}+ qρ(1− qρ)
E{V (ρ|M)} = E{V (M2X +M3)|M}
= E{V (M2X)|M}
= E{M22V (X)}
= V (X)E(M22 )
= V (X){1− 2qρ}
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+ qρ(1− qρ) + {1− 2qρ}
{
2 + 2b− b2
36
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When qρ = 0, the mean and variance of ρ are those of the trapezoidal distribution,
X, defined earlier. Table 3.10 summarizes values of E(ρ), V (ρ) and m by choices for
b and qρ. Appendix 3.6.1.3, includes code for this prior on lines 18 through 30.
3.6.1.3 Outline of the code written in JAGS
The code presented below corresponds to the applying the model to the data as
presented in Section 3.4 for the simple case with no covariates.
#Defining the model.bug file1
model {2
c < − 1000 #a constant used in defining the mixture prior3
#Define the likelihood for each of the N subjects4
for (i in 1:N) {5
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prob[i]< − 1- exp( -alpha* ( dose[i] - rho*maxprevdose[i])*step(dose[i] -rho*maxprevdose[i])6
- beta*cumdose[i])7
response[i] ∼ dbern(prob[i]) }8
#Setting up the priors9
#prior on α - E(α) = 1 and V ar(α) = 9 and qα = 0.04, the point mass at zero10
Using these values µg = (1 − 0.04)−1 = 1.04 and σ2g = (1 − qα)−1σ2α − µ2gqα = 9.3311
the mean and variance for the random variable X described in 3.6.1.1.12
mu1 < − -1.09313
tau1 < − 0.441614
alpha1 ∼ dlnorm(mu1,tau1)15
alphazero ∼ dbern(0.96) #point mass of 0.04 at zero16
alpha < − (1-alphazero)*0 + alphazero*alpha117
#prior on ρ based on 3.6.1.218
intercept < − 0.20 ; slope < − 2 - 2*intercept19
zero1 ∼ dpois(phi1)20
phi1< − -log(intercept + slope*(rho1)) +c21
rho1 ∼ dunif(a1,b1)22
a1 < − 0 b1 < − 123
#Mimicking the Multinomial by using a Uniform distribution for the two point24
masses25
u ∼ dunif(0,1)26
z1 < −(u <= 0.04)27
z2 < −(u > 0.04&u < 0.96)28
z3 < −(u >= 0.96)29
rho < −z1 ∗ 0 + z2 ∗ rho1 + z3 ∗ 130
#Truncated Normal prior on β - µbeta = −5.44 and σ2β = 1/0.047 = 21.3731
# Using the zeroes trick to simulate a non-standard prior32
zero ∼ dpois(phi)33
phi < − 0.047*0.5*pow(beta+5.44,2) +c34
beta ∼ dunif(a2,b2)35
a2 < − -alpha*(1-rho)/436
b2 < − 100037
#calculate the probabilities of toxicity38
#define the two dose groups39
d1 < −-log(1-0.05)40
d2 < −-log(1-0.10)41
#probability of no toxicity on each of the four cycles for the lower dose group42
prob11 < − exp(-alpha*d1)43
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prob12 < − exp(-alpha*(d1-rho*d1)*step(d1-rho*d1) - beta*d1)44
prob13 < − exp(-alpha*(d1-rho*d1)*step(d1-rho*d1) - beta*2*d1)45
prob14 < − exp(-alpha*(d1-rho*d1)*step(d1-rho*d1) - beta*3*d1)46
#probability of no toxicity on each of the four cycles for the higher dose group47
prob21 < − exp(-alpha*d2)48
prob22 < − exp(-alpha*(d2-rho*d2)*step(d2-rho*d2) - beta*d2)49
prob23 < − exp(-alpha*(d2-rho*d2)*step(d2-rho*d2) - beta*2*d2)50










jags < − jags.model(file=”prior.bug”, data = data, inits=inits, n.chains = 2, n.adapt61
= 5000)62
adapt(jags,n.iter=1000)63
update(jags,20500) # burin samples64










sim1.dic< −dic.samples(jags, n.iter=40000,n.thin=35, type=”pD”)75





3.6.1.4 Function code in R to find the parameters of the truncated Nor-
mal for β prior
# x[1] is the mean µβ and x[2] is the standard deviation or σβ1
# y[1] gives the mean µ and y[2] the corresponding σ.2
findbetaroots = function(x) {3
y = numeric(2)4
a.low=0 #the truncation point when ρ = 05
a.low=-1/3 # the truncation point when ρ 6= 06
pdf.fun = dnorm( (a.low-x[1]/x[2]),0,1)7
cdf.fun= 1-pnorm((a.low-x[1])/x[2],0,1)8
y[1]=x[1] + x[2]*pdf.fun/cdf.fun - 39
alp= a.low - x[1]/ x[2]10
delta.alp=pdf.fun/cdf.fun * (pdf.fun/cdf.fun - alp)11




Table 3.8: Parameters for obtaining truncated Normal prior, fβ(β|α, ρ) ∼ N(µ, σ2)
on β from a Normal(µβ, σ
2
β) distribution truncated at zero.
µ/σ2 0.5 1 2 3 4 5
1 0.40, 1.10 - - - - -
2 2.00, 0.51 1.89, 1.21 0.80, 4.39 -5.16, 17.32 - -
3 2.99, 0.50 2.99, 1.01 2.89, 2.30 2.57, 4.28 1.83, 7.50 0.31, 13.08
4 4.00, 0.50 3.99, 1.00 3.98, 2.04 3.93, 3.28 3.79, 4.82 3.54, 6.81
5 5.00, 0.50 4.99, 1.00 4.99, 2.00 4.99, 3.06 4.95, 4.22 4.89, 5.56
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Table 3.9: Parameters for obtaining truncated Normal prior, fβ(β|α, ρ) ∼ N(µ, σ2)
on β from a Normal(µβ, σ
2
β) distribution truncated at −1/3, α = 1, ρ = 0, k = 3.
µ/σ2 0.5 1 2 3 4 5
1 0.90, 0.64 -0.26, 2.68 - - - -
2 2.00, 0.50 1.96, 1.09 1.54, 3.08 -0.028, 7.73 -5.44, 21.37 -42.64, 109.16
3 2.99, 0.50 2.99, 1.00 2.95, 2.16 2.77, 3.75 2.83, 6.06 1.64, 9.52
4 4.00, 0.50 3.99, 1.00 3.99, 2.02 3.96, 3.17 3.88, 4.53 3.72, 6.21
5 5.00, 0.50 5.00, 1.00 4.99, 2.00 4.99, 3.03 4.97, 4.15 4.93, 5.38
Table 3.10: Values of slope m,E(ρ) and V (ρ) for different values of the intercept b
and point mass qρ based on the expressions derived in Section 3.6.1.2
qρ=0 qρ=0.02 qρ=0.04
b = 0,m = 2 0.6670, 0.0556 0.6600, 0.0644 0.6533, 0.0732
b = 0.2,m = 1.6 0.6330, 0.0656 0.6280, 0.0736 0.6227, 0.0816
b = 0.4,m = 1.2 0.6000, 0.0733 0.5960, 0.0808 0.5920, 0.0882
b = 0.6,m = 0.8 0.5667, 0.0789 0.5640, 0.0859 0.5613, 0.0929
b = 0.8,m = 0.4 0.5333, 0.0822 0.5320, 0.0890 0.5307, 0.0957
b = 1,m = 0 0.5000, 0.0833 0.5000,0.0900 0.5000, 0.0967
b = 1.2,m = −0.4 0.4667, 0.0822 0.4680, 0.0890 0.4693, 0.0957
b = 1.4,m = −0.8 0.4333, 0.0789 0.4360, 0.0859 0.4387, 0.0929
b = 1.6,m = −1.2 0.4000, 0.0733 0.4040, 0.0808 0.4080, 0.0882
b = 1.8,m = −1.6 0.3667, 0.0656 0.3720, 0.0736 0.3773, 0.0816
b = 2.0,m = −2.0 0.3333, 0.0556 0.3400, 0.0644 0.3467, 0.0732
CHAPTER 4
Adaptive Phase I Clinical Trial Design Using
Markov Models in Oncology for Patients with
Ordinal Outcomes with Repeated Measures
4.1 Introduction/Background
Most dose finding clinical trial designs including the ‘3+3’ [Storer, 1989] and
the continual reassessment method (CRM) [O’Quigley et al., 1990] are based on
dichotomizing the response into either a dose limiting toxicity (DLT) or no DLT,
typically using the Common Toxicity Criteria defined by National Cancer Institute
[NCI, 2003] that classifies grade 3 or higher toxic response as DLT. The literature that
considers expanded levels of toxicity [Iasonos et al., 2011, Lee et al., 2012, Ivanova
and Kim, 2009] confirms loss of information by grouping grade 1 or 2 toxicities into
the ‘no DLT’ category. There are many examples of the extension of the CRM to
an ordinal response [Lee et al., 2011, Van Meter et al., 2012, 2011, Bekele and Thall,
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2004, Yuan et al., 2007, Wang et al., 2000] showing benefits in using ordinal response
outcomes but are primarily for trials involving single dose administrations of the
drug to the patient.
Instead of allowing patients to receive only a single dose, [Simon et al., 1997]
provided the rationale for the accelerated titration design where patients could have
intra-patient dose escalation. A random effects models with a continuous response
was considered in this design with cut-offs for classifying the toxicity into four cat-
egories. This model was used to simulate data for the evaluation of the accelerated
titration method, but the model was not used for data analysis. Motivated by con-
siderations of pharmacokinetics [Legedza and Ibrahim, 2000] developed a model for
repeated toxicity measures for each patient but dichotomized the response at each
cycle for the patients. Both these methods assumed that the dose would remain
constant for the patient on every cycle in the study.
There are ethical benefits in allowing a patient to receive a higher dose on subse-
quent cycles if no DLTs are manifested in the previous cycles. Alternatively the dose
could be reduced if a higher than expected number of toxicities are observed in other
patients in the study. Such a study conduct with repeated doses per patient in a
binary outcome setting has been described in Chapter 2. Potential efficiency gains in
estimating the dose-toxicity relationship through use of dose escalation/de-escalation
have also been demonstrated in Chapter 2 especially in the setting of small sample
sizes.
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The use of ordinal outcomes is especially important in the setting when a patient
is allowed to have multiple doses with possible dose escalation schemes so that the
dose could be de-escalated or kept the same on the next cycle if a mild toxicity
is observed on the current cycle. More recently [Doussau et al., 2013] provided a
mixed effects proportional odds model to incorporate ordinal outcomes in a phase I
setting to identify the probability of a severe toxicity and trend in risk of toxicity
with time at the end of the trial. This method does not explicitly model the tendency
to discontinue cycles for patients who have demonstrated previous DLT, although
the resulting estimated toxicity rates may be conditional in nature. In addition the
cumulative effect of the dose is not captured and patients are not allowed to escalate
or de-escalate doses. In this setting where there are multiple cycles, doses may change
and there are more than two levels of toxicity a large number of parameters may be
necessary to capture all features of the dose-toxicity relationship. Furthermore, with
the typically small sample size available for modeling purposes, a Bayesian approach
is an attractive alternative. The ordinal Markov model presented in this chapter
is an extension to the dichotomous Markov Model 2.1 from Chapter 2 which is an
example of transitional models with Markov chains [Agresti, 2002] considering the
toxicity on previous cycles.
In this chapter we will discuss extensions to the Markov Model in Chapter 2 for
ordinal outcomes in phase I clinical trials using the concepts of the cumulative logit
models. The binary outcomes are extended to three ordinal outcomes - none, mild
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and severe denoted by 1, 2 and 3 respectively. A patient experiencing a severe toxicity
would be considered a DLT and would not receive any further doses, while patients
having a mild or no toxicity on the previous cycle would be considered eligible for
further dose assignments. If a patient experiences a severe toxicity on any cycle they
are typically taken off the study and they would not provide further data for the
assessment of toxicity. The data for each patient would either consist of a series of
ones (for example 11111) for a patient with no toxicity or a series of ones with some
mild toxicities, (for example 1122) and some terminating with a severe toxicity (for
example 11223). Typically in practice if a mild toxicity is observed the dose is lowered
or kept the same on the next cycle. As an alternative to the 2 state Markov model
we develop a three state Markov model with the states being 1, 2 and 3. Because 3 is
a terminating state, we only need to consider the transition probabilities out of state
1 and 2. We explicitly model conditional probabilities of toxicity in a cycle given
that the patient is either toxicity-free or has mild toxicities to date. The proposed
model allows for a cumulative effect of dose on toxicity after the first cycle and allows
covariates to influence the toxicity profile over cycles. A parameter is included to
reflect an individual’s tendency to respond consistently with past dose experience.
Another parameter is included to account for the ordinal responses. In Section
4.2, we formulate the model, describe the Bayesian estimation method and provide
intuition on model behavior. We then study finite sample operating characteristics
and adaptive design through simulations in Sections 4.3 and 4.4 respectively and end
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with a discussion in Section 4.5.
4.2 Methodology
4.2.1 Notation and data structure
We assume that there are five increasing dose levels of an experimental study
drug represented by dg, g = 1, . . . 5, that will be studied in i = 1 . . . N patients.
Each patient i completes Ki ≤ 6 cycles, where Ki may be less than six if a patient
experiences a DLT. On each cycle k = 1, . . . , Ki, patient i receives a dose di,k equal to
one of the five values of dg. The toxicity response for patient i on cycle k is Yi,k with
Yi,k = 1 indicating none toxicity and Yi,k = 2 or Yi,k = 3 indicating a mild or severe
toxicity respectively. Patients stop receiving further administrations of the the drug if
they experience a severe toxicity which is usually a DLT. Thus the possible patterns of
Yi,k values for a patient are a sequence of ones or a sequence of ones and twos followed
by a three. The observed data is {(Yi,1, . . . , Yi,Ki , di,1, . . . , di,Ki), i = 1, . . . , N}. A
patient’s cumulative dose prior to cycle k = 1, . . . , Ki is Di,k =
∑k
j=1 di,j−1, so that
Di,1 = 0.
Borrowing on the idea from Chapter 2, the history of tolerating the previous doses
is captured through the dose term d‡i,k which is designed to represent the maximum
dose level a patient has tolerated with no toxicity on the past cycles. If a patient i
had a mild toxicity on any dose level then d‡i,k = φ×min (di,j | Yi,j = 2, j = 1 . . . k−1)
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and if the patient had no toxicities in the past then d‡i,k = max(di,j × I [Yi,j=1], j =
1 . . . k−1), where I [Yi,j=1] denotes the indicator function that takes value 1 if Yi,j = 1
and 0 otherwise. The intuition behind this is that the maximum dose level tolerated
is set to be slightly lower by a factor φ, than the minimum dose at which the mild
toxicity occurred. Note that d‡i,k = 0 for cycle k = 1.
4.2.2 Proposed Markov model
For a patient i from a set of N patients, receiving k(1 . . . K) repeated cycles until
a severe toxicity (grade 3 or higher) occurs, we define pi,k(3) to be the probability
of severe outcome, Yi,k = 3, at dose di,k on cycle k and pi,k(2+) be the cumulative
probability of severe and mild outcomes, Yi,k = 2 or 3. Using the concepts of the
cumulative logit models for modeling ordinal outcomes we define the following prob-
abilities,
P (Yi,k ≥ 3) = P (Yi,k = 3) = pi,k(3)
P (Yi,k ≥ 2) = P (Yi,k = 2, 3) = pi,k(2+)
P (Yi,k = 1) = pi,k(1) = 1− pi,k(2+)
P (Yi,k = 2) = pi,k(2) = pi,k(2+) − pi,k(3)
Where pi,k(1), pi,k(2) and pi,k(3) are the probabilities of observing one of the three
outcomes which follow a multinomial distribution. The ordinal Markov Model 4.1
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for the ordinal outcomes is as follows,




















where α, β, ρ and θ are required to be non-negative. Model intuition can be obtained
by beginning with the first cycle, k = 1, when the probability of the severe toxicity
is pi,1(3) = 1− exp(−αdi,1) and pi,1(2+) = 1− exp(−(θ + 1)αdi,1) is the probability of
having a mild or severe toxicity. The only parameters that are relevant are α and
θ on the first cycle. The probability of severe toxicity on the first cycle is captured
by α ≥ 0. Because θ ≥ 0, the probability of severe toxicity is less than or equal
to the probability of severe or mild toxicity. The parameter θ tries to capture the
probability of observing a mild toxicity and can be thought of as a scaling parameter
in the probability estimation of severe toxicity, which will be determined by the
prevalence of mild toxicities.
On subsequent cycles, k > 1, the probability of toxicity is modified by the effect
of the current dose and the cumulative dose captured by the two linear terms. In the
first term (di,k − ρd‡i,k) consider first the role of φ which is set to a constant factor -
ranging from 0− 1 and comes into play through d‡i,k. A value of φ = 0 implies that
the patient cannot tolerate the dose level at which the mild toxicity occurred on a
previous cycle while φ = 1 implies that the mild toxicity can be ignored and assumed
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(or override) that the patient could handle the full dose. The parameter φ in some
sense captures the dependency of the patient responses on past doses to tolerability
of the dose level in the presence of mild toxicity.
The term (di,k − ρd‡i,k)+ is not allowed to be negative to ensure that pi,k ∈ [0, 1].
The parameter ρ can be thought of as reflecting the amount of memory about whether
a dose was tolerable, with ρ = 1 reflecting perfect memory and ρ = 0 reflecting no
memory. Thus this term tries to capture the within-patient correlation between dose
cycles. If ρ = 1, (di,k − ρd‡i,k)+ reduces to (di,k − d
‡
i,k)
+ as the difference between the
current assigned dose and the dose tolerated from previous cycles. If the current dose
is less or equal to dose tolerated from previous cycles, the difference will be zero and
will not contribute towards the probability estimate i.e., there is a strong memory
that a higher or equal dose to the current one was tolerable hence the current dose is
more likely to be tolerable. When ρ = 0, the term (di,k − ρd‡i,k)+ reduces to di,k and
thus there is no memory of the previous doses that had been tolerated. Intermediate
values of ρ between zero and one have intermediate amount of memory.
The second linear term βdi,kDi,k, β ≥ 0 is designed to capture the idea that there
may be “damage” accumulated from prior doses and the amount of this “damage”
plays a role in determining the probability of toxicity when a new dose is adminis-
tered. The impact of the accumulated damage will be larger if di,k is larger and will
not be relevant if di,k = 0. In the case of a dose de-escalation and if the (di,k−ρd‡i,k)+
term is equal to zero then the cumulative effect is the only term that would account
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for the probability of toxicity and will not be the driving force when the contribution
from the current dose is too little or none at all.
Figure 4.1 plots the conditional probability of mild and severe toxicity in left and
right columns respectively for different values of θ along the rows for fixed values of
α = 1, β = 0, φ = 0.8 and ρ = 0.8 and aids in understanding the working properties
of the ordinal Markov Model 4.1. The solid circles with dashed lines in the plots on
the left panels represent the probability of mild toxicity on the first cycle at each of
the five possible doses and is provided as a reference for comparison. While in the
right panels the solid triangles represent the equivalent probability of severe toxicity
on the first cycle at each of the five possible doses. The probabilities of toxicity
on the second cycle are calculated at each of the five dose levels assuming that the
patient received the third dose level on the first cycle. In both the mild/severe panels
the open circles and crosses correspond to the probability of mild/severe toxicity on
second cycle assuming mild and none toxicity respectively on the first cycle. In
the first row when θ = 0.1 there is not much difference between the probability of
a mild toxicity on both cycle 1 and cycle 2. In contrast the probability of severe
toxicity on the second cycle is lower than that on the first cycle. The probability of
severe toxicity on second cycle given a mild toxicity on the first cycle is higher than
the probability of severe toxicity given no toxicity on the first cycle as indicated by
the open circles and crosses. Varying the values of θ does not have any effect on
the probability of severe toxicity as evidenced by the identical left panel plots. For
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increasing values of θ the probability of mild toxicity increases with the probability
of observing a mild toxicity on the second cycle given that a mild toxicity occurred
on the first cycle being higher than that when a none toxicity was observed on the
first cycle. The non-zero value of ρ = 0.8 confers patients in cycle 2 to be less likely
to experience a toxicity as a function of dose and hence the probability of toxicity
on the second cycle is always lower than that on the first cycle.
The effect of using different values of φ is explored through Figure 4.2 with fixed
values of α = 1, β = 0, ρ = 0.8 and θ = 1 with the layout of the panels and symbols in
the plots holding the same definitions as Figure 4.1 and differing only by the varying
values of φ along the rows. When φ = 0 the probability of having a mild toxicity on
the second cycle given that a mild toxicity was observed on the first cycle overlaps
with the probability of observing a mild toxicity on the first cycle. Since φ = 0 the
patient is not given any credit on the second cycle for surviving the first cycle with a
mild toxicity but surviving the first cycle with none toxicity confers a lower chance
of mild toxicity on the second cycle as seen by the crosses. For increasing values
of φ the probability of mild toxicity on the second cycle begins to differ from the
first cycle and eventually for φ = 1 the probability of a mild toxicity is the same
irrespective of whether a mild or none toxicity was observed on the first cycle. The
trends are similar in the case of the panels on the left for the probability of severe
toxicity. There will be a positive contribution to the probability of both mild and
severe toxicity on the second cycle when a non zero value of β is used in both these
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plots. It is also easy to see that probability of toxicity on the first cycle will be
higher/lower for increasing/decreasing values of α.
We can now compare the ordinal Markov model 4.1 to the model presented by
Doussau [Doussau et al., 2013] using the mixed effects proportional odds model for
three response outcomes as,
logit(P (Yi,j ≤ k|dl)) = αk − β1dl − ui, ui ∼ N(0, σ20)
Doussau’s model has four parameters, α1, α2, β1 and σ0, which are equal to the
number of parameters estimated using the Markov model. The correlation between
patient responses is captured by the random effects term ui. The authors also impose
the condition that the dose levels remain constant within the patient. In contrast
the ordinal Markov Model 4.1 allows patients the possibility of dose escalation or
de-escalation especially when a mild toxicity is observed during the course of their
treatment. Doussau’s model formulation allows for a non-zero probability of toxicity
in the absence of any dose, in general when dose (dl) is zero the probability of toxicity
should be zero, which is ensured in the ordinal Markov Model 4.1. Doussau’s model
does not capture the effect of the cumulative dose through an implicit parameter as
is done in the Markov model through β. The probability of toxicity is assumed to be
only due to the current dose although there exists a possibility for cumulative effect of
toxicity. The random effect term ui might be inadequate in capturing the additional
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Figure 4.1: Conditional probability of mild and severe on the second cycle in the left
and right columns respectively for different dose levels on the x-axis and assuming
dose level three was given on cycle 1. The probability of mild and severe on the
first cycle is in solid circles and triangles respectively for reference. The open circles
correspond to assuming a mild toxicity while the crosses to none toxicity on cycle 1.
Probabilities on cycle 2 are arranged by increasing values of θ from top to bottom


















































































































Figure 4.2: Conditional probability of mild and severe on the second cycle in the left
and right columns respectively for different dose levels on the x-axis and assuming
dose level three was given on cycle 1. The probability of mild and severe on the first
cycle is in solid circles and triangles respectively. The open circles correspond to
assuming a mild toxicity while the crosses to no toxicity on cycle 1. Probabilities on
cycle 2 are arranged by increasing values of φ from top to bottom with fixed values
of α = 1, β = 0, θ = 1 and ρ = 0.8
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effect of the cumulative dose. Maximum likelihood estimates were obtained using
Laplace approximations and adaptive Gauss-Hermite quadrature through a package
in R. In contrast we set priors on the parameters and use Bayesian MCMC methods
for parameter estimation through R.
4.2.3 Probability Skeleton
The dose levels to be studied are transformed to dg via pre-specified skele-
ton probabilities denoted by qg, g = 1 . . . 5. The skeleton probabilities incorporate
prior knowledge of the dose-toxicity relationship and correspond to the probabil-
ity of observing a severe toxicity on the first cycle for each of the dose levels. On
the first cycle the probability of severe toxicity is parameterized only by α since,
1− pi,1(3) = exp(−αdi,1). Using the probability skeleton values qg, the corresponding
values for dg are calculated assuming α = 1 and solving dg = −log(1 − qg). These
transformed values of dg are used as doses in the model formulation. Such use of
probability skeleton is seen in the works of other authors like [O’Quigley et al., 1990,
Lee and Cheung, 2009] in the context of the CRM and [Lee et al., 2011, Cheung and
Elkind, 2010] in other contexts.
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4.2.4 Prior and posterior distribution
Based on the study design, patients contribute to the likelihood until they expe-
rience a DLT or the final Kth cycle is completed. In general, subject i contributes,












to the likelihood, where I [Yi,k=j] denotes the indicator function that takes value 1 if
Yi,k = j and 0 otherwise. The resulting likelihood for the entire study population is
given by,





Li,k(Yi,k|α, β, ρ, θ).
Our goal lies in estimating the posterior distributions of pi,k(1), pi,k(2), pi,k(3), k =
1, . . . , K in terms of the posterior distributions of parameters α, β, ρ and θ. Prior
distributions on these parameters should reflect any auxiliary knowledge of the tox-
icity profile for the drug/agents being used in the trial, with a large prior variance
when this knowledge is limited. In setting the prior on α ≥ 0 a lognormal (µ, σ2) is
used as a suitable prior having the form:




The prior mean for α is set at 1 to align with the use of the probability skele-
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ton information. Setting the variance of the prior to 4, provides a coefficient of
variance (CV) of 2. Parameters µ and σ are estimated using the expressions for
the mean and variance of the lognormal density, E(α|µ, σ) = exp(µ + σ2/2) and
V ar(α|µ, σ) = exp{2(µ+ σ2)} − exp(2µ+ σ2).
As mentioned earlier in Section 4.2.2, ρ ∈ [0, 1], captures the correlation within
patients receiving multiple doses, with values near zero indicating that the toxicity
outcome is not influenced by previously administered doses and a value near one
indicating a lower chance of toxicity from a previously administered dose. Since there
is limited information to estimate ρ, we use a prior distribution with a small variance
to allow some uncertainty in ρ, rather then choosing a fixed value. A Beta(a, b) prior
is used on ρ having density of the form:
π(ρ|a, b) = (ρ)a−1(1− ρ)1−b
The hyperparameters are set to a = 5 and b = 1 and using the expressions for the
mean a/(a+ b) and variance ab/{(a + b)2(a + b + 1)} the prior on ρ has a mean of
0.833 and variance of 0.02
The probability of toxicity is assumed to increase with an increase in the cumu-
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lative dose and hence the lognormal density is used as the prior on β ≥ 0. The prior
mean is set to 0.5 and variance is set 1 obtaining a CV of 2.
In the case of θ a lognormal prior with mean 4 and variance 16 is used to span
the positive real axis conforming to its bounds of 0 ≤ θ ≤ ∞. Simulation studies
proved that it was difficult to estimate all the five parameters and hence φ has been
set to a constant. Simulation results explore the effects of using φ=0.8 or 0.9.
The posterior distribution for α, β, ρ and θ given the observed data Y is then















k=1 Li,k(Yi,k|α, β, ρ, θ)πα(α)πβ(β)πρ(ρ)πθ(θ)dαdβdρdθ
.
The posterior distribution of α, β, ρ and θ can be estimated via Markov Chain Monte
Carlo (MCMC) methods [Robert and Casella, 1999] using just another Gibbs sam-
pler (JAGS) rjags [Plummer, 2011] package through [R Development Core Team,
2011]. JAGS includes several algorithms for sampling from the posterior distributions
produced from the MCMC iterations, for instance the standard Gibbs sampler is
available for this purpose. Details of setting up the MCMC simulations are given in
Section 4.2.5.
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4.2.5 Implementation in JAGS
The data likelihood and the density definitions of the priors are specified in a
model file saved under a .bug extension. The model file and the data are passed into
the JAGS for compilation along with the list of parameters, α, β, ρ and θ, that have
to be monitored. The number of parallel chains to be run by JAGS are also defined
at the compilation stage, where each parallel chain produces independent samples
from the posterior distribution. The compiled model then needs to be initialized for
all the parameters that need to be monitored in each of the chains. The JAGS code
is provided in Appendix 4.6.1. Samplers are automatically assigned by JAGS at the
initialization stage after a pre-specified adaptive phase for each of the parameters
based on the likelihood definition of the model. A relatively large burn-in period of
1000K samples with posterior samples of 500K (thinned by 5) are used in simulations
presented in later sections. A slightly longer burn-in period is used when there are
fewer patients in the sequential trial design. Before using the samples from the two
chains for reporting they are monitored and assessed through diagnostic tests. The
correlation between samples generated at each iteration of the MCMC chain for each
of the parameters needs to be sufficiently low. The posterior means, α̂, β̂, ρ̂ and θ̂, of
the four parameters, are used to calculate the various probabilities of interest.
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4.3 Operating Characteristics/Results
This section presents simulation results studying the working properties of the
Ordinal Markov model in two different settings, 1) a static setting, demonstrating the
parameter estimation and 2) an adaptive setting with patients recruited sequentially.
4.3.1 Parameter Estimation
A 100 datasets were generated each having N = 30 patients. Patients were
distributed equally over the five dose levels receiving the same dose over six cycles.
The probability skeleton used for the five dose levels was (0.02,0.05,0.10,0.16,0.23),
implying that the lowest and highest doses expected a 2% and 23% chance of severe
toxicity on the first cycle respectively. The priors used on the parameters are as
discussed earlier in Section 4.2.4, α, β and θ with lognormal prior distributions while
ρ with a Beta prior distribution. Ordinal responses were generated for the patients
under two different scenarios. The true values of the parameters were α = 1, β =
0.5, φ = 0.9, ρ = 0.8, θ = 4 in scenario 1 and α = 1, β = 0.8, φ = 0.9, ρ = 0.8, θ = 3
in scenario 2.
Table 4.1 shows the results of the simulations from 100 datasets. The parameters
in the rows are grouped by the two scenarios. The columns provide 1) true value 2)
mean of the prior with SD in parenthesis 3) mean of the estimates from 100 datasets
with the bias from the true value in parenthesis 4) mean SD (MSD) from the 100
datasets 5) empirical SD (ESD) of the parameter from 100 datasets and 6) coverage
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rate of the true value in the 95% credible intervals. Based on the results in Table
4.1 there seems to be an acceptable level of bias in the parameter estimates. The
estimates of θ are close to the true values used in generating the data. The values of
the MSD and ESD are comparable (slightly higher) indicating sufficient variability,
except for ρ where we used a tight prior. In comparison to the prior SD of the first
three parameters the data provided information and hence the MSD was reduced
considerably compared to the prior SD. But for ρ there was a small decrease from
the prior because the data was minimally informative about this parameter. The
coverage rates are between 89% and 100%. These results are from simulations where
the patients receive the same dose on all the cycles. Similar simulation results could
be obtained when patients are allowed to escalate or de-escalate. We conclude that
the model is able to provide accurate estimates of the parameters.
4.4 Adaptive Trial Design and Simulation
This section describes application of the ordinal Markov Model 4.1 in designing
a sequential clinical trial to be used in practice assuming that patients would be
assigned to one of the five dose levels. On completion of the first cycle without
any severe toxicity the patient would be eligible to either stay at the same dose
level or escalate to a higher dose level or de-escalate to a lower dose level based
on the recommendations of the algorithm using the ordinal Markov Model 4.1 and
the specified safety criterion. It will be assumed that a new patient is ready to
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be assigned a dose once other continuing patients in the trial have completed their
dosing cycle. That is, all active patients in the study and the new patient to be
enrolled all receive their dose assignment simultaneously. Maximizing the expected
total dose is the optimizing strategy used in choosing the best dose to be assigned to
a patient on the next cycle when multiple choices are presented. In the next section
we begin by defining the safety criteria for dose assignment and the notation used for
the probabilities in defining the criterion, followed by defining the particulars of the
maximizing strategy to be used in dose assignment. Finally a simulation example
of a trial and results evaluating trial conduct properties comparing various criterion
through simulations will be presented in this section.
4.4.1 Safety Criteria
We begin by defining the safety criteria rules for dose assignment in carrying out
a trial with dose escalation and/or de-escalation. Define rg,k = g, g = 1 . . . 5 as one
of the five dose levels on cycle k corresponding to dg, g = 1 . . . 5 the transformed
doses using the probability skeleton. The following commonly used dose escalation
rules will be followed in defining the safety criteria to be used while carrying out an
adaptive clinical trial based on ordinal Markov Model 4.1.
• The first and the second patient on the trial will be assigned the second lowest
dose level, rg,1 = 2, on cycle 1. Given that there is no severe toxic response,
the same dose level will be assigned on the second cycle for the first patient.
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For subsequent patients and cycles the following rules will be used.
• A patient will only be allowed single dose jumps in dose escalations, i.e., a
patient i completing cycle k on dose level rg,k could have a maximum dose
level min(rg,k + 1, 5) on cycle k + 1.
• A patient can have a maximum of three dose levels in a dosing regimen, unless
de-escalation to a lower dose is required i.e.,a patient i receiving dose level rg,1
on cycle 1 can possibly receive rg,1 + 2, as its highest dose level in the dosing
regimen. In combination with the previous rule a patient i completing cycle
k on dose level rg,k, can have r
max
g,k+1 = min(rg,1 + 2,rg,k + 1, 5) as its highest
possible dose level on any cycle k + 1 in the study.
• For a new patient, î, on the first cycle, to ensure a considerable degree of safety
especially during the early stages of the trial, the maximum dose level choice
would be limited to rmaxg,1 = max(r
‡




g,1 is the maximum of
all the past dose levels assigned to the patients on cycle k = 1 and r‡g,k is the
maximum of all the past dose levels assigned to the patients in the study on
cycles k > 1. This ensures that new patient î on the first cycle will not jump
a dose level that has not been assigned previously to any patient in the study
(there could be a possibility of a dose jump on the first cycle).
• The study will conclude when none of the dose levels are included in the toler-
able range as determined by the safety criteria defined below.
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4.4.1.1 Notation for probabilities used in safety criteria
Monitoring the safety of the patients is ensured by assigning doses that satisfy a
set of safety criteria and the following notation is useful to understand these rules. For
a patient i who has completed cycle k on dose level rg,k without a DLT, the possible
dose levels for this patient are j = 1 . . . rmaxg,k+1, allowing for dose de-escalation.
Define Ai,k+1,j as the event of severe toxicity on cycle k + 1 for patient i at dose
level j given that there were no DLTs in the past. Hence P(Ai,k+1,j) = pi,k+1(3),
where pi,k+1(3) is calculated using the Markov Model 4.1 for dose level j.
Given rmaxg,k+1 for patient i the potential regimens considered are denoted by the set
Rregimeni,k+1 . Members, r
regimen
i,k+1,m , of this regimen set have length K = 6, corresponding
to the number of cycles, where the first k elements are the doses received and future
doses constrained by min(rg,1 + 2,rg,k + 1, 5) for cycles (k + 1) . . . K.
Define Bi,k+1,m as the event of having a severe toxicity on any cycle k + 1 until
K for a member m of the regimen set Rregimeni,k+1 , where P(Bi,k+1,m) = 1−
∏K
l=k+1(1−
pi,m(3)). For regimen m from patient i’s regimen set define Ci,k+1,m as the event of
severe toxicity for that regimen on any cycle from 1 through K i.e., Ci,k+1,m = Bi,1,m.
P (Bi,k+1,m) captures the probability of severe toxicity for a patient on the remaining
cycles while P(Ci,k+1,m) captures the overall probability of severe toxicity on the
entire regimen m.
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4.4.1.2 Target probability bounds
In conducting a clinical trial with multiple doses we define the following prob-
ability bounds P̊ (A), P̊ (B) and P̊ (C) based on clinical inputs. P̊ (A) is a vector
of K = 6 probabilities corresponding to the acceptable conditional probability of
severe toxicity on the next cycle. P̊ (A1) is the acceptable probability of severe
toxicity limit on first cycle, while P̊ (A2) . . . P̊ (Ak) . . . P̊ (A6) are the corresponding
limits on subsequent cycles. Given the properties of the current Markov model
used to specify the dose toxicity relationship wherein the conditional probabili-
ties post cycle 1 are much lower and affected mainly by the cumulative effect, the
bounds on the conditional probabilities are assumed to be equal to each other i.e.,
P̊ (A2) = P̊ (A3) = . . . = P̊ (A6), and will be referred to as P̊ (A2). For a contin-
uing patient, P̊ (B) is the acceptable probability of severe toxicity limit on all the
remaining cycles while P̊ (C) is the acceptable probability of severe toxicity limit on
the entire regimen. The relationship between these target probabilities is explored
as follows.
Typically in single dose trials the acceptable level of toxicities is set at 30% which
in the case of multiple dose trial would correspond to P̊ (C), the probability of se-
vere toxicity bound on all the cycles. For the bounds to be consistent with each
other, 1 − P̊ (C) ≤
∏6
k=1{1 − P̊ (Ak)} which further reduces to {1 − P̊ (C)} ≤
{1 − P̊ (A1)} × {1 − P̊ (A2)}5. Assuming this relationship, provides an easy way to
specify the bounds on P̊ (A2), given the acceptable bounds on P̊ (A1) and P̊ (C). In
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the simulations presented slightly higher bounds are used to demonstrate differences
in results. P̊ (B) controls the bounds on the probability of toxicity on the remain-
der of the cycles and its value is chosen in relation to P̊ (C) and would typically be
≤ P̊ (C). We have set the value of P̊ (B) = P̊ (C) in the simulations presented in this
chapter.
4.4.2 Maximizing the Expected dose
With the safety criteria rules in place an optimizing strategy needs to be defined
upfront in the event that multiple dose level qualify on the next cycle. As mentioned
earlier the goal of the study is to maximize the total dose assigned to every patient
and we proceed by deriving the expression for the expected dose followed by the
algorithm for dose maximization.
4.4.2.1 Expected dose
In the presence graded toxicity outcomes the expected dose is calculated condi-
tional on the past responses. A patient having a severe toxicity is considered to be
a DLT and a terminating state hence the past responses of mild and none toxicities
need to be accounted for in calculation of the expected dose. The following equations
indicate the pattern in estimating the probabilities needed for the calculation of the
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expected dose.
P(severe on cycle 1)
P (Yi,1 = 3) = pi,1(3)
P(severe on cycle 2)
P (Yi,2 = 3) = P (Yi,2 = 3, Yi,1 = 1) + P (Yi,2 = 3, Yi,1 = 2)
= P (Yi,2 = 3|Yi,1 = 1)P (Yi,1 = 1) +
P (Yi,2 = 3|Yi,1 = 2)P (Yi,1 = 2)
= pi,1(1)pi,2(3|1) + pi,1(2)pi,2(3|2)
P(severe on cycle 3)
P (Yi,3 = 3) = pi,1(1)pi,2(1|1)pi,3(3|11) + pi,1(1)pi,2(2|1)pi,3(3|12) +
pi,1(2)pi,2(1|2)pi,3(3|21) + pi,1(2)pi,2(2|2)pi,3(3|22)
Similarly the P(mild on cycle 3) is given by,
P (Yi,3 = 2) = pi,1(1)pi,2(1|1)pi,3(2|11) + pi,1(1)pi,2(2|1)pi,3(2|12) +
pi,1(2)pi,2(1|2)pi,3(2|21) + pi,1(2)pi,2(2|2)pi,3(2|22)
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And the P(none on cycle 3) is given by,
P (Yi,3 = 1) = pi,1(1)pi,2(1|1)pi,3(1|11) + pi,1(1)pi,2(2|1)pi,3(1|12) +
pi,1(2)pi,2(1|2)pi,3(1|21) + pi,1(2)pi,2(2|2)pi,3(1|22)
The probability of observing a severe toxicity on cycle 3 for a given dose combi-
nation is a functional sum of the four combinations of past responses; none toxicities
on the first two cycles, none toxicity on the first cycle and a mild toxicity on the
second cycle, a mild toxicity on the first cycle and none toxicity on the second cy-
cle and lastly both mild toxicities on the first two cycles. The exact probability of
severe toxicity on every cycle k is calculated by forming a binary tree branch that
tracks the past responses with 2(k−1) combinations of mild and none toxicity. Using
the expressions for exact probabilities of severe toxicity defined above and extending
them mild and none toxicity, the expected dose for a patient i having a particular























P (Yi,K = 1).
4.4.2.2 Recommending a regimen
At the conclusion of the study, the estimates α̂, β̂, ρ̂ and θ̂ are used to estimate
the overall probability of toxicity P(Cj) for all of the j = 1 . . . 19 regimens listed in
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Table 2.3. During the conduct of the trial the target probability bounds used were
P̊ (A), P̊ (B) and P̊ (C). These bounds especially, P̊ (C), are usually set at higher
than acceptable values in practice and when selecting the final regimen we would
use P r(A1) and P
r(C) which might be lower than or equal to P̊ (A1) and P̊ (C)
respectively. For example in running the trial P̊ (C) = 0.40 could be used which
implies an overall toxicity of 40% but in practice 30% toxicities are what we would
want to see in the trials. Results will be presented when the final selection of the
regimen is based on P r(A1) and P
r(C). The recommended regimen satisfies P (A1) ≤
P r(A1) on the first cycle and P(Cj) ≤ P r(C) and has the highest possible maximum
expected dose. The target regimen (T) is identified using the true parameter values
of α, β, ρ and θ instead of the estimates obtained at the trial conclusion and is used
as a reference for gauging the properties of the trial.
4.4.2.3 Algorithm maximizing the expected dose
The algorithmic plan for maximizing the expected dose on the study for each
patient i is outlined below.
• For new patient î on cycle 1
1. Estimate P̂ (Aî,1,j) using current estimates α̂, β̂, ρ̂ and θ̂ at each of the









maximum of all the past dose levels assigned to the patients on cycle k = 1
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and r‡g,k is the maximum of all the past dose levels assigned to the patients
in the study on cycles k > 1.
2. Subset the dose levels that satisfy P̂ (Aî,1,j) ≤ P̊ (A1) over all dose levels.
3. For the dose levels satisfying P̂ (Aî,1,j) ≤ P̊ (A1) subset the list of possible
regimens from Table 2.3 and calculate the overall probability of severe
toxicity P̂ (Cî,1,j) tracking all combinations of mild and none toxicities.
4. Select the dose level that has an overall probability of toxicity P̂ (Cî,1,j) ≤
P̊ (C) and maximum expected dose.
5. If none of the doses satisfy P̂ (Aî,1,j) ≤ P̊ (A1) and if there are continuing
patients in the study then wait until updated estimates α̂, β̂, ρ̂ and θ̂ allow
doses to be assigned else the study is terminated.
• For continuing patient i on cycle k > 1,
1. List doses P̂ (Ai,k+1,j) ≤ P̊ (A2) from rmaxg,k+1 = min(rg,1 + 2,rg,k + 1, 5)
possible choices.
2. If there is more than one satisfying dose level then list the possible dose
regimen set Rregimeni,k+1 .
3. Calculate the probability of severe toxicity P̂ (Bî,k+1,m) assuming all com-
binations of mild and none toxicities on the remainder of the cycles for
each of the regimens m in Rregimeni,k+1 and the corresponding expected dose
using the current estimates α̂, β̂, ρ̂ and θ̂.
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4. Select the dose level that has probability of toxicity P̂ (Bî,k+1,m) ≤ P̊ (B)
and maximizes the expected dose.
5. If none of the doses satisfy P̂ (Aî,k+1,j) ≤ P̊ (A2) and if there are continuing
patients in the study then wait until updated estimates α̂, β̂, ρ̂ and θ̂ allow
doses to be assigned else the study is terminated.
For the purposes of evaluating the properties of the simulation of clinical trials over
multiple replications and comparing the properties of the target probabilities various
test statistics will be calculated that can be grouped into 1) trial conduct or patient
characteristics and 2) recommended regimen characteristics as explained below.
Patient characteristics
1. Mean dose per patient over all the replicates. In each of the replicates the
total dose given to all the patients will be tracked and then averaged across the
number of the patients in that trial. High values of mean dose are considered
favorable indicating that the patients received higher quantities of the drug in
the study.
2. Mean number of severe toxicities per study across all the replicates. The num-
ber of patients having a severe toxicity are averaged across the number of
patients in the trial. Low values of severe toxicities are considered favorable.
3. The trials that stop early without recruiting allN = 30 patients. Lower number
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of trials stopping are considered favorable because in the situations considered
there is a regimen that is not too toxic.
4. Mean number of patients having a regimen that matches the recommended
regimen.The distance from the recommended regimen is calculated for each of
the patients in the study, and the proportion of patients having distance less
than or equal to two are summarized and the average proportion across all the
replications is presented. High values of patients matching or very similar to
the recommended regimen are considered favorable implying that the regimen
recommended at study conclusion was actually observed in patients in the trial.
Recommended regimen characteristics
1. Mean of expected dose using the true values of α, β, ρ and θ given the recom-
mended regimen. High values of mean expected dose are considered favorable
implying that the recommended regimen if completed on all the six cycles would
provide the highest and safest amount of the study drug to the patients.
2. Mean of probability of severe toxicity on any cycle using the true values of
α, β, ρ and θ given the recommended regimen. Low values of mean toxicities
are considered favorable since the recommended regimen should provide low
levels of severe toxicities.
3. The fraction of recommended regimens that have toxicity less than say 40%
calculated using the true values is also presented. Higher proportions are fa-
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vorable and imply that the recommended regimen does not have a high toxicity
level.
4. A green region is defined as the list of five target regimens with highest ex-
pected dose that satisfy the safety constraints. The proportion of times the
recommended regimen belongs to this green region is also presented. High val-
ues of the proportion values are considered favorable and indicating a higher
degree of concordance between the recommended and target regimens.
4.4.3 Simulation results
Simulation results demonstrating the algorithm in sequential clinical trials are
presented in this section. Additional details of the set-up are that each trial enrolls a
maximum of N = 30 patients with each patient having a maximum of six cycles. A
total of 100 replicates are conducted with the true values of α = 1, β = 0.5, ρ = 0.8
and θ = 4.0 used in generating the patient responses. Dose assignment is based on
the algorithm outlined in Section 4.4.2.3 with a focus on maximizing the dose received
by each patient on the trial. The skeleton probability for cycle 1 used for the doses
was 0.02, 0.05, 0.10, 0.16, 0.23. The priors used on the parameters are as outlined in
the Section 4.2.4, specifically α, β and θ with lognormal prior distributions while ρ
with a Beta prior distribution. Data from a 100 replicates/trials were simulated to
study the design properties under different settings.
1. Effect of using two different values of φ = 0.8, 0.9, implying that a patient could
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handle about (80%, 90%) of the drug effect if a mild toxicity occurred at that
dose level.
2. Effect of using different values of P̊ (A), P̊ (B) and P̊ (C) during trial conduct.
Table 4.2 presents simulation result summaries of trials carried out under different
settings. Each row corresponds to summaries from 100 different replicates and are
grouped firstly by φ = 0.8 or φ = 0.9 followed by P̊ (B) = 0.3 and P̊ (C) = 0.4
or P̊ (B) = P̊ (C) = 0.4 with three different combinations of P̊ (A1) and P̊ (A2).
The columns correspond to the four patient and three regimen characteristics as
mentioned in Section 4.4.2.3. While Table 4.2 has P̊ (A1) = P̊ (A2), Table 4.3 presents
results with P̊ (A1) 6= P̊ (A2) and all other settings remaining the same.
The results from Table 4.2 indicate a very slight increase in the mean dose in trials
with φ = 0.9 as compared to φ = 0.8. This aligns with the model intuition that lower
values of φ imply the patient is able to handle a lower proportion of the dose when
experiencing a mild toxicity. The mean dose also increases with a higher threshold of
P̊ (B) = 0.4 as compared to P̊ (B) = 0.30 as expected since patients can be assigned
a higher dose level with a lenient threshold of P̊ (B) = 0.4. The mean dose increases
with higher thresholds of P̊ (A1) and P̊ (A2) since higher dose levels qualify for dose
assignment. Within a category of P̊ (B) and P̊ (C) the mean toxicity is the highest
when P̊ (A1) and P̊ (A2) are at the highest threshold of 0.2 conveying the trade off
between being lenient in dose assignment and patient safety. The number of trials
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stopping early due to an inability to assign doses is highest when P̊ (A1) and P̊ (A2)
are the most stringent at 0.05 essentially allowing only 5% severe toxicities at each
cycle. The mean on the recommended dose is calculated using the true values given
the recommended regimen. When P̊ (A1) = 0.05 the mean dose is lower than mean
recommended dose implying that the patients received a lower dose during the study
conduct. There is a close match between the mean dose and the recommended mean
dose when P̊ (A1) = 0.10 and when P̊ (A1) = 0.20 the mean dose is higher than that
mean of the recommended dose. The mean toxicity of the recommended regimen
given the true values is always below 30% which is a very good feature. The fraction
of recommended regimens that have toxicity less than say 40% is always ≥ 95%.
Also the recommended regimens are mostly above 72% in the green region.
The results from Table 4.3 are generated with P̊ (A1) 6= P̊ (A2) and better un-
derstanding of the results can be obtained by comparing the results to the corre-
sponding row in Table 4.2. For example consider the first row corresponding to
φ = 0.8 and P̊ (C) = 0.4, P̊ (B) = 0.30, P̊ (A1) = 0.05 and the difference is only due
to P̊ (A2) = 0.05 or P̊ (A2) = 0.10. As expected the higher value of P̊ (A2) increases
the mean dose assigned from 10.96 to 13.91 along with an increase in the mean tox-
icity from 0.17 to 0.29. The mean dose is now slightly higher than the mean of the
recommended expected dose and the proportion of patients having the recommended
regimen during the course of the trial also increases. In contrast notice the case when
P̊ (A1) = 0.20 and P̊ (A2) = 0.20 or P̊ (A2) = 0.05 the mean dose decreases from 17.45
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to 13.20 and the mean toxicities from 0.40 to 0.20 with none of the trials stopping
early in both cases. In general Table 4.3 results indicate that having P̊ (A2) lower
than P̊ (A1) provides lower values of mean toxicity and closer agreement between the
mean dose and the recommended mean dose. Also the recommended regimens are
mostly above 73% in the green region, the instance when the value drops to 69%
could be ascribed to φ = 0.90 and the stringent bounds during trial conduct and
regimen selection at the end of the trial.
4.4.3.1 Comparison the dichotomous Markov model
Simulation results will now be presented showing the benefit in using an ordinal
outcome Markov model in comparison to the dichotomous Markov Model 2.1. For
the dichotomous outcome the algorithm set up for running the sequential trial is
similar to that used earlier except that the ordinal outcome model is considered to
be the true model when assigning the responses to the patients. When assigning
dose levels to the patients, the mild response is assumed to be a none toxicity. All
other details of the model set up are similar to that used in Section 4.4.3.
Tables 4.4 and 4.5 have a layout similar to Tables 4.2 and 4.3 respectively and
allow an easy comparison. First consider the results from Table 4.4. There does not
seem to be any effect of φ on the mean toxicities while there is a slight increase in
the mean dose when φ = 0.9 as compared to φ = 0.8. The mean dose differs from
the mean recommended dose in most cases and is comparable when P̊ (A1) = 0.10.
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The proportion of recommended doses in the green are mostly around 50%. There
are trials stopping early in every scenario the lowest value is when P̊ (A1) = 0.20.
The results in Table 4.5 when P̊ (A1) 6= P̊ (A2) can be explained by comparing the
results from Table 4.4. For example the mean dose increases from 11.62 to 14.13
when P̊ (A2) = 0.10 as compared to P̊ (A2) = 0.05 with φ = 0.8 and P̊ (A1) = 0.05.
Differences in other results can be explained similarly.
In comparing the results across two modes of trial conduct with the truth as
ordinal model and using either ordinal model or the dichotomous Markov model for
the trial conduct there are some noticeable differences. Comparing the results from
Table 4.4 to Table 4.2 and Table 4.5 to Table 4.3 we notice that the proportion of trials
stopping early is higher for the dichotomous outcome. The proportion of patients
having a distance ≤ 2 from the recommended regimen is lower and the proportion
of recommended regimen being in the green are also very low. The mean dose and
mean toxicity reverse equality based on the values of P̊ (C), P̊ (B), P̊ (A1) and P̊ (A2).
The mean toxicities are usually higher but low only when P̊ (A1) = P̊ (A2) = 0.20.
There seems to be a considerable improvement in the performance of the trial when
the information provided by the mild toxicities is taken into account.
4.5 Discussion
One of the main goals of a phase I clinical trial is to arrive at an accurate es-
timate of the MTD without having too many patients experience a severe toxicity.
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Assigning multiple doses to patients ensures that patients are more likely to receive
an efficacious dosage before having a toxicity. Keeping track of the graded toxicity
outcomes of patients prevents patients from receiving dose levels that could result in
more severe toxicities on future cycles and thereby making sure that patients remain
in the study for longer and receive dose levels closer to their range of tolerability.
The ordinal outcome Markov model presented in this chapter is a novel method of
incorporating both the repeated measure information from all the patients and the
ordinal toxicity information of the responses on dose levels in the past. The advan-
tage of using the data from all the patients allows making correct dose assignment
decisions in the future for the patients.
The benefits of using this model are demonstrated through comparisons with
the dichotomized Markov model. There were improved gains in trial properties by
incorporating the ordinal outcomes. The number of overall toxicities were lower and
the proportion of trials recommending the true dose regimen were also considerably
higher. We know of one other method that incorporates individual grades or toxicity
scores [Doussau et al., 2013] and having some form of comparison between the two
methods could be a great possibility for future work.
The other advantage to using the ordinal Markov model in carrying out the trial
is that the dose levels are adjusted based on the past responses of the patients espe-
cially if a mild toxicity had occurred. Such an adaptive design ensures that patients
with frail dispositions are not exposed to higher doses levels. In this regard finding
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an accurate estimate of φ instead of setting to a constant would be an advantage.
Investigating the estimation of φ merits further research in future work.
The results from using the trial in an adaptive trial setting could be more dramatic
if we used the probability of mild toxicity in dose assignment decisions. By doing do
we could have assigned doses to continuing patients by incorporating their chance
of having a mild toxicity on a particular dose level instead of only looking at the
probability of a severe toxicity. This would add to the burden of defining another set
of target probabilities on the lines of P̊ (C), P̊ (B) and P̊ (A) pertaining to the chance
of observing a mild toxicity. Although this has not been done in this chapter the
algorithm in its present form could be easily extended to do this.
The Markov model presented in this chapter is most relevant to clinical trials
involving cytotoxic drugs where the toxicity is assumed to increase with the cumu-
lative effect. Having non-delayed outcomes is also essential to the study design so
that the DLT could be assigned at the end of the cycle to the appropriate dose level
for the patient.
There exist various other possibilities for further developments of the method.
In this chapter we showed improvements over the dichotomized Markov model. The
ordinal Markov model could be further extended to include the un-grouped five
classes of toxicity ranging from zero (none) to five (death) as defined by National
Cancer Institute [NCI, 2003]. The model currently allows treating patients at the
dose level that would not result in any severe toxicity thereby focusing only on the
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safety of the patients. More recently much interest is generated in estimating a safe
and efficacious dose level [Zhang et al., 2006], such approaches could be extended to
the ordinal Markov model with repeated measures from the patients.
Table 4.1: Parameter estimates obtained through simulation of a 500 datasets with
N = 30 patients under two different scenarios of true parameter values with φ = 0.90.
True Value Prior Mean (SD) Estimate(Bias) MSD1 ESD2 Coverage
Scenario 1
α 1 1 (2) 1.114 ( 0.114 ) 0.408 0.375 99
β 0.5 0.5 (1) 0.553 ( 0.053 ) 0.325 0.315 96
θ 4 4 (4) 4.387 ( 0.387 ) 1.752 1.666 97
ρ 0.8 0.83 (0.14) 0.802 ( 0.002 ) 0.111 0.076 99
Scenario 2
α 1 1 (2) 1.044 ( 0.044 ) 0.392 0.405 93
β 0.8 0.5 (1) 0.813 ( 0.013 ) 0.405 0.423 95
θ 3 4 (4) 3.440 ( 0.440 ) 1.337 1.385 89
ρ 0.8 0.83 (0.14) 0.796 ( -0.004 ) 0.122 0.075 100
1 MSD is mean of the SD from 500 estimates
2 ESD is empirical SD of the 500 estimates
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Table 4.2: Trial/Patient summary using φ = 0.8, 0.90 while conducting 100 sequential
trials with N = 30 patients and P̊ (A1) = P̊ (A2), P̊ (B) = 0.3, 0.4 and P̊ (C) = 0.4.
True model used for generating responses is Model 4.1 and model used in running the
trial is Model 4.1. Columns correspond to the mean dose received per patient, the
mean number of severe toxicities over 100 trials, number of trials stopping early, mean
number of patients having distance less than two from the recommended regimen,
the mean expected dose for the recommended regimen, mean probability of toxicity
for the recommended regimen, the proportion of trials having recommended regimen
with an overall toxicity under 40% and the proportion of trials having recommended
regimen in the green region as defined in Section 4.4.2.3.
Mean Mean Early P.R.Dist Mean R Mean R Prop Prop in
Dose Tox Stop Trials ≤ 2 R.EDose R.Tox ≤ 40% Green
φ = 0.80
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.05 10.96 0.17 5 6.31 12.86 ( 95 ) 0.23 0.95 0.78
P̊ (A1) = 0.1, P̊ (A2) = 0.1 14.86 0.28 2 13.53 14.39 ( 98 ) 0.27 0.95 0.77
P̊ (A1) = 0.2, P̊ (A2) = 0.2 17.45 0.40 0 9.36 15.37 ( 100 ) 0.29 0.99 0.80
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.05 10.96 0.17 5 6.38 12.91 ( 95 ) 0.23 0.95 0.77
P̊ (A1) = 0.1, P̊ (A2) = 0.1 15.14 0.30 2 13.41 14.48 ( 98 ) 0.27 0.95 0.79
P̊ (A1) = 0.2, P̊ (A2) = 0.2 17.64 0.43 0 8.74 15.21 ( 100 ) 0.28 0.99 0.86
φ = 0.90
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.05 10.97 0.17 6 6.5 12.75 ( 94 ) 0.22 0.94 0.77
P̊ (A1) = 0.1, P̊ (A2) = 0.1 15.17 0.29 2 14.45 14.82 ( 98 ) 0.27 0.95 0.75
P̊ (A1) = 0.2, P̊ (A2) = 0.2 17.55 0.40 0 9.42 15.47 ( 100 ) 0.28 0.97 0.74
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.05 10.97 0.17 6 6.1 12.89 ( 94 ) 0.23 0.94 0.73
P̊ (A1) = 0.1, P̊ (A2) = 0.1 15.31 0.29 2 13.78 14.81 ( 98 ) 0.27 0.95 0.72
P̊ (A1) = 0.2, P̊ (A2) = 0.2 17.88 0.42 0 9.02 15.59 ( 100 ) 0.28 0.99 0.74
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Table 4.3: Trial/Patient summary using φ = 0.8, 0.90 while conducting 100 sequential
trials with N = 30 patients and P̊ (A1) 6= P̊ (A2), P̊ (B) = 0.3, 0.4 and P̊ (C) = 0.4.
True model used for generating responses is Model 4.1 and model used in running
the trial is Model 4.1.
Mean Mean Early P.R.Dist Mean R Mean R Prop Prop in
Dose Tox Stop Trials ≤ 2 R.EDose R.Tox ≤ 40% Green
φ = 0.80
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.1 13.91 0.29 5 10.32 12.84 ( 95 ) 0.23 0.95 0.79
P̊ (A1) = 0.1, P̊ (A2) = 0.15 15.97 0.36 2 12.04 14.49 ( 98 ) 0.26 0.97 0.86
P̊ (A1) = 0.2, P̊ (A2) = 0.05 13.20 0.20 0 9.49 14.87 ( 100 ) 0.27 1 0.81
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.1 13.92 0.29 5 9.69 12.86 ( 95 ) 0.23 0.95 0.78
P̊ (A1) = 0.1, P̊ (A2) = 0.15 16.25 0.38 2 10.18 14.53 ( 98 ) 0.27 0.97 0.80
P̊ (A1) = 0.2, P̊ (A2) = 0.05 13.16 0.20 0 9.79 14.87 ( 100 ) 0.27 1 0.86
φ = 0.90
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.1 14.09 0.28 5 9.64 12.97 ( 95 ) 0.23 0.95 0.74
P̊ (A1) = 0.1, P̊ (A2) = 0.15 16.20 0.35 2 11.85 14.49 ( 98 ) 0.25 0.98 0.82
P̊ (A1) = 0.2, P̊ (A2) = 0.05 13.32 0.20 0 9.93 15.27 ( 100 ) 0.27 0.99 0.73
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.1 14.20 0.29 5 8.20 13.10 ( 95 ) 0.24 0.95 0.69
P̊ (A1) = 0.1, P̊ (A2) = 0.15 16.51 0.37 2 10.36 14.79 ( 98 ) 0.27 0.95 0.80
P̊ (A1) = 0.2, P̊ (A2) = 0.05 13.26 0.21 0 10.17 15.32 ( 100 ) 0.27 0.99 0.77
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Table 4.4: Trial/Patient summary using φ = 0.8, 0.90 while conducting 100 sequential
trials with N = 30 patients and P̊ (A1) = P̊ (A2), P̊ (B) = 0.3, 0.4 and P̊ (C) = 0.4.
True model used for generating responses is Model 4.1 and model used in running
the trial is Model 2.1.
Mean Mean Early P.R.Dist Mean R Mean R Prop Prop in
Dose Tox Stop Trials ≤ 2 R.EDose R.Tox ≤ 40% Green
φ = 0.80
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.05 11.62 0.22 8 4.59 13.66 ( 92 ) 0.23 0.91 0.58
P̊ (A1) = 0.1, P̊ (A2) = 0.1 14.91 0.34 5 12.92 14.80 ( 95 ) 0.26 0.94 0.45
P̊ (A1) = 0.2, P̊ (A2) = 0.2 15.55 0.34 2 12.51 15.42 ( 98 ) 0.27 0.96 0.55
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.05 11.71 0.22 9 4.54 13.83 ( 91 ) 0.24 0.90 0.54
P̊ (A1) = 0.1, P̊ (A2) = 0.1 15.30 0.38 5 13.98 14.89 ( 95 ) 0.25 0.94 0.63
P̊ (A1) = 0.2, P̊ (A2) = 0.2 16.88 0.44 2 7.92 15.34 ( 98 ) 0.26 0.96 0.58
φ = 0.90
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.05 11.81 0.22 8 4.50 13.98 ( 92 ) 0.25 0.90 0.50
P̊ (A1) = 0.1, P̊ (A2) = 0.1 15.03 0.33 5 12.69 14.91 ( 95 ) 0.26 0.94 0.43
P̊ (A1) = 0.2, P̊ (A2) = 0.2 15.63 0.34 2 13.12 15.50 ( 98 ) 0.27 0.96 0.57
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.05 11.82 0.22 8 4.32 13.93 ( 92 ) 0.24 0.91 0.52
P̊ (A1) = 0.1, P̊ (A2) = 0.1 15.73 0.38 5 12.80 15.21 ( 95 ) 0.27 0.91 0.53
P̊ (A1) = 0.2, P̊ (A2) = 0.2 17.11 0.44 2 8.78 15.58 ( 98 ) 0.27 0.97 0.53
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Table 4.5: Trial/Patient summary using φ = 0.8, 0.90 while conducting 100 sequential
trials with N = 30 patients and P̊ (A1) 6= P̊ (A2), P̊ (B) = 0.3, 0.4 and P̊ (C) = 0.4.
True model used for generating responses is Model 4.1 and model used in running
the trial is Model 2.1.
Mean Mean Early P.R.Dist Mean R Mean R Prop Prop in
Dose Tox Stop Trials ≤ 2 R.EDose R.Tox ≤ 40% Green
φ = 0.80
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.1 14.13 0.34 11 10.91 13.97 ( 88 ) 0.24 0.88 0.52
P̊ (A1) = 0.1, P̊ (A2) = 0.15 15.11 0.36 5 12.52 14.84 ( 95 ) 0.25 0.94 0.55
P̊ (A1) = 0.2, P̊ (A2) = 0.05 14.13 0.26 2 10.09 15.34 ( 98 ) 0.27 0.92 0.58
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.1 14.34 0.36 9 6.56 13.57 ( 91 ) 0.23 0.91 0.56
P̊ (A1) = 0.1, P̊ (A2) = 0.15 16.11 0.44 5 7.99 14.76 ( 95 ) 0.25 0.95 0.58
P̊ (A1) = 0.2, P̊ (A2) = 0.05 14.35 0.26 2 9.83 15.34 ( 98 ) 0.27 0.94 0.60
φ = 0.90
P̊ (C) = 0.4 P̊ (B) = 0.3
P̊ (A1) = 0.05, P̊ (A2) = 0.1 14.21 0.34 11 10.27 13.81 ( 88 ) 0.24 0.88 0.53
P̊ (A1) = 0.1, P̊ (A2) = 0.15 15.21 0.36 5 12.43 14.92 ( 95 ) 0.26 0.95 0.54
P̊ (A1) = 0.2, P̊ (A2) = 0.05 14.23 0.26 2 10.07 15.46 ( 98 ) 0.27 0.90 0.55
P̊ (C) = 0.4 P̊ (B) = 0.4
P̊ (A1) = 0.05, P̊ (A2) = 0.1 14.46 0.35 9 6.58 13.69 ( 91 ) 0.24 0.90 0.55
P̊ (A1) = 0.1, P̊ (A2) = 0.15 16.31 0.43 5 8.23 14.84 ( 95 ) 0.25 0.93 0.57
P̊ (A1) = 0.2, P̊ (A2) = 0.05 14.51 0.26 2 10.04 15.51 ( 98 ) 0.27 0.95 0.56
4.6 Appendix
4.6.1 Outline of the code written in JAGS
The code presented below corresponds to applying ordinal Markov Model 4.1 in
simulations for parameter estimation from the posterior samples.
#Defining the model.bug file1
model {2
#Define the likelihood for each of the N subjects3
for (i in 1:N) {4
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prob[i,3]< −1-exp(-alpha* ( dose[i]-rho*phi.flag[i])*step(dose[i]-rho*phi.flag[i])5
-beta*dose[i]*cumdose[i])6
prob32[i] < − 1- exp((theta+1) *(-alpha* ( dose[i] - rho*phi.flag[i])*step(dose[i] -7
rho*phi.flag[i]) - beta*dose[i]*cumdose[i] ))8
p[i,2] < − p32[i] - p[i,3]9
p[i,1] < −1 - p32[i]10
pat.response[i] ∼ dcat (p[i,])11
}12
#Setting up the priors13
#prior on α - E(α) = 1 and V ar(α) = 414
mu1 < − -0.3465736; tau1 < − 1.442695015
alpha ∼ dlnorm(mu1,tau1)16
#prior on ρ17
a1 < − 5 ; b1 < − 118
rho ∼ dbeta(a1,b1)19
#Prior on β - E(β) = 0.5 and V ar(β) = 120
mu2 < − -1.498; tau2 < − 0.62121
beta ∼ dlnorm(mu2,tau2) #Prior on θ - E(θ) = 4 and V ar(θ) = 1622
mu3 < − 1.356; tau3 < − 16.49523








jags < − jags.model(file=”prior.bug”, data = data, inits=inits, n.chains = 2, n.adapt32
= 10000)33
adapt(jags,n.iter=1000)34
update(jags,1000000) # burin samples35














4.6.2 Example of an adaptive trial in progress
Based on the algorithm presented in Section 4.4.2.3 for maximizing the total ex-
pected dose received by a patient, an example of a trial in progress is presented in
this section for demonstrating the dose assignment in practice. The target proba-
bility bounds used during the execution are P̊ (C) = 0.40, P̊ (B) = 0.30, P̊ (A1) =
0.10, P̊ (A2) = 0.10 and the true values of the parameters are α = 1, β = 0.5, ρ =
0.8, θ = 4. The fixed parameter φ = 0.80 in these simulations.
Table 4.6 presents the current patient profile in the trial. The rows correspond to
the unique patients added sequentially in the trial. The columns correspond to the
six cycles with the dose level assigned to the patient and the response in parenthesis.
A one signifies none toxicity while a two and three denote mild and severe toxicity
respectively. A cross is placed in all cycles once a severe response is observed for a
patient. There are 13 patients in the trial and decisions need to be made for dose
assignment to patients 9, 11, 12 and 13 and a new patient 14. Before patient 13 was
added to the trial the parameter estimates were α̂ = 1.082(0.436), β̂ = 0.335(0.277),
ρ̂ = 0.903(0.102) and θ̂ = 4.111(0.959) with the posterior standard deviations in
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parenthesis. The updated current estimates of the parameters are α̂ = 1.163(0.441)
β̂ = 0.338(0.279), ρ̂ = 0.906(0.099) and θ̂ = 4.241(0.981). Notice that the estimate
of θ̂ increases in response to the mild toxicity observed by patient 11 on cycle 3.
The probability of toxicity on dose levels 1 through 4 for patient 9 are 0.003,0.023,
0.089,0.168 of which dose level 3 has probability of toxicity≤ P̊ (A2) = 0.10 and is also
able to provide a regimen combination that satisfies the P̊ (C) = 0.40, P̊ (B) = 0.30
and hence is assigned to patient 9 on cycle 6. Using the true values of the parameters
and the current dose assignment the true probability of toxicity is calculated and a
Bernoulli response is generated. In a similar fashion the remaining patients are
assigned doses and responses and the updated patient profile is presented in Table
4.7. The updated parameter estimates are now α̂ = 1.079(0.407), β̂ = 0.309(0.252),
ρ̂ = 0.905(0.099) and θ̂ = 4.214(0.974). Notice the slight decrease in estimates α̂, β̂
and θ̂ since no fresh toxicities are observed.
At the end of the trial the completed patient profile is presented in Table 4.8.
The parameter estimates at the conclusion of the trial are α̂ = 0.958(0.291), β̂ =
0.478(0.302), ρ̂ = 0.826(0.124) and θ̂ = 3.398(0.727) The probability of toxicity
on the first cycle and on any cycle is calculated using the current estimates of the
parameters for all the 19 regimens in Table 2.3 to select the recommended regimen
and by using the true parameter values to select the target regimen. By setting
P r(A1) = P̊ (A1) = 0.10 and P
r(C) = 0.3 and using the true parameter values the
target regimen selected is 333333 while the recommended regimen is 33333 using the
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parameter estimates obtained at the conclusion of the trial. If only P r(C) = 0.3 is
used the target regimen is 333333 while the recommended regimen is 333333.
Table 4.6: Table showing the dose level assignment and patient responses in paren-
thesis for an adaptive trial in progress using Model 4.1 with accrual of 13 patients.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 2 (1) 2 (1) 3 (1) 4 (2) 3 (1) 3 (2)
2 2 (1) 3 (3) X X X X
3 3 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
4 3 (2) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1)
5 2 (2) 2 (1) 2 (1) 3 (2) 2 (1) 2 (1)
6 2 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
7 2 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
8 2 (2) 2 (1) 3 (1) 2 (1) 2 (1) 2 (1)
9 2 (1) 3 (2) 2 (1) 3 (1) 3 (1) ?
10 2 (1) 3 (3) X X X X
11 2 (1) 3 (1) 4(2) ? ? ?
12 2 (1) 3 (2) ? ? ? ?
13 2 (1) ? ? ? ? ?
X Terminated patient having a severe toxicity (3)
? Continuing patient
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Table 4.7: Table showing the dose level assignment and patient responses in paren-
thesis for an adaptive trial in progress using Model 4.1 with accrual of 14 patients.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 2 (1) 2 (1) 3 (1) 4 (2) 3 (1) 3 (2)
2 2 (1) 3 (3) X X X X
3 3 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
4 3 (2) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1)
5 2 (2) 2 (1) 2 (1) 3 (2) 2 (1) 2 (1)
6 2 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
7 2 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
8 2 (2) 2 (1) 3 (1) 2 (1) 2 (1) 2 (1)
9 2 (1) 3 (2) 2 (1) 3 (1) 3 (1) 3(1)
10 2 (1) 3 (3) X X X X
11 2 (1) 3 (1) 4(2) 3(1) ? ?
12 2 (1) 3 (2) 2(1) ? ? ?
13 2 (1) 3(1) ? ? ? ?
14 2 (1) ? ? ? ? ?
X- Terminated patient having a severe toxicity (3)
? Continuing patient
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Table 4.8: Table showing the dose level assignment and patient responses in paren-
thesis for a completed adaptive trial using Model 4.1.
Patient ID Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
1 2 (1) 2 (1) 3 (1) 4 (2) 3 (1) 3 (2)
2 2 (1) 3 (3) X X X X
3 3 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
4 3 (2) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1)
5 2 (2) 2 (1) 2 (1) 3 (2) 2 (1) 2 (1)
6 2 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
7 2 (1) 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
8 2 (2) 2 (1) 3 (1) 2 (1) 2 (1) 2 (1)
9 2 (1) 3 (2) 2 (1) 3 (1) 3 (1) 3(1)
10 2 (1) 3 (3) X X X X
11 2 (1) 3 (1) 4(2) 3(1) 3 (1) 3 (1)
12 2 (1) 3 (2) 2(1) 3 (1) 3 (1) 3 (3)
13 2 (1) 3(1) 4(1) 4(1) 4(1) 4(3)
14 2 (1) 3(1) 4(1) 4(1) 4(3) X
15 2 (2) 2 (1) 2(2) 3(3) X X
16 2 (1) 3 (1) 4(3) X X X
17 2 (1) 3 (1) 3(2) 3 (1) 3 (1) 3 (1)
18 2 (1) 3 (1) 3(1) 3 (3) X X
19 2 (1) 3 (1) 3(1) 3 (3) X X
20 2 (1) 3 (1) 3(1) 3 (1) 3 (1) 3 (2)
21 2 (1) 3 (1) 3(1) 3 (1) 3 (1) 3 (1)
22 2 (3) X X X X X
23 2 (2) 1 (1) 2 (1) 2 (1) 2 (1) 2 (1)
24 2 (1) 3 (1) 3(1) 3 (1) 3 (1) 3 (1)
25 2 (1) 3 (1) 3(1) 3 (1) 3 (1) 3 (1)
26 2 (2) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1)
27 2 (1) 3 (1) 3(1) 3 (1) 3 (1) 3 (1)
28 2 (1) 3 (1) 3(1) 3 (1) 3 (2) 4 (1)
29 2 (1) 3 (1) 3(2) 3 (1) 3 (1) 3 (1)
30 2 (1) 3 (1) 3(1) 3 (1) 3 (1) 3 (1)
X -Terminated patient having a severe toxicity (3)
CHAPTER 5
Discussion and future work
We have proposed novel models for the conditional probability of toxicity to
specify the dose-toxicity relationship in clinical trials in oncology having repeated
dose administrations. Using Bayesian methods the models can be fit to data that
arises in the conduct of a trial that allows patients to have dose escalation or de-
escalation. Allowing for intra-patient dose escalation and de-escalation gives the
patient a greater chance to be treated at a therapeutic dose, an advantage over the
current trials in oncology that restrict patients to have the same dose over all the
cycles.
The first model in Chapter 2 had three parameters to account for the effect of
the current dose, the cumulative dose and the effect of dependency between patient
responses. Benefits in modeling the data from all cycles were demonstrated. In ad-
dition estimation of parameters by allowing patients to vary doses over the course of
treatment was presented. The model application in conducting a sequential clinical
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trial by assigning doses to patients based on the all the available information was also
demonstrated. Chapter 3 demonstrated extensions of the model incorporating dose
and gender covariates. An ingenious way to build priors for the three parameters
was presented. Application of the model to the sarcoma dataset demonstrated its
ability to include covariates in modeling the dose-toxicity relationship. Chapter 4
demonstrated the extension of the Markov model to include ordinal outcomes ac-
counting for none, mild or severe toxicities. Sequential design of a clinical trial using
the model was presented. Benefits of using the ordinal model in comparison to the
dichotomized, two-state Markov model, were also demonstrated through simulations.
Overall, the methods proposed in this dissertation represent a meaningful con-
tribution to the field of adaptive clinical trial design. Although many statistical
methods have been proposed for adaptive clinical trials most are not used in practice
[Dent and Eisenhauer, 1996]. We are hopeful that with current interest in the CRM
in carrying out clinical trials there will be an eventual shift towards within-patient
dose-escalation trials and the methods presented in this dissertation would provide
the necessary tools and framework to carry them out. Our models provide a simple
way to model a complex data structure parsimoniously.
In general for dose escalation studies the design should be influenced by the
steepness of the dose-response curves, interpatient variability in pharmacokinetics
and whether the toxicities are reversible [Chevret, 2006]. In our setting when intra-
patient dose changes are allowed and repeated measurements of toxicity response are
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used it is also necessary that the toxicity can be attributed to the dose received in
the current cycle and that it occurs within the time frame of the cycle.
There are numerous pros and cons to using the model based methods presented in
this dissertation for adaptive clinical trial designs. It is hard to ignore the complexity
of the model design and the algorithm for dose assignment. The need to set up the
probability skeleton for the dose levels to be studied, the priors on the different
parameters of interest, the safety criteria rules for intra-patient dose escalation/de-
escalation, the choice of plans for optimizing the dose given to the patients, the
bounds for the various target probabilities and the bounds for the probabilities for
the eventual selection of a dosing regimen are a wide array of factors to consider
before carrying out the trial. The calculation of the probabilities that are used in
deciding the dose for the next cycle for a patient are based on accumulated data
that must be available in real time. In comparison the most widely used ‘3+3’
algorithmic design has a simpler approach to arriving at the maximum tolerable
dose level in a single dose setting. In actuality the model based approach presented
in this dissertation incorporates the safety criteria rules used in the algorithmic ‘3+3’
design but in contrast provides the additional benefit of treating patients close to the
safer dose level by incorporating information from all the patients in the trial and
additionally allowing patients to receive multiple doses. In situations where there are
limited patients to be recruited our model based methods provide efficient estimates
and allow the patients to be treated at the best dose level thereby making the extra
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effort of setting up the study design worthwhile.
In the evaluation of the methods we considered regimens of six cycles and the
only reason a patient would drop out prior to that was if they experienced a DLT.
In practice patients may drop out for other reasons. The Bayesian estimation ap-
proach can still be used as long as at least a few patients have a long sequence of
toxicity measurements, however there would be less precision of the parameter es-
timates with less accumulated data. In the dichotomous Markov model presented
in Chapter 2, three parameters were estimated of which the parameter ρ captured
the dependency of the within-patient responses. Estimating this parameter is chal-
lenging in the presence of limited data especially at the start of the trial. Others
including [Whitehead et al., 2001, 2006] seem to have encountered similar problems
when trying to estimate the dependency between patient responses and have resorted
to setting it to a constant. We have circumvented this issue by using a tight Beta
prior on ρ. These difficulties in estimating ρ were less profound when the sample size
increased as was the case in Chapter 3 when the Markov model was used in a Phase
II setting. This chapter presented other non-standard priors on ρ offering options to
incorporate prior belief in dependency of patient responses. A tight Beta prior was
also used on ρ in Chapter 4 since it was difficult to estimate all the four parameters
in the ordinal Markov model.
Since the parameter estimation is done via MCMC methods a fairly high under-
standing of the use of MCMC techniques is crucial and might pose a limitation to
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the use of the methods. In the simulation results presented in this dissertation a
relatively large fixed number (2000K) of simulations have been used as the burn-in
period for the initial 15 patients to ensure convergence of the posterior distributions
and a lower burn-in period (500K) for the subsequent patients in the ordinal out-
come model. The burn-in periods were determined based on the initial testing phase
of the method. A more stringent monitoring of the burn-in and convergence of the
posterior distributions is advocated when the method is being used in practice for
dose assignment in actual clinical trials.
A better understanding of the operation of the method for different values of the
target probabilities and safety criteria through simulations is advocated. The sim-
ulation results presented in Chapters 2 and 4 demonstrated the effect of the safety
criteria set up, the target probability bounds and the optimization criteria for the
dose assignment on the trial properties. Additional safety criteria rules can be incor-
porated, for example to prevent a new patient from escalating to a higher and new
dose level (rg + 1) on the first cycle given that the previous patient had a DLT on
dose level rg, the new patient could be assigned a dose level of rg or less. Clinicians
often hesitate in de-escalating the dose level when a patient tolerates the dose on
previous cycles. The algorithm could be modified to prevent continuing patients in
the trial from escalating to a higher dose level thus overriding the dose recommen-
dations made by the model algorithm. Studying the effect on the trial properties by
incorporating such safety criteria rules is strongly advocated via simulation studies.
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We have focused on using the models since they provide a good estimate of
the expected dose for the recommended regimen. In the context of multiple dose
administrations per patient once a recommended regimen is selected, the expected
dose corresponding to this regimen can be calculated and the probability of surviving
the entire regimen without a DLT can also be estimated. Given this value of the
recommended expected dose a number of dose level combinations are possible that
could match the expected dose and yet have an acceptable level of overall probability
of toxicity. Hence having an estimate of the tolerable expected dose gives rise to the
possibility of proposing various regimen combinations meeting the expected dose
level and the overall toxicity rate on all the cycles and could be used to narrow down
the possible choices of regimens for recommending to the next phase of testing.
Simulations are presented for five dose levels in Chapter 2 and 4 and for two dose
levels in Chapter 3 but in practice the model could be easily extended to different
number of dose level combinations. Also the number of cycles for the regimen are
not limited to four or six cycles are presented in Chapter 3 and Chapters 2 and 4
respectively. Currently all simulations demonstrating the sequential operation of the
models assumed that the patients complete their cycles simultaneously and that a
new patient is ready for dose assignment at the same time. Dose assignment happens
for the continuing patients and the new patient based on the parameter estimates
available at that stage. This simplistic assumption reduced the computational time of
the simulations and also minimized the complexity of the results during comparisons.
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In practice patient arrival could be generated using an exponential distribution and
the length of individual cycles could also be programmed when considering patient
completion. This would entail estimating the parameters more often since patients
would not be aligned to complete their cycles simultaneously. Simulations can be
done to study the effects of perturbation on differences in accrual rates of new pa-
tients, varying cycle duration/length and possibly varying cycle duration/length per
patient.
Another obvious extension to the models presented would be to include time to
event outcomes. We currently use the information from patients who have completed
their ongoing cycle. Using a time to event outcome on the lines of the TITE-CRM
[Cheung and Chappell, 2000, Braun, 2006], we could incorporate the partial informa-
tion from patients currently in a cycle by using weights for the period of time without
a DLT. This could provide a more accurate estimate of probability of toxicity rates
when deciding the dose level for a new patient or a continuing patient.
Thus far, we have considered incorporating only the safety information through
the occurrence of a DLT. There is an increasing use of early clinical trials to demon-
strate efficacy in addition to safety. Many authors including [Thall and Cook, 2004,
Braun, 2002, Thall et al., 1999] have provided models to be used in the phase I/II
setting to simultaneously arrive at a safe and efficacious dose level. In a similar vein
extensions to the Markov models can be envisioned that include a bivariate trial de-
sign in which the MTD is based jointly on both the toxicity and disease progression
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information.
Yet another possibly complex extension of the Markov models could be to study
the dose-toxicity profiles of two study drugs simultaneously. [Thall et al., 2003]
provided a two stage Bayesian method giving acceptable dose-pairs of two agents in
the phase I cancer chemotherapy setting. Similar extensions could be designed for
the multiple dose cycles per patient setting using the Markov models either in the
binary or the ordinal outcome setting presented in this dissertation.
One of the most promising results from the research in this dissertation is that the
use of ordinal responses can lead to improved selection of the recommended regimen
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J.R. van Dorp, S.C. Rambaud, J.G. Pérez, and R.H. Pleguezuelo. An elicitation
procedure for the generalized trapezoidal distribution with uniform central stage.
Decision Analysis, 4(3):156–166, 2007.
E.M. Van Meter, E. Garrett-Mayer, and D. Bandyopadhyay. Proportional odds
model for dose finding clinical trial designs with ordinal toxicity grading. Statistics
in Medicine, 30(17):2070–2080, 2011.
E.M. Van Meter, E. Garrett-Mayer, and D. Bandyopadhyay. Dose-finding clinical
trial design for ordinal toxicity grades using the continuation ratio model: an
extension of the continual reassessment method. Clinical Trials, 9(3):303–313,
2012.
C. Wang, T. Chen, and I. Tyan. Designs for phase I cancer clinical trials with differ-
entiation of graded toxicity. Communications in Statistics-Theory and Methods,
196
29:975–987, 2000.
J. Whitehead, S. Patterson, D. Webber, S. Francis, and Y. Zhou. Easy-to-implement
Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics,
2(1):47–61, 2001.
J. Whitehead, Y. Zhou, A. Mander, S. Ritchie, A. Sabin, and A. Wright. An evalua-
tion of Bayesian designs for dose-escalation studies in healthy volunteers. Statistics
in Medicine, 25(3):433–445, 2006.
F.P. Worden, J.M.G. Taylor, J.S. Biermann, V.K. Sondak, K.M. Leu, R. Chugh,
C.J. McGinn, M.M. Zalupski, and L.H. Baker. Randomized phase II evaluation of
6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor
(G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the
treatment of poor-prognosis soft tissue sarcoma. Journal of Clinical Oncology, 23
(1):105–12, 2005.
Z. Yuan, R. Chappell, and H. Bailey. The continual reassessment method for multiple
toxicity grades: A Bayesian quasi-likelihood approach. Biometrics, 63(1):173–179,
2007.
J. Zhang and T.M. Braun. A phase I Bayesian adaptive design to simultaneously
optimize dose and schedule assignments both between and within patients. Journal
of the American Statistical Association, 108(503):892–901, 2013.
W. Zhang, D.J. Sargent, and S. Mandrekar. An adaptive dose-finding design incor-
porating both toxicity and efficacy. Statistics in Medicine, 25(14):2365–83, 2006.
